| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bio-Techne Corp$70.92
+0.09 (+0.13%)
0Pipeline Score Tools & Services
Market Cap
7.55 B
EPS
0.70
P/E Ratio
69.25 $
Value Trade
112.32 M
SEC Financials
Q1 2026Dilution Risk
Revenue
311.42 M
R&D Expenses
23.45 M
Total Assets
2.55 B
Total Liabilities
2.55 B
Equity
2.09 B
D/E Ratio
12,345
7.52 %
Week
-20.16 %
1 Month
-16.44 %
3 Month
-18.05 %
6 Month
-53.43 %
5 Year
43,977.71 %
All Time
Cash Data
Cash Position
209.82 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
6.78 M
52 Week Range
43.20 - 72.16
% held by Insiders
0.41 %
% held by Institutions
116.56 %
Enterprise Value
7.63 B
Total Shares
156.51 M
Short %
11.67 %
Float Shares
154.94 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bio-Techne Corp
453Total events
1Upcoming
98Tier-1 (high impact)
2014 – 2027Coverage
Upcoming catalysts 1
Dec 31, 2027
T1Partnership / License
Bio-Techne has right to acquire remaining ownership of Wilson Wolf upon achievement of $226M revenue or $136M EBITDA milestone
Event history 452
Q3 2026
●Manufacturing MilestoneCMC / Inspection
Customer Experience Centre opening in Düsseldorf, Germany
May 31, 2026
May 12, 2026
◆Oral PresentationPresentation
Bio-Techne to present at Bank of America Securities 2026 Global Healthcare Conference
May 6, 2026
◆Quarterly UpdateCorporate
Bio-Techne to announce third quarter fiscal 2026 financial results
Feb 16, 2026
▲Other Regulator MilestoneEllaEx-US Regulatory
Ella platform receives CE-IVD marking for European Union
Feb 4, 2026
Jan 28, 2026
▲Product LaunchPost-Market
Launch of Simple Plex Ultra-Sensitive Assays on Ella platform
neurodegenerative diseasesource ↗
Jan 13, 2026
◆Oral PresentationPresentation
Bio-Techne to present at 2026 J.P. Morgan Healthcare Conference
2026
◆IND SubmissionIND
IND data package submission to FDA for WT1-targeted TCR-T cell therapy
WT1-targeted TCR-T cell therapysource ↗
Drug Pipeline Intelligence
0
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 1%
Micro Cap (rank 898 of 906)
Percentile RankClinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
— | metastatic melanoma | — | 2025-11-04 | 42 pre-treatment biopsies, three treatment arms incorporating Immune Checkpoint Blockade (ICB) Read More | AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients Read More | |
— | metastatic melanoma | — | 2025-11-04 | 42 pre-treatment biopsies, three treatment arms incorporating Immune Checkpoint Blockade (ICB) Read More | AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients Read More | |
— | metastatic melanoma | — | 2025-11-04 | 42 pre-treatment biopsies, three treatment arms incorporating Immune Checkpoint Blockade (ICB) Read More | AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TECH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TECH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TECHBio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization Bio‑Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass...
Bio-Techne Corporation and Refeyn have launched a novel integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars. This new approach combines Bio-Techne's MauriceFlex imaged capillary isoelectric focusing system with Refeyn's TwoMP mass photometry platform. The innovation allows researchers to streamline their characterization process, significantly reducing the time required for analysis. This development is expected to enhance the understanding of complex biotherapeutics, potentially accelerating their development in the market.
Read more →TECHBio-Techne Declares Dividend Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended...
Bio-Techne Corporation (NASDAQ: TECH) has announced a dividend payment of $0.08 per share for the quarter ending March 31, 2026. This quarterly dividend will be payable on May 29, 2026, to shareholders on record by May 18, 2026. The Board of Directors will consider future dividends on a quarterly basis, highlighting the company's ongoing commitment to shareholder value. Despite this positive development, the company has acknowledged potential risks that could impact its operations and share price.
Read more →TECHBio-Techne Releases Third Quarter Fiscal 2026 Results
Bio-Techne Corporation reported its third quarter fiscal 2026 results, revealing a 2% decline in revenue to $311.4 million, impacted by prior-year orders and shipment timing. Despite this, GAAP EPS rose to $0.32, and large pharma continued its growth trend. The company remains optimistic about future demand as funding activity stabilizes.
Read more →TECHBio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference
Bio-Techne Corporation announced that CEO Kim Kelderman will present at the Bank of America Securities 2026 Global Healthcare Conference on May 12, 2026. The presentation will be accessible via a live webcast on the company's Investor Relations website. Bio-Techne has a rich history of 50 years in the life sciences sector and operates globally.
Read more →TECHBio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
Bio-Techne Corporation has introduced a streamlined brand architecture to improve customer navigation of its life science solutions. The new structure organizes products into three focused brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, aligning with the progression of scientific research. This initiative aims to empower scientists and clinicians by providing easier access to essential tools and technologies.
Read more →TECHBio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results
Bio-Techne Corporation announced a conference call scheduled for May 6, 2026, to discuss its third quarter fiscal 2026 financial results. The call will be accessible via dial-in and webcast, with a replay available for those unable to attend live. The company continues to thrive in the life sciences sector, generating significant revenue.
Read more →TECHBio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite
Bio-Techne Corporation has expanded its COMET solution portfolio by introducing SPYRE Focus Panels and SPYRE Amplification Kits. These innovations aim to enhance the modular, automated spatial biology workflow, providing researchers with greater flexibility and sensitivity. The new features in HORIZON Image Analysis Software further support these advancements, facilitating deeper biological insights from tissue samples.
Read more →TECHBio-Techne to Present at Upcoming Investor Conferences
Bio-Techne Corporation has announced its participation in two upcoming investor conferences. The TD Cowen 46th Annual Health Care Conference is scheduled for March 3, 2026, and the Leerink Partners Global Healthcare Conference will take place on March 10, 2026. Live webcasts of these presentations will be available on the company's Investor Relations website.
Read more →TECHBio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
Bio-Techne Corporation's Ella platform has received CE-IVD marking, allowing its sale in the European Union. This compact, cartridge-based immunoassay system provides rapid and accurate biomarker results, enhancing clinical workflows. The certification enables European laboratories to utilize Ella for in-house test development and clinical trials, supporting precision medicine initiatives.
Read more →TECHBio-Techne Announces Changes to its Leadership Team
Bio-Techne Corporation announced a leadership change, with Dr. Matt McManus transitioning from his role as President of the Diagnostics and Spatial Biology Segment effective March 1, 2026. Steve Crouse, previously Senior Vice President of the Analytical Solutions Division, will take over as President. The transition aims to ensure continuity and leverage Crouse's extensive experience in the life sciences sector.
Read more →TECHBio-Techne Declares Dividend
Bio-Techne Corporation has declared a quarterly dividend of $0.08 per share for the period ending December 31, 2025. This dividend will be paid on February 27, 2026, to shareholders recorded by February 16, 2026. The company reported over $1.2 billion in net sales for fiscal 2025 and will evaluate future dividends quarterly.
Read more →TECHBio-Techne Releases Second Quarter Fiscal 2026 Results
Bio-Techne Corporation reported its financial results for Q2 FY2026, highlighting double-digit growth in large pharma for the fourth consecutive quarter. The company experienced stabilization in its U.S. academic market and growth in Asia. Despite flat net sales year-over-year, adjusted earnings per share increased, reflecting ongoing profitability initiatives. The company celebrates its 50th anniversary in 2026, emphasizing its commitment to innovation.
Read more →TECHBio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
Bio-Techne Corporation has launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix designed to enhance 3D stem cell and organoid research. This product aims to reduce variability in research and support regulatory-aligned workflows, aligning with FDA goals for innovation. The hydrogel is expected to improve the scalability and consistency of organoid culture, thus facilitating drug screening and personalized medicine applications.
Read more →TECHBio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers
Bio-Techne Corporation has launched Simple Plex Ultra-Sensitive Assays on its Ella platform, enabling femtogram-level detection of neurological biomarkers. This advancement allows for early detection of neurodegenerative diseases by improving analytical sensitivity and quantification of key biomarkers. The automated workflow enhances reproducibility and reduces manual variability, supporting high-throughput research.
Read more →TECHBio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
Bio-Techne Corporation announced a conference call scheduled for February 4, 2026, to discuss its second quarter fiscal 2026 financial results. The call will be accessible via a live webcast and a recorded rebroadcast for those unable to attend. The company continues to grow, having achieved significant sales in the previous fiscal year.
Read more →TECHBio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference
Bio-Techne Corporation announced that its CEO, Kim Kelderman, will present at the 2026 J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be accessible via a live webcast on the company's Investor Relations website. Bio-Techne is recognized for its innovative tools and bioactive reagents in the life sciences sector.
Read more →TECHBio-Techne s'associe au Wyss Center Geneva pour accélérer la biologie spatiale en automatisant la multiomique 3DFrance - FrançaisUSA - EnglishDeutschland - English
Bio-Techne Corporation has announced a strategic collaboration with the Wyss Center for Bio and Neuroengineering to develop an automated protocol for simultaneous detection of RNA and proteins in 3D samples. This initiative aims to enhance multi-omic analysis and improve understanding of tissue structure and cellular interactions. The partnership seeks to overcome limitations of traditional methods, potentially accelerating drug discovery and reducing reliance on animal models.
Read more →TECHBio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial BiologyUSA - EnglishFrance - FrançaisDeutschland - English
Bio-Techne Corporation has announced a strategic collaboration with the Wyss Center for Bio and Neuroengineering to develop automated workflows for simultaneous RNA and protein detection in 3D specimens. This partnership aims to enhance multiomic analysis capabilities, thereby accelerating drug discovery and improving diagnostic development. The initiative seeks to make spatial biology technologies more accessible to researchers.
Read more →TECHBio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis
Bio-Techne Corporation has launched the next-generation Leo System, enhancing protein analysis with dual-channel fluorescence detection and chemiluminescence. This system allows for increased data throughput and the ability to analyze multiple targets simultaneously. Researchers can process up to 100 capillaries in three hours, achieving high precision with minimal variability. The Leo System aims to accelerate clinical research and streamline development timelines.
Read more →TECHBio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio
Bio-Techne Corporation has entered into a licensing agreement with Monod Bio to obtain exclusive commercial rights to a subset of AI-designed NovoBody™ Duo molecules. This partnership aims to enhance Bio-Techne's recombinant protein portfolio, allowing for improved targeting of complex biology and accelerated therapeutic development. The collaboration underscores the integration of AI in advancing scientific research.
Read more →TECHBIO-TECHNE DECLARES DIVIDEND
Bio-Techne Corporation has announced a quarterly dividend of $0.08 per share for the quarter ending September 30, 2025. This dividend will be payable on November 28, 2025, to shareholders of record as of November 17, 2025. The company reported over $1.2 billion in net sales for fiscal 2025 and continues to evaluate future dividends quarterly.
Read more →TECHBio-Techne Releases First Quarter Fiscal 2026 Results
Bio-Techne Corporation reported its first quarter fiscal 2026 results, highlighting a 1% decrease in net sales to $286.6 million. Despite this decline, the company noted strong performance from large pharmaceutical customers and growth in its ProteinSimple segment. The CEO mentioned challenges in order timing for GMP proteins but expressed optimism about future growth, particularly in Cell Therapy with FDA Fast Track Designation for some customers.
Read more →TECHAI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
Bio-Techne and Nucleai presented pivotal data from the SECOMBIT clinical trial at the SITC 2025 Annual Meeting. The study highlights the integration of AI-driven spatial biology with immuno-oncology to identify predictive biomarkers in metastatic melanoma patients. Key findings suggest that immune cell interactions within tumors significantly influence treatment outcomes, paving the way for personalized cancer therapies.
Read more →TECHScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sonoma Biotherapeutics has...
ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, announced that Sonoma Biotherapeutics has been awarded a $300,000 G-Rex Grant. This funding will support the development of a G-Rex-based manufacturing process for gene-modified regulatory T cell therapies aimed at treating autoimmune disorders. The grant will facilitate a transition to a commercially viable system, enhancing the scalability of production. Additionally, ScaleReady continues to provide extensive support to advance cell and gene therapy development.
Read more →TECHBio-Techne Launches ProximityScope™ Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of the...
Bio-Techne Corporation has launched the ProximityScope assay, designed for high-resolution visualization of protein-protein interactions on the BOND RX platform from Leica Biosystems. This assay integrates with the RNAscope Multiomic LS kit, enhancing the detection of both RNA and proteins in research samples. The innovation aims to offer unparalleled accuracy while minimizing tissue use, facilitating advancements in understanding complex biological systems and therapeutic development. The new automated solution will be showcased at the upcoming Society for Immunotherapy of Cancer meeting in Washington, DC.
Read more →TECHScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at Children's National Hospital ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, announced four G-Rex Grants have...
ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne, has awarded four G-Rex Grants totaling $375,000 to researchers at Children's National Hospital. The grants aim to enhance the development and manufacturing processes of cell and gene therapy initiatives. Each grant supports distinct projects, including CAR-T cell manufacturing and Virus Specific T cell optimization. This initiative reflects a commitment to advancing pediatric oncology and streamlining treatment production methods.
Read more →TECHBio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results
Bio-Techne Corporation has announced a conference call scheduled for November 5, 2025, at 8:00 a.m. CST to discuss its first quarter fiscal 2026 financial results. The call will be accessible via dial-in and webcast, with a recorded rebroadcast available for those unable to attend live. The company continues to demonstrate its commitment to transparency and investor relations.
Read more →TECHBio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032 Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced a significant...
Bio-Techne Corporation has expanded its agreement with Oxford Nanopore Technologies, extending their collaboration to develop a broader portfolio of genetic testing products through 2032. This enhancement comes after the successful launch of the AmplideX® Nanopore Carrier Plus Kit. The collaboration aims to innovate diagnostic solutions, making genetic testing faster and more accessible to laboratories globally, while combining the expertise of both companies.
Read more →TECHBio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced new advancements in ...
Bio-Techne Corporation has announced advancements in its spatial biology portfolio, specifically in RNAscope ISH technology and Lunaphore COMET. These solutions facilitate the detection of RNA and protein biomarkers on the same tissue section, bridging gaps between translational research and clinical applications. The company will showcase these innovations at the National Society of Histotechnology Convention, emphasizing their role in enhancing diagnostic workflows, especially in cases with limited tissue availability. The advancements highlight Bio-Techne's commitment to improving patient care through innovative research solutions.
Read more →TECHBio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate...
Bio-Techne Corporation has released its 2025 Corporate Sustainability Report, showcasing its dedication to enhancing human health while ensuring environmental protection. The report includes commitments to renewable electricity and greenhouse gas emissions reductions. President and CEO Kim Kelderman highlighted the importance of aligning science with sustainable business practices. The company aims to create impactful value for their employees, customers, and communities through innovation.
Read more →TECHScaleReady Awards G-Rex® Grants to Support Cell and Gene Therapy Manufacturing in California ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that eight (8)...
ScaleReady, in partnership with Wilson Wolf Manufacturing and Bio-Techne Corporation, announced the awarding of eight G-Rex Grants totaling nearly $2 million to support cell and gene therapy manufacturing. This initiative aims to enhance operations at California’s non-profit academic GMP manufacturing facilities, furthering the state's position as a leader in the CGT sector. In addition, ScaleReady introduced a free program focused on improving manufacturing efficiency through a series of LEAN Cell & Gene events.
Read more →TECHBio-Techne to Present at Upcoming Investor Conferences Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: 2025 Wells Fargo Healthcare...
Bio-Techne Corporation (NASDAQ: TECH) has announced its participation in several upcoming investor conferences, including the 2025 Wells Fargo Healthcare Conference and the Baird 2025 Global Healthcare Conference. These presentations are scheduled for September 3, 9, and 10, 2025, respectively. Live webcasts of the presentations will be made available on the company's Investor Relations website. Bio-Techne is a prominent global life sciences firm known for its innovative tools and reagents used in research and diagnostics.
Read more →TECHScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences...
ScaleReady, alongside Wilson Wolf and Bio-Techne, has announced that the Gates Institute has been awarded a $300,000 G-Rex Grant to create a modular CAR T-cell manufacturing platform. This grant aims to enhance the efficiency and adaptability of cell and gene therapy manufacturing processes. The project will leverage a structured Design of Experiments to optimize CAR-T cell manufacturing steps. Additionally, the Gates Institute will gain early access to CellReady's G-CAR-T product, which is designed for high-throughput manufacturing.
Read more →TECHBIO-TECHNE DECLARES DIVIDEND Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended...
Bio-Techne Corporation has announced a dividend of $0.08 per share for the quarter ending June 30, 2025, which will be payable on August 29, 2025, to shareholders of record on August 18, 2025. The announcement reflects Bio-Techne's financial strength, reporting approximately $1.2 billion in net sales for fiscal 2025. The Board of Directors will consider future cash dividends quarterly, indicating a commitment to shareholder returns. Bio-Techne is recognized for providing innovative tools and bioactive reagents for research and clinical diagnostics.
Read more →TECHBio-Techne Releases Fourth Quarter Fiscal 2025 Results Minneapolis/
Bio-Techne Corporation reported its financial results for Q4 FY2025, highlighting a 3% increase in organic revenue to $317.0 million. Despite this growth, GAAP EPS fell to ($0.11), a significant drop from the previous year's $0.25. Adjusted EPS improved to $0.53, reflecting operational strength in their Protein Sciences and cell therapy segments. The company announced the divestiture of its Exosome Diagnostics business as part of a strategic shift towards high-growth areas. Overall, the report indicates a mixed performance amidst ongoing market uncertainties.
Read more →TECHBio-Techne Announces Exosome Diagnostics Divestiture Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including...
Bio-Techne Corporation (NASDAQ: TECH) has agreed to divest its Exosome Diagnostics Inc. business to Mdxhealth SA. This acquisition includes the ExoDx Prostate test and is expected to strengthen Mdxhealth's position in urology and prostate cancer diagnostics. Bio-Techne anticipates that this strategic move will allow the company to focus on developing innovative and high-margin products. The deal will add $5 million in MDXH stock to Bio-Techne's assets and is set to be completed in the first quarter of fiscal 2026.
Read more →TECHScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sidra Medicine, a women and...
ScaleReady, in partnership with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced that Sidra Medicine in Qatar has received a $100,000 G-Rex Grant. This funding will facilitate the development of a CAR-T cell production platform, aimed primarily at pediatric oncology applications. The grant will also enable the implementation of a closed system for G-Rex production, compliant with good manufacturing practices, which is expected to enhance scalability and cost-effectiveness in CAR-T manufacturing. Additionally, Sidra Medicine will gain early access to innovative processes currently under development in collaboration with other industry leaders.
Read more →TECHScaleReady announces multiple G-Rex® Grants have been awarded to investigators at University of Minnesota's Center for Genome Engineering ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that three...
ScaleReady, together with Wilson Wolf Manufacturing and Bio-Techne Corporation, announced the awarding of G-Rex Grants totaling $665,000 to three investigators at the University of Minnesota's Center for Genome Engineering. The grants will support the development of various cell therapies, including treatments for advanced epithelial ovarian cancer and Batten Disease. This funding is part of ScaleReady's ongoing commitment to advancing the field of cell and gene-modified cell therapy, with over $40M allocated through the G-Rex Grant Program. Additionally, ScaleReady has introduced a new program to enhance CGT manufacturing processes.
Read more →TECHBio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a....
Bio-Techne Corporation has announced that it will host a conference call and webcast on August 6, 2025, at 8:00 a.m. CDT to discuss its fourth quarter and fiscal 2025 financial results. The call will be accessible via dial-in and a webcast link, allowing for broad participation. A recorded version will also be available after the live event for those unable to attend.
Read more →TECHBio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays,...
Bio-Techne Corporation has entered a strategic partnership with Spear Bio to distribute next-generation ultrasensitive immunoassays capable of detecting low-abundance biomarkers in neurology. The initial focus will be on key Alzheimer's disease biomarkers, leveraging Spear Bio's innovative SPEAR technology. This collaboration aims to improve early interventions and research capabilities in neurodegenerative diseases. The partnership is expected to broaden the application of Spear Bio's technology in clinical trials and patient access to treatments.
Read more →TECHBio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of...
Bio-Techne Corporation announced that its Simple Western Technology was instrumental in the FDA approval of ZEVASKYN, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The technology enabled precise identification and quantification of Collagen VII, a key therapeutic target, thus supporting lot release testing in a GMP setting. ZEVASKYN aims to address the unmet medical needs of RDEB patients, who currently have no durable therapies available.
Read more →TECHBio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP...
Bio-Techne Corporation has entered into a distribution agreement with the U.S. Pharmacopeia (USP) to sell USP monoclonal antibody and AAV reference standards. This collaboration aims to support the development and commercialization of monoclonal antibodies and gene therapies by providing quality benchmarks essential for regulatory compliance. Both companies emphasize the importance of maintaining high quality in biotherapeutic products, thereby enhancing patient safety in drug development. The partnership enables Bio-Techne to offer advanced analytical solutions to the scientific community globally.
Read more →TECHScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has...
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced that Immuneel Therapeutics has received a $150,000 G-Rex Grant. The grant will aid in the process development to enhance the scalability and cost-effectiveness of CAR-T cell manufacturing in India. This initiative aims to address the significant blood cancer burden in the country and ensure greater accessibility to advanced cancer therapies. The program highlights the collaboration's commitment to improving cancer treatment landscapes in India.
Read more →TECHBio-Techne to Present at Investor Conferences Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: William Blair 45th Annual Growth...
Bio-Techne Corporation (NASDAQ: TECH) has announced its participation in several upcoming investor conferences, including the William Blair 45th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference. These presentations provide an opportunity for Bio-Techne to connect with investors and showcase its innovative products. With a diverse portfolio of research and clinical diagnostic tools, the company has demonstrated strong financial performance, generating around $1.2 billion in net sales in fiscal 2024.
Read more →TECHScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA) ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady announced today three G-Rex Grants...
ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, has awarded three G-Rex Grants totaling $1,025,000 to researchers at the University of Southern California and the Children's Hospital of Los Angeles. The funding will advance various cell and gene therapy projects, including novel CAR-T cell therapies. Recipients include prominent faculty members who aim to improve manufacturing processes and develop new therapies for metastatic solid tumors and other cancers. This initiative highlights the growing importance of innovative technology in the field of cell therapy.
Read more →TECHBio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025 Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the ...
Bio-Techne Corporation (NASDAQ: TECH) is set to showcase its latest developments in spatial biology and cell and gene therapy at the ASGCT 2025 meeting in New Orleans from May 13 to 17. The company will highlight innovations such as the RNAscope™ workflow and ProPak™ GMP cytokines aimed at enhancing cell therapy manufacturing. Additionally, Bio-Techne will present a talk on protein quantitation applications that support gene therapy development. CEO Kim Kelderman stated that the conference underscores their commitment to advancing safe and effective therapies.
Read more →TECHBio-Techne to Present at the BofA Securities 2025 Health Care Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities...
Bio-Techne Corporation has announced that its CEO, Kim Kelderman, will present at the BofA Securities 2025 Health Care Conference on May 13, 2025. The event highlights Bio-Techne's ongoing commitment to engaging with the investment community. The presentation will be accessible via a live webcast, indicating openness and transparency with stakeholders. As a notable player in the life sciences sector, Bio-Techne's participation in this conference may enhance its corporate visibility and investor relations.
Read more →TECHBIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS Minneapolis/
Bio-Techne Corporation reported its financial results for the third quarter of fiscal 2025, highlighting a 6% organic revenue growth to $316.2 million. While adjusted earnings per share improved to $0.56 from $0.48, GAAP earnings per share fell to $0.14 from $0.31. The Protein Sciences segment saw significant growth, contributing to an adjusted operating margin of 34.9%. Nevertheless, GAAP operating income declined by 42%, which was influenced by a non-recurring arbitration award.
Read more →TECHBIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended...
Bio-Techne Corporation (NASDAQ: TECH) has announced a quarterly dividend of $0.08 per share payable on May 30, 2025, to shareholders of record on May 19, 2025. Additionally, the Board of Directors has approved a new share repurchase program authorizing the buyback of up to $500 million of common stock, which begins on May 8, 2025. This new program replaces the previous one and reflects the company's commitment to enhance shareholder value. The share repurchase will depend on various market factors and economic conditions.
Read more →TECHScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc. ScaleReady, in collaboration with Wilson Wolf, Bio-Techne Corporation and CellReady, today announced that A2 Biotherapeutics, Inc. ( A2 ) has been...
ScaleReady, in collaboration with Wilson Wolf, Bio-Techne Corporation, and CellReady, has awarded A2 Biotherapeutics a $300,000 G-Rex Grant. This funding will facilitate the development and qualification of a G-Rex-based production system for evaluating cell therapies. A2 aims to leverage the grant to enhance its CAR-T pipeline and the G-CART process for efficient manufacturing. The G-Rex Grant Program has been extended with millions in additional funding, enhancing support for organizations involved in cell and gene-modified cell therapy.
Read more →TECHScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March Biosciences has been...
ScaleReady announced that March Biosciences has received a $200,000 G-Rex Grant aimed at advancing the manufacturing of MB-105, an investigational CAR-T cell therapy targeting CD5 for T-cell lymphomas. The funding will facilitate a robust cGMP manufacturing process, enabling March to overcome scalability challenges. Additionally, MB-105 recently attained orphan drug designation from the U.S. FDA. The G-Rex Grant program has been extended due to its success, indicating strong backing for innovative cell therapies.
Read more →TECHBio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection Bio-Techne Corporation (NASDAQ: TECH), a global provider of cutting-edge life science tools, today announced an Early Access Program for its latest...
Bio-Techne Corporation (NASDAQ: TECH) has launched an Early Access Program for a new assay that enables high-resolution detection of protein proximity within tissues. This technology provides spatial visualization of protein interactions, significantly enhancing research capabilities in molecular signaling and disease processes. The assay is particularly valuable for studying immune checkpoint dynamics and synaptic protein interactions. The scientific team will present proof-of-concept data at the upcoming 2025 AACR annual meeting.
Read more →TECHBio-Techne to Showcase Cutting-Edge Solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest advancements in cancer research tools at the 2025 American...
Bio-Techne Corporation announced its participation in the upcoming 2025 American Association for Cancer Research Annual Meeting, which will be held from April 25-30 in Chicago, IL. At the event, Bio-Techne will present its extensive oncology research tools, including high-performance proteins and automated analysis platforms. The company aims to highlight its innovative solutions that facilitate progress in cancer research and therapeutic development. The event will feature a variety of presentations and poster sessions showcasing groundbreaking research in cancer science.
Read more →TECHBio-Techne to Host Conference Call on May 7, 2025, to Announce Third Quarter Fiscal 2025 Financial Results Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 7, 2025, at 8:00 a.m. ...
Bio-Techne Corporation announced that it will host a conference call and webcast to discuss its third quarter fiscal 2025 financial results on May 7, 2025, at 8:00 a.m. CDT. The company has generated approximately $1.2 billion in net sales for fiscal 2024. Investors can access the call through a dial-in number or through a webcast. Additionally, there will be a recorded rebroadcast for those unable to participate in the live event.
Read more →TECHLeica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell...
Bio-Techne Corporation announced an expansion of its partnership with Leica Biosystems to improve spatial multiomics research capabilities. This collaboration will feature the automation of the RNAscope™ Multiomic LS Assay and introduce protease-free workflows. The RNAscope™ assay allows for the simultaneous detection of multiple biomarkers while maintaining tissue integrity, enhancing the application of spatial biology in both research and clinical settings. This partnership builds on a relationship established in 2015, aimed at streamlining in-situ hybridization workflows.
Read more →TECHBio-Techne Announces New Customer Experience Centre in Düsseldorf, Germany Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across...
Bio-Techne Corporation (NASDAQ: TECH) announced plans to open a new Customer Experience Centre in Düsseldorf, Germany, by summer 2026. This centre aims to serve customers across the Europe, Middle East, and Africa (EMEA) region and supports the company's long-term growth strategy. The facility will feature a state-of-the-art Demonstration Laboratory to showcase Bio-Techne's instrument portfolio and enable hands-on experience. Its location in Düsseldorf was selected due to the city's thriving life sciences sector and its strategic proximity to other European markets.
Read more →TECHBio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care ...
Bio-Techne Corporation announced advancements in RNAscope technology aimed at enhancing biomarker detection and improving pathology workflows. These developments will be presented during the USCAP Annual Meeting in Boston from March 22-27, where leading pathologists will discuss their applications of the technology. Dr. Matt McManus highlighted the significance of these innovations in clinical and translational research. Bio-Techne, a global leader in life sciences tools, aims to enhance patient care through these initiatives.
Read more →TECHBio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands...
Bio-Techne Corporation has commenced the shipment of its Leo™ System, utilizing Simple Western™ Technology. This innovative system enhances research efficiency by enabling scientists to complete studies with fewer resources. Beta testers have reported satisfaction with Leo's performance and versatility across various applications in the protein sciences field. The company plans to showcase data on Leo's performance in an upcoming webinar.
Read more →TECHBio-Techne Launches New Panel Resolving Hard-to-Decipher Carrier Screening Genes Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, has teamed up with Oxford Nanopore Technologies to launch...
Bio-Techne Corporation announced the launch of the AmplideX Nanopore Carrier Plus Kit, developed in collaboration with Oxford Nanopore Technologies. This innovative genetic panel aims to enhance carrier screening research by resolving challenging genes that conventional short-read sequencing cannot analyze. The kit offers a more comprehensive sequencing solution than previous methods and includes supporting software that simplifies data analysis. Designed for research use only, it specifically targets prevalent genes contributing to genetic disorders and helps laboratories implement a streamlined testing workflow.
Read more →TECHBio-Techne to Present at Investor Conferences Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: TD Cowen 45th Annual Health Care...
Bio-Techne Corporation (NASDAQ: TECH) announced its participation in several upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. The presentations are scheduled for March 4, 2025, March 11, 2025, and March 12, 2025. A live webcast of the presentations will be available on the company's Investor Relations website. Bio-Techne continues to bolster its presence in the life sciences sector, supporting research and clinical diagnostics with a vast array of products.
Read more →TECHBio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse...
Bio-Techne Corporation has launched an expanded menu of RNAscope probes aimed at improving spatial biology research for human and mouse transcriptomes. This development allows customers to accelerate the validation of RNA biomarkers and streamline research workflows, particularly in single-cell genomics and therapeutic response studies. The probes are available in both manual and automated formats, compatible with the Lunaphore COMET system, enhancing their usability in translational research and clinical assay development. Bio-Techne continues to expand its offerings in innovative life science tools to support scientific investigations and clinical diagnostics.
Read more →TECHBio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of...
Bio-Techne Corporation has launched the GMP TcBuster non-viral genome engineering system, aimed at enhancing the development of immune and stem cell-based therapies. This release is expected to facilitate the introduction of genetic modifications in cell therapies, such as CAR-T and TCR generation, while reducing costs and timeframe compared to traditional methods. The enhanced transposase allows for multiple gene delivery with maintained efficiency, making it a versatile tool for clinical applications. Bio-Techne's reliable supply chain will support researchers and developers as they transition to clinical trials and commercial manufacturing.
Read more →TECHBIO-TECHNE RELEASES SECOND QUARTER FISCAL 2025 RESULTS Minneapolis/
Bio-Techne Corporation reported its financial results for the second quarter of fiscal 2025, with organic revenue growing 9% to $297.0 million and improved GAAP earnings per share of $0.22. The Protein Sciences segment saw significant growth at 8%, while the Diagnostics and Spatial Biology segment grew by 12%. Despite these positive results, the operating margin in the Diagnostics segment decreased compared to the previous year. Overall, the performance indicates a strong execution from the company amidst improving biopharma market conditions.
Read more →TECHBio-Techne Appoints Dr. Amy E. Herr to Board of Directors Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's...
Bio-Techne Corporation has appointed Dr. Amy E. Herr as an independent director on its Board of Directors, effective February 1, 2025. Dr. Herr, a Chancellor's Professor at UC Berkeley and Vice President of the Chan Zuckerberg Biohub Network, brings a wealth of experience in bioengineering and leadership in various scientific initiatives. Her appointment completes a succession process for retiring directors and is expected to enhance the company's strategic focus on proteomic analytical instruments. Executives at Bio-Techne expressed optimism about her role and contributions to the board.
Read more →TECHScaleReady Announces a G-Rex® Grant has been awarded to BrainChild Bio ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that BrainChild Bio has been...
ScaleReady, in partnership with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, has awarded a $300,000 G-Rex Grant to BrainChild Bio. This funding will facilitate the development of BCB-276, an autologous CAR-T therapy aimed at treating diffuse intrinsic pontine glioma (DIPG), a pediatric brain tumor that has no approved treatment. BrainChild Bio plans to initiate a multi-center Phase 2 pivotal clinical trial for this therapy in 2025. The G-Rex Grant Program is part of a $20 million initiative to support advancements in cell and gene-modified cell therapy development and manufacturing.
Read more →TECHBio-Techne to Host Conference Call on February 5, 2025, to Announce Second Quarter Fiscal 2025 Financial Results Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, February 5, 2025, at 8:00 ...
Bio-Techne Corporation announced a conference call to discuss its second quarter fiscal 2025 financial results on February 5, 2025, at 8:00 a.m. CST. Interested parties can participate via phone or a webcast. A recorded rebroadcast will also be available after the live event. This initiative reflects the company's commitment to transparency regarding its financial performance.
Read more →TECHBio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of new designer proteins engineered using...
Bio-Techne has announced the launch of new designer proteins engineered through advanced AI design platforms, aimed at enhancing cell therapy and regenerative medicine. The expanded portfolio includes various agonists and is designed to improve cell culture performance and optimize cell expansion. These innovations reflect Bio-Techne's commitment to delivering high-performance solutions to advance clinical and research applications in the life sciences sector.
Read more →TECHBIO-TECHNE TO PRESENT AT PHACILITATE ADVANCED THERAPIES WEEK 2025 Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products...
Bio-Techne Corporation (NASDAQ: TECH) announced it will present at Phacilitate's Advanced Therapies Week from January 20-23, 2025, in Dallas, Texas. The company will showcase its innovative ProPak GMP cytokines and other products that enhance cell and gene therapy development and manufacturing. Dr. David Hermanson will lead a breakout session on closed system manufacturing, discussing strategies for flexibility and scalability in cell therapy programs. The presentation follows the integration of ProPak cytokines with G-Rex bioreactors, aiming to streamline T cell manufacturing workflows.
Read more →TECHScaleReady Announces a G-Rex® Grant has been awarded to Seattle Children's Therapeutics ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, today announced that Seattle Children's Therapeutics, a...
ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, has announced that Seattle Children's Therapeutics has been awarded a $125,000 G-Rex Grant. This grant will support the integration of advanced technologies into the CAR-T cell therapy manufacturing process. The funding will also give Seattle Children's access to specialized G-Rex bioreactors and Bio-Techne's GMP-grade cytokines, aiming to improve manufacturing efficiency for future CAR-T trials. Additionally, the G-Rex Grant Program provides significant resources and expertise for participants, promoting advancements in cell and gene-modified therapies.
Read more →TECHBIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies ...
Bio-Techne Corporation (NASDAQ: TECH) announced that it has won another legal claim against Miltenyi Biotec B.V. & Co. KG for unlawfully reverse engineering its proprietary antibodies. The Cologne Regional Court found that Miltenyi's antibodies were identical to Bio-Techne's R&D Systems branded products. As a result, Bio-Techne is entitled to monetary damages and reimbursement for costs incurred during the legal proceedings. The CEO expressed satisfaction with the court's decision and emphasized the company’s commitment to defending its intellectual property. Miltenyi has the option to appeal the ruling.
Read more →TECHBIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 43rd Annual J.P. ...
Bio-Techne Corporation (NASDAQ: TECH) has announced that Kim Kelderman, the President and CEO, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 14, 2025, at 10:30 a.m. PST, and will be accessible via a live webcast on the company's Investor Relations website. Bio-Techne is recognized for its innovative tools and reagents used in research and clinical diagnostics, generating significant net sales in the previous fiscal year.
Read more →TECHBIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and...
Bio-Techne Corporation (NASDAQ: TECH) has announced a strategic co-marketing and co-promotion agreement aimed at enhancing biotherapeutic characterization. The collaboration involves joint activities including webinars, conference presentations, and the release of an application note. The initiative seeks to integrate the capabilities of both companies to improve laboratory workflows and expedite the development of life-saving therapies. This strategic effort signifies a forward step in the partnership, leveraging combined expertise in the biopharma sector.
Read more →TECHScaleReady awards a G-Rex® Grant to Moonlight Bio ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio...
ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, has awarded a G-Rex Grant to Moonlight Bio to support the development of their CAR T cell therapy aimed at solid tumors. This grant facilitates access to a cost-effective and scalable manufacturing platform, enabling Moonlight to advance their IND-enabling studies. Furthermore, the initiative is part of a $20 million program designed to support cell and gene therapy development, offering significant resources and expertise to recipient companies.
Read more →TECHBIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical ...
Bio-Techne Corporation announced a distribution agreement with MedSanTek, allowing MedSanTek to distribute Bio-Techne's extensive portfolio of brands across Turkey. This partnership aims to enhance access to Bio-Techne's innovative research and clinical diagnostic products in the region. MedSanTek is recognized for its expertise in in vitro diagnostics and has established a strong reputation in Turkey and Azerbaijan's life sciences sectors. The collaboration is expected to improve scientific research and medical advancements in these markets.
Read more →TECHBIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay....
Bio-Techne Corporation has announced the launch of a new ESR1 mutation monitoring assay under its Asuragen brand. This highly sensitive assay is designed to detect mutations linked to hormone receptor-positive metastatic breast cancer, which can emerge following endocrine therapies. It will be showcased at the San Antonio Breast Cancer Symposium. The assay's capability to detect multiple mutations at high sensitivity could greatly benefit clinical research by enabling earlier identification of treatment resistance.
Read more →TECHBIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global ...
Bio-Techne Corporation (NASDAQ: TECH) has announced that its CEO, Kim Kelderman, will present at the Citi 2024 Global Healthcare Conference on December 4, 2024. This presentation signifies Bio-Techne's commitment to engaging with the healthcare investment community and showcasing its contributions to life sciences. The event will offer insights into the company’s innovations and its role in research and clinical diagnostics.
Read more →TECHBIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical ...
Bio-Techne Corporation has entered into a distribution agreement with Leader Life Sciences, allowing the latter to distribute Bio-Techne's products in the Gulf Cooperation Council countries. This partnership aims to enhance the availability of innovative life sciences tools and bioactive reagents to the research and diagnostic community in the region. The collaboration is expected to leverage Leader Life Sciences' extensive distribution network and expertise to catalyze scientific advancements across the GCC.
Read more →TECHBIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative...
Bio-Techne Corporation has formed a strategic partnership with ALZpath, Inc. to enhance research and treatment avenues for neurodegenerative diseases, particularly Alzheimer's disease. This collaboration will utilize Bio-Techne's advanced immunoassay platform alongside ALZpath's proprietary pTau217 antibody, which is essential for detecting biomarkers linked to Alzheimer's. Both companies express optimism about the partnership's potential to drive significant advancements in this critical field of study, particularly as global Alzheimer's cases continue to rise. The combined technology aims to provide researchers with a powerful tool to explore new treatment methods.
Read more →TECHBIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO Bio-Techne Corporation (NASDAQ: TECH) today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP)...
Bio-Techne Corporation (NASDAQ: TECH) announced its participation at the AMP 2024 Annual Meeting & Expo set for November 19-23 in Vancouver, where it will showcase novel solutions for breast cancer monitoring and carrier screening. Asuragen, a Bio-Techne brand, will exhibit advanced research products and conduct workshops focusing on high-sensitivity variant detection and complex genetic alterations. The event reflects Bio-Techne's ongoing commitment to enhance clinical diagnostics and laboratory efficacy through innovative technologies and educational initiatives.
Read more →TECHUPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology...
Bio-Techne Corporation has successfully achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators, upgrading its classification from Class C to Class B. This certification ensures that their products meet stringent EU regulations for in-vitro diagnostic devices. The company emphasizes its commitment to providing high-quality products that improve patient testing accuracy in laboratory settings. Dr. Matt McManus, the President of Bio-Techne's Diagnostics & Spatial Biology Segment, expressed excitement about offering certified products to healthcare professionals.
Read more →TECHBIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology...
Bio-Techne Corporation (NASDAQ: TECH) has announced that it has received In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms adherence to EU guidelines for in-vitro diagnostic devices, assuring customers of their quality and reliability in laboratory settings. The company emphasizes its commitment to improving patient outcomes by providing compliant and rigorously tested products.
Read more →TECHBIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference...
Bio-Techne Corporation (NASDAQ: TECH) has announced its participation in several upcoming investor conferences. These include the UBS Global Healthcare Conference on November 12, the Stifel 2024 Healthcare Conference on November 19, and the Stephens NASH 2024 Conference on November 20. Investors can access a live webcast of these presentations through the company’s Investor Relations website. The announcement reflects Bio-Techne's commitment to engage with its stakeholders and share insights about its operations in the life sciences industry.
Read more →TECHScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation and CellReady, has awarded G-Rex Grants totaling $475,000 to...
ScaleReady, alongside Wilson Wolf Manufacturing and Bio-Techne Corporation, has awarded G-Rex Grants totaling $475,000 to three prominent researchers at Baylor College of Medicine's Center for Cell and Gene Therapy. The grants will support the development of innovative therapies, including tumor-associated neoantigen specific T cell therapies for acute myeloid leukemia and the establishment of 3D tumor spheroid models. This initiative reflects ScaleReady's ongoing commitment to advancing cell and gene-modified cell therapy through its G-Rex technology and collaboration with leading experts in the field.
Read more →TECHBIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery...
Bio-Techne Corporation (NASDAQ: TECH) will present its advanced portfolio at the Society for Immunotherapy of Cancer's 39th Annual Meeting in Houston, Texas. The company is focusing on its spatial biology innovations, including products from Advanced Cell Diagnostics and Lunaphore, aimed at improving cancer research and therapeutic development. Scientists from Bio-Techne will also showcase their work through various poster presentations highlighting new assay technologies and research methodologies. The overall emphasis is on enhancing patient outcomes through tailored immunotherapies and diagnostic tools.
Read more →TECHLUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH Bio-Techne Corporation (NASDAQ: TECH) today announced the release of clinically relevant spatial biology data. The data was generated using...
Bio-Techne Corporation has launched spatial biology data generated from its Lunaphore COMET platform, focusing on immunotherapy for metastatic melanoma. The data reveals tumor microenvironment features that may predict therapy responses, based on collaborative research with prominent institutions and AI technology. This innovative approach aims to enhance understanding in drug development and improve patient outcomes. The findings will be presented at the upcoming SITC Annual Meeting, showcasing the platform's contribution to advancing clinical research.
Read more →TECHBIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS Minneapolis/
Bio-Techne Corporation (NASDAQ: TECH) reported first quarter fiscal 2025 results, achieving an organic revenue increase of 4% to $289.5 million. The Diagnostics & Spatial Biology segment showed strong performance with a 14% organic growth. While adjusted EPS slightly improved, GAAP EPS fell due to a significant decrease in operating income, affecting margins. The company expressed optimism about recovery in the biotech market, supported by favorable funding and ongoing growth in their product offerings.
Read more →TECHScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH), today announced that Luminary Therapeutics has ...
ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, announced that Luminary Therapeutics has received a $300,000 G-Rex Grant. This funding will facilitate the process development and early studies for several novel CAR γδ T cell therapies aimed at treating autoimmune conditions. These therapies utilize advanced technology including an 'immune cloaking' mechanism and promise improved efficiency. Luminary anticipates filing multiple IND applications to begin Phase 1 clinical trials in the near future.
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON OCTOBER 30, 2024, TO ANNOUNCE FIRST QUARTER FISCAL 2025 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, October 30, 2024, at 8:00 ...
Bio-Techne Corporation (NASDAQ: TECH) has scheduled a conference call and webcast for October 30, 2024, at 8:00 a.m. CDT to discuss its first quarter fiscal 2025 financial results. Investors can access the call via dial-in or through a webcast link provided by the company. A recorded rebroadcast will also be available following the live event. This initiative highlights the company's focus on communication with shareholders about its financial performance.
Read more →TECHScaleReady announces a G-Rex® Grant has been awarded to LIfT Biosciences ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, and LIfT BioSciences, ('LIfT' or...
LIfT Biosciences has received a $300,000 G-Rex Grant to support the clinical manufacturing of its innovative Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform. This collaboration, which includes ScaleReady, Wilson Wolf Manufacturing, and Bio-Techne Corporation, aims to establish a scalable manufacturing process for N-LIfT, designed to improve treatment outcomes in solid tumors. The G-Rex platform is recognized for its efficiency in gene-modified cell therapy development, positioning LIfT for a potentially significant advancement in cancer treatment.
Read more →TECHScaleReady announces a G-Rex® Grant has been awarded to renowned cancer immunologist Dr. Christopher A. Klebanoff ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Christopher...
ScaleReady, in collaboration with Bio-Techne Corporation, announced the awarding of a G-Rex Grant to Dr. Christopher A. Klebanoff for his development of a novel CD8α/β-armored TCR-T cell therapy targeting a specific neoantigen. The $300,000 grant will aid in process development and clinical manufacturing, facilitating a Phase 1 clinical trial. The initiative aims to provide significant treatment options for cancer patients, leveraging advanced manufacturing techniques and innovative therapies. Early patient enrollment is anticipated due to MSK's prescreening program for mutated genes.
Read more →TECHLUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, Lunaphore, is partnering with Discovery Life Sciences...
Bio-Techne Corporation's Lunaphore has partnered with Discovery Life Sciences to incorporate its high-throughput COMET platform into Discovery's lab services. This collaboration is expected to enhance specialized lab offerings and facilitate the development of CLIA-compliant hyperplex tests for pharmaceutical companies. With robust automation and multiomics capabilities, Lunaphore's technology aims to improve clinical research and patient outcomes across various therapeutic areas.
Read more →TECHBIO-TECHNE TO PRESENT AT NEUROSCIENCE 2024-THE SOCIETY FOR NEUROSCIENCE (SfN) ANNUAL MEETING Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming...
Bio-Techne Corporation (NASDAQ: TECH) has announced its participation in the Society for Neuroscience annual meeting, Neuroscience 2024, to be held in Chicago from October 5-9, 2024. The company will showcase its advanced portfolio of life science reagents, immunoassays, and proteomic analytical instruments designed to enhance neuroscience research. Presentations will include studies on aging in the brain and intracellular signaling in Alzheimer's disease, highlighting the use of innovative technologies like the Simple Western automated system. This event marks an important opportunity for Bio-Techne to underscore its contributions to drug discovery and treatment development.
Read more →TECHBIO-TECHNE ISSUES 2024 CORPORATE SUSTAINABILITY REPORT Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its...
Bio-Techne Corporation (NASDAQ: TECH) has released its 2024 Corporate Sustainability Report, highlighting its advancements in Environmental, Social, and Governance (ESG) initiatives. The report details the company's commitments to improving sustainability, including a letter of commitment to reduce greenhouse gas emissions and notable achievements in the EcoVadis sustainability assessment. With a corporate culture centered on empowerment, innovation, and operational integrity, Bio-Techne aims to grow responsibly and enhance global healthcare through its products and advancements. The report is available on Bio-Techne's website.
Read more →TECHScaleReady announces a G-Rex® Grant has been awarded to ImmunoScape ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that ImmunoScape...
ImmunoScape Pte. Ltd. has been awarded a $250,000 G-Rex Grant from ScaleReady in collaboration with Wilson Wolf and Bio-Techne Corporation. This grant will assist ImmunoScape in process development and IND-enabling studies for their novel WT1-targeted TCR-T cell therapy. The funding aims to expedite the therapy's clinical readiness and access to proprietary GMP cytokines essential for manufacturing. Additionally, it will support technology transfers and manufacturing batch record generation for FDA submissions planned for 2026.
Read more →TECHScaleReady and Bio-Techne Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to...
ScaleReady and Bio-Techne Corporation have launched the G-Rex optimized ProPak GMP Cytokines, aimed at enhancing the manufacturing process for CAR-T and TCR therapies. This product features a weldable bag containing liquid-formulated GMP-grade cytokines, specifically interleukin-7 and interleukin-15, which simplifies the administration and storage processes. The initiative is expected to lower operating costs and streamline the cell therapy manufacturing workflow, making it advantageous for numerous organizations in the field. Bio-Techne emphasizes their commitment to improving the efficiency of lifesaving therapies through this innovative product.
Read more →TECHScaleReady announces the inaugural G-Rex® Grant has been awarded to Stanford Medicine Laboratory for Cell and Gene Medicine ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Dr. Steve...
ScaleReady, alongside Wilson Wolf Manufacturing and Bio-Techne Corporation, has awarded the first G-Rex Grant to Dr. Steve Feldman of Stanford Medicine's Laboratory for Cell and Gene Medicine. This $300,000 grant aims to accelerate the development of the G-Rex platform for CAR-T cell therapy manufacturing, which will support more clinical trials. The initiative is part of ScaleReady's $20M G-Rex Grant Program, designed to enhance the state of cell and gene-modified cell therapy development and manufacturing.
Read more →TECHBIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following...
Bio-Techne Corporation announced that its CEO, Kim Kelderman, will present at three notable investor healthcare conferences in early September 2024. The conferences include the Morgan Stanley 22nd Annual Global Healthcare Conference, the Wells Fargo Healthcare Conference, and the Baird 2024 Global Healthcare Conference. These presentations aim to provide insights into the company's performance and future strategies to investors. A live webcast of each presentation will be available through Bio-Techne's Investor Relations website.
Read more →TECHBIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS Minneapolis/
Bio-Techne Corporation (NASDAQ: TECH) reported its financial results for the fourth quarter of fiscal 2024, revealing a 1% organic revenue growth. GAAP earnings per share decreased significantly to $0.25 compared to $0.47 the previous year. However, the company experienced substantial growth in its Diagnostics & Genomics segment, with a 9% organic growth rate. Overall cash flow from operations improved by 18%, indicating strong financial execution despite challenges in certain market segments.
Read more →TECHBIO-TECHNE ANNOUNCES NEXT-GENERATION HIGH THROUGHPUT SIMPLE WESTERN SYSTEM Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce the launch of the Leo™ System. This next-generation Simple Western™ instrument offers...
Bio-Techne Corporation has announced the launch of its Leo™ System, a next-generation Simple Western™ instrument designed to enhance throughput, flexibility, and efficiency. The system can simultaneously process up to 100 samples in just three hours, a significant improvement over previous models. With four times the experimental size capacity, it facilitates more robust assay designs for the drug development process. The Leo System is set to begin shipping in 2025, representing a substantial advancement in protein analysis technology.
Read more →TECHBIO-TECHNE ANNOUNCES STRATEGIC INVESTMENT IN SPEAR BIO Bio-Techne Corporation (NASDAQ: TECH) today announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio will use the...
Bio-Techne Corporation has announced its participation in a $45 million Series A funding round for Spear Bio, aimed at enhancing product development and scaling manufacturing. Spear Bio, established in 2021, specializes in ultra-sensitive immunoassays capable of measuring protein biomarkers at extremely low levels. The investment reflects confidence in Spear Bio's proprietary technology, which is expected to facilitate early disease diagnosis, particularly in neurodegenerative disorders. Spear Bio’s assays are compatible with standard qPCR instruments, presenting significant market opportunities.
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 7, 2024, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2024 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a....
Bio-Techne Corporation will host a conference call on August 7, 2024, to discuss its fourth quarter and fiscal 2024 financial results. The call is scheduled for 8:00 a.m. CDT and will be accessible via dial-in or webcast. A recorded replay of the discussion will also be made available for a month following the event. The company continues to demonstrate its commitment to transparency with stakeholders.
Read more →TECHBIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following...
Bio-Techne Corporation has announced that CEO Kim Kelderman will present at several upcoming investor conferences, including the William Blair 44th Annual Growth Conference, Jefferies Global Healthcare Conference, and Goldman Sachs 45th Annual Global Healthcare Conference. These presentations are scheduled for early June 2024, showcasing the company's commitment to engaging with investors. The live webcasts of these events will be available on the company's Investor Relations website, indicating a focus on transparency and investor communication.
Read more →TECHBIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched MauriceFlex™ System at the 72nd ASMS Conference on ...
Bio-Techne Corporation (NASDAQ: TECH) will present its MauriceFlex System at the 72nd ASMS Conference, focusing on innovative applications in protein characterization. The system allows for efficient charge variant fraction collection and integrates with various mass spectrometry methods. Highlights include a breakfast seminar on protein charge heterogeneity and multiple poster presentations showcasing collaborations with industry leaders. The event underscores Bio-Techne's commitment to providing essential tools for advancements in biopharmaceutical development.
Read more →TECHScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced the launch of the...
ScaleReady has launched the G-Rex® Grant Program, a $20 million initiative aimed at advancing cell and gene therapy (CGT) development and manufacturing. This program will support academic and commercial institutions by offering resources, including G-Rex® devices and manufacturing consultation services. Participating programs can receive up to $300,000 to enhance their processes. The initiative is designed to facilitate faster development timelines and improve the transition from research to GMP manufacturing, ultimately leading to increased patient access to crucial therapies.
Read more →TECHBIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink...
Bio-Techne Corporation (NASDAQ: TECH) announced that its President and CEO, Kim Kelderman, will present at the 2024 Leerink Partners Healthcare Crossroads Conference on May 29, 2024. The presentation will be webcast live and aims to provide insights into the company's innovations in life sciences. Bio-Techne is noted for its contribution to research and clinical diagnostics, generating over $1.1 billion in net sales in fiscal 2023.
Read more →TECHBIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of...
Bio-Techne Corporation and Regulus Therapeutics have announced continued collaboration following the release of positive topline results from Regulus' Phase 1b study of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study utilized Bio-Techne’s Simple Western technology for biomarker analysis, demonstrating the efficacy of measuring polycystin levels in urine. This partnership aims to support the development of innovative therapies targeting ADPKD, showcasing Bio-Techne's contributions to advancing clinical research.
Read more →TECHBIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024 Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities...
Bio-Techne Corporation announced that its CEO, Kim Kelderman, will present at the BofA Securities Health Care Conference on May 14, 2024. The presentation is set to take place at 2:20 p.m. PDT, and attendees can access a live webcast through the company's Investor Relations website. Bio-Techne is known for its contributions to life sciences, aiding research and clinical diagnostics with a wide range of products.
Read more →TECHBIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming...
Bio-Techne Corporation will present its workflow solutions for cell and gene therapy at the ASGCT annual meeting from May 7-11, 2024. The company plans to showcase its advanced reagents and analytical instruments at booth #1627. They will host speaker sessions on important topics such as biodistribution safety and protein analytics strategies. Additionally, several scientists will present posters on various aspects of gene therapy and immune cell culture.
Read more →TECHBIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS Minneapolis/
Bio-Techne Corporation reported its financial results for the third quarter of fiscal 2024, highlighting a 2% increase in organic revenue, reaching $303.4 million. Despite the growth, GAAP earnings per share (EPS) fell to $0.31 compared to $0.43 in the same quarter the previous year. The Diagnostics & Genomics segment experienced strong performance with a 10% growth, while overall adjusted operating margin decreased to 33.0%, reflecting challenges amid restructuring costs and market conditions. The firm remains optimistic about its differentiated portfolio and future growth opportunities.
Read more →TECHBIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS Minneapolis
Bio-Techne Corporation has appointed Dr. Judith Klimovsky as an independent director on its Board of Directors, effective April 24, 2024. She will also serve on the Science and Technology Committee. Dr. Klimovsky brings over two decades of experience in biopharma, having held leadership roles at Genmab, Novartis Oncology, Merck & Co., and Bristol-Myers Squibb. Her expertise is expected to be beneficial as Bio-Techne looks to expand its global reach.
Read more →TECHBIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH THERMO FISHER SCIENTIFIC Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical ...
Bio-Techne Corporation has announced a strategic distribution agreement with Thermo Fisher Scientific, effective May 1, 2024. This partnership will allow Thermo Fisher to distribute Bio-Techne's extensive range of products, including antibodies and reagents, throughout Europe. The collaboration is expected to enhance support for researchers and contribute to advancements in scientific research in various fields, including healthcare. Both companies expressed their excitement about the positive impacts of this partnership on the research community.
Read more →TECHBIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker...
Bio-Techne Corporation and Novomol-Dx have announced the development of the Bio-Marker Pathfinder (BMP), a novel ocular biomarker kit for point-of-care applications. This kit aims to address a critical need for improved ocular diagnostics, especially for the millions in India suffering from ophthalmic diseases. The BMP kit is designed to produce actionable clinical data through the analysis of tear samples. Furthermore, the technology may pave the way for future diagnostic applications across a variety of conditions beyond ophthalmic diseases.
Read more →TECHBIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical ...
Bio-Techne Corporation has filed a patent infringement lawsuit against Molecular Instruments in the Unified Patent Court in Europe. The lawsuit claims that Molecular Instruments' HCR 3.0 technology infringes Bio-Techne's RNAscope patented technology. Bio-Techne aims to seek damages and an injunction to stop the infringement in European markets. The company emphasizes its leadership in the space and commitment to defending its intellectual property.
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024, at 8:00 a.m. ...
Bio-Techne Corporation announced that it will host a conference call on May 1, 2024, to discuss its third quarter fiscal 2024 financial results. The call will take place at 8:00 a.m. CDT and will be accessible via a dial-in and webcast. A recorded rebroadcast will be available for those who cannot attend the live event. The announcement highlights the company's ongoing commitment to transparency with investors regarding its financial performance.
Read more →TECHBIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has...
Bio-Techne Corporation announced that its Advanced Cell Diagnostics division has surpassed 10,000 peer-reviewed publications citing the RNAscope technology. This milestone underscores the increasing global adoption of RNAscope, with more than half of these publications released in the past three years. The technology is recognized for its applications across various fields, including cancer and neuroscience, and offers unparalleled sensitivity and specificity. The achievement reflects the scientific community's trust in RNAscope to drive significant advancements in spatial biology.
Read more →TECHBIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE Bio-Techne Corporation (NASDAQ:TECH) today announced it will showcase its portfolio of solutions to advance cancer research from target discovery to...
Bio-Techne Corporation (NASDAQ: TECH) will showcase its innovative solutions and advancements in cancer research at the 2024 AACR Conference in San Diego, California. The company will present high-grade life science reagents, immunoassays, and automated proteomic instruments at its booth, along with a new interactive video experience. Several scientists from Bio-Techne will also present posters on various aspects of drug discovery, including RNA and protein profiling techniques. This presence at the conference underscores Bio-Techne's significant contributions to the development of next-generation cancer therapies.
Read more →TECHBIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative tools and bioactive reagents for the research and clinical diagnostic...
Bio-Techne Corporation (NASDAQ: TECH) has been honored with CiteAb's 'ELISA Kit Supplier of the Year' award, highlighting the strong citation record of its R&D Systems brand products. Additionally, the company's Advanced Cell Diagnostics division received the 'Innovation Award' for its RNAscope™ ISH technology, which facilitates spatial detection of RNA. Bio-Techne was also 'Highly Commended' for its efforts in educational initiatives within spatial biology research. These recognitions underscore the company's continued focus on advancing scientific discovery.
Read more →TECHBIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore, part of Bio-Techne's Spatial Biology Division, is partnering with Nikon...
Bio-Techne Corporation has announced a partnership with Nikon Instruments Inc. to expand access to spatial biology services through the COMET platform. This collaboration will allow US-based biotech, pharma, and academic customers to utilize advanced imaging and analysis technology. The partnership will enhance research capabilities with Lunaphore's automated imaging solutions and image analysis software. This strategic initiative signifies a commitment to innovative research in life sciences and healthcare.
Read more →TECHBIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C...
Bio-Techne Corporation has announced that its subsidiary Asuragen has obtained Class C Certification under the European Union In Vitro Diagnostic Regulation (IVDR) for the QuantideX qPCR BCR-ABL IS Kit. This kit is designed for monitoring chronic myeloid leukemia (CML) patients by quantifying specific transcripts in their blood samples. The certification enhances compliance with updated diagnostic regulations in Europe and underscores Bio-Techne's commitment to quality in molecular diagnostics.
Read more →TECHBIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences ...
Bio-Techne Corporation announced that Will Geist, President of the Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024. This presentation indicates the company's commitment to engaging with investors and highlighting its innovations in the life sciences sector. Bio-Techne has a robust portfolio of products designed for research and clinical diagnostics, generating over $1.1 billion in net sales in fiscal 2023. The event will be accessible via a live webcast for wider audience participation.
Read more →TECHBIO-TECHNE TO PRESENT AT THE BARCLAYS 26th ANNUAL GLOBAL HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Barclays 26th...
Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Kim Kelderman will present at the Barclays 26th Annual Global Healthcare Conference on March 13, 2024. The event is aimed at showcasing the company's developments in the healthcare sector. Interested parties can access a live webcast of the presentation via the Investor Relations website.
Read more →TECHBIO-TECHNE RELEASES SECOND QUARTER FISCAL 2024 RESULTS Minneapolis/
Bio-Techne Corporation (NASDAQ: TECH) reported its financial results for the second quarter of fiscal 2024, indicating a 2% decline in organic revenue. Despite this decline, the company reported an 18% increase in cash flow generated from operations. The earnings report noted significant decreases in GAAP earnings per share and operating income compared to the previous year. However, the company also highlighted positive trends in instrument consumables and academic markets, suggesting some resilience amidst challenging conditions.
Read more →TECHBIO-TECHNE'S ADVANCED CELL DIAGNOSTICS (ACD) SETS NEW STANDARD IN SPATIAL BIOLOGY WITH PROTEASE-FREE RNASCOPE MULTIOMICS Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new...
Bio-Techne Corporation has announced a groundbreaking advancement through its Advanced Cell Diagnostics (ACD) brand, introducing a protease-free RNAscope spatial multiomics workflow. This innovation allows for simultaneous detection of RNA and protein biomarkers on the same slide, significantly enhancing sensitivity and tissue integrity. The new method, suitable for both manual and automated assays, promises to simplify the analysis of subcellular gene expression and multiomic changes, providing valuable insights into disease pathology. ACD plans to showcase its innovative technology at the upcoming Advances in Genome Biology and Technology (AGBT) 2024 General Meeting in Orlando, Florida.
Read more →TECHLUNAPHORE AND ACD REVOLUTIONIZE SPATIAL BIOLOGY RESEARCH WITH THE LAUNCH OF THE FIRST FULLY AUTOMATED, SAME-SECTION, HYPERPLEX MULTIOMICS APPLICATION Bio-Techne Corporation (NASDAQ: TECH) today announced that its spatial biology brands, Lunaphore and Advanced Cell Diagnostics (ACD), will launch the ...
Bio-Techne Corporation (NASDAQ: TECH) has announced the launch of its innovative, fully automated spatial multiomics workflow, developed by its brands Lunaphore and Advanced Cell Diagnostics (ACD). This application allows researchers to analyze RNA and protein biomarkers simultaneously at the subcellular level, significantly advancing predictive biomarker research and drug development. Set to be commercially available in Q2 2024, the solution integrates critical spatial information and enhances throughput, providing a powerful tool for translational research. The multiomics application will be featured at the upcoming Advances in Genome Biology and Technology conference in Orlando, Florida.
Read more →TECHSCIENTISTS AT THE WCBP CONFERENCE HIGHLIGHT ADVANCEMENTS IN PROTEIN BIOTHERAPEUTIC CHARGE HETEROGENEITY CHARACTERIZATION USING THE MauriceFlex™ SYSTEM Bio-Techne Corporation (NASDAQ: TECH) had the honor of welcoming presentations from leading scientists from two major biopharmaceutical companies,...
Bio-Techne Corporation showcased its MauriceFlex™ system at the WCBP conference, where leading scientists from Pfizer and Sanofi presented its impact on biotherapeutic development. The MauriceFlex™ system facilitates automated charge variant characterization and overcomes challenges faced with traditional methods. Key presentations illustrated its application in accelerating AAV gene therapy development and enhancing efficiency in mass spectrometry characterization. The conference underscored the importance of continuous innovation in analytical techniques within the biopharmaceutical sector.
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2024, TO ANNOUNCE SECOND QUARTER FISCAL 2024 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, February 1, 2024, at 8:00...
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call on February 1, 2024, at 8:00 a.m. CST to discuss its second quarter fiscal 2024 financial results. The conference call will be accessible via phone and webcast, allowing both local and international participants to join. A recorded rebroadcast of the call will be available for those unable to attend live. Bio-Techne remains a key player in the biotechnology sector, providing a range of products crucial for biomedical research and diagnostics.
Read more →TECHBIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT Minneapolis/
Bio-Techne Corporation announced the appointment of Matthew F. McManus as President of its Diagnostics and Genomics Segment, effective January 8, 2024. He succeeds Kim Kelderman, who will become the Chief Executive Officer on February 1, 2024. Dr. McManus brings over 20 years of experience and previously held significant leadership roles in life sciences, including with Bio-Techne's Molecular Diagnostics Division. His knowledge and experience are viewed positively by the current COO, who expressed confidence in his ability to drive growth in the segment.
Read more →TECHBIO-TECHNE TO SHOWCASE CELL AND GENE THERAPY MANUFACTURING TOOLS AT PHACILITATE ADVANCED THERAPIES WEEK 2024 Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to enable cell and gene therapy...
Bio-Techne Corporation will present its cell and gene therapy manufacturing solutions at Phacilitate's Advanced Therapies Week from January 16-19, 2024, in Miami. The company's booth will highlight products like the TcBuster transposon system for gene editing and optimized cytokines for immune cell expansion. David Hermanson will give a technical talk on efficiently manufacturing gene-modified CAR-T therapies. Additionally, Bio-Techne will feature its collaboration with ScaleReady, focusing on scalable solutions for CAR-T cell production.
Read more →TECHBIO-TECHNE TO PRESENT AT THE 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, current Chief Operating Officer, and Chief Executive Officer effective...
Bio-Techne Corporation (NASDAQ: TECH) has announced that Kim Kelderman, currently the Chief Operating Officer, will assume the role of Chief Executive Officer on February 1, 2024. He is set to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The company is recognized for its broad range of high-quality scientific products, which are critical in biomedical and clinical research. Bio-Techne reported approximately $1.1 billion in net sales for fiscal 2023.
Read more →TECHBIO-TECHNE ANNOUNCES SUBMISSION OF FDA DRUG MASTER FILE FOR EXCELLERATE GMP IPSC EXPANSION MEDIUM SUPPORTING STEM CELL THERAPY Bio-Techne Corporation (NASDAQ: TECH) today announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for ...
Bio-Techne Corporation announced the submission of a Drug Master File (DMF) for its ExCellerate GMP iPSC Expansion Medium to the FDA. This medium supports regenerative medicine and stem cell therapies by ensuring consistency and reproducibility in stem cell manufacturing. The DMF provides essential details about manufacturing processes that developers can reference when filing Investigational New Drug applications. The product is designed to assist developers in creating therapies more efficiently.
Read more →TECHLUNAPHORE AND SIB AWARDED INNOSUISSE FUNDING TO DEVELOP INNOVATIVE AI-BASED ASSAY DEVELOPMENT TOOLS Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore, a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics, have been...
Bio-Techne Corporation (NASDAQ: TECH) has announced that its brand Lunaphore, in collaboration with the SIB Swiss Institute of Bioinformatics, has received Innosuisse funding for a project focused on developing AI-based assay development tools. The collaboration aims to enhance the adoption of multiplex sequential immunofluorescence technology in spatial biology research. By automating standardized multiplex immunofluorescence protocols, the project seeks to reduce technical complexity and human error. Ultimately, the initiative is expected to improve human health and lower healthcare costs through advanced automated technologies.
Read more →TECHBIO-TECHNE TO PRESENT AT THE 6TH ANNUAL EVERCORE ISI HEALTHCONx CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Kim Kelderman, Chief Operating...
Bio-Techne Corporation (NASDAQ: TECH) will present at the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023. The presentation will be led by CEO Chuck Kummeth and COO Kim Kelderman. Bio-Techne is known for its development and manufacturing of high-quality purified proteins and various diagnostic and genomic products, important for biomedical research and clinical applications. The company reported significant net sales and has a large workforce, reflecting its established position in the biopharma industry.
Read more →TECHBIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: Stifel 2023 Healthcare Conference...
Bio-Techne Corporation (NASDAQ: TECH) has announced its participation in two upcoming investor conferences: the Stifel 2023 Healthcare Conference and the Stephens Annual Investment Conference, scheduled for November 15, 2023. Attendees can access a live webcast of the presentations via Bio-Techne's Investor Relations website. The company is recognized for its extensive range of high-quality products including proteins, reagents, and diagnostic tools, contributing significantly to biomedical research and clinical applications.
Read more →TECHASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCE Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing...
Bio-Techne Corporation (NASDAQ: TECH) announced that its brand Asuragen will present new clinical laboratory testing data at the AMP 2023 Conference in Salt Lake City, Utah, from November 14-18. The new data focuses on areas such as cystic fibrosis variant detection and advances in cancer monitoring. Attendees will have opportunities to engage in workshops and see poster presentations outlining these innovations. Additionally, Dr. Jordan Laser of Bio-Techne will receive the AMP Meritorious Service Award during the event, spotlighting his contributions to advancing molecular pathology.
Read more →TECHBIO-TECHNE RELEASES FIRST QUARTER FISCAL 2024 RESULTS Minneapolis/
Bio-Techne Corporation reported its financial results for the first quarter of fiscal 2024, revealing a 2% increase in organic revenue to $276.9 million. While the company saw notable growth in certain sectors, such as a 49% increase in volume for its ExoDx prostate test, GAAP earnings per share fell to $0.31 from $0.55 the previous year. The company's CEO, Chuck Kummeth, stated that despite challenges in the biotech funding environment, their disciplined approach allowed them to maintain profitability. The newly appointed CEO, Kim Kelderman, will take over in February 2024, as Kummeth plans to retire in July 2024.
Read more →TECHLEADING RESEARCH INSTITUTES TO PRESENT NEW DATA USING LUNAPHORE'S COMET™ TECHNOLOGY AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 38th ANNUAL MEETING Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore, a Bio-Techne brand, will have its technologies featured in several...
Bio-Techne Corporation has announced that its brand Lunaphore will showcase its COMET™ technology at the upcoming SITC 38th Annual Meeting in San Diego from November 1-5, 2023. The technology is noted for its unmatched spatial biology capabilities and will be featured in presentations detailing novel anti-cancer therapy approaches. Researchers aim to demonstrate the efficacy of the hyperplex-based characterization of tumor microenvironments and innovative immunotherapy enhancements. Lunaphore will also provide live demonstrations of the COMET™ system at the event.
Read more →TECHBIO-TECHNE
Bio-Techne Corporation announced the appointment of Kim Kelderman as President and CEO, effective February 1, 2024. Kelderman will transition from his current role as President of the Diagnostics and Genomics Segment and will also take on the responsibilities of COO starting November 1, 2023. His extensive experience in leading global life science businesses positions Bio-Techne for further growth, and he succeeds Chuck Kummeth, who is retiring after a decade of leadership. The company has outlined a strong growth strategy under Kelderman’s leadership going forward.
Read more →TECHBIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER Bio-Techne Corporation (NASDAQ: TECH) today announced that its Board of Directors appointed Kim Kelderman as President and Chief Executive Officer...
Bio-Techne Corporation has appointed Kim Kelderman as its new Chief Executive Officer, effective February 1, 2024. Kelderman, who will also serve as the Chief Operating Officer starting November 1, 2023, succeeds Chuck Kummeth, who is retiring after a decade of leadership. Kelderman has been with Bio-Techne since 2018, demonstrating success in expanding the company’s diagnostics and genomics segments. The board expresses confidence in his ability to continue driving growth and innovation in the company’s strategic initiatives.
Read more →TECHBIO-TECHNE ACHIEVES ISO 13485 CERTIFICATION FOR ITS WALLINGFORD, CT MANUFACTURING FACILITY Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and Immunoassays today announced that its Wallingford, CT facility...
Bio-Techne Corporation has achieved ISO 13485 certification for its manufacturing facility in Wallingford, CT, which is recognized globally as a standard for quality in medical device and in vitro diagnostic production. This certification highlights the company's commitment to excellence and the reliable design and manufacturing processes for its products. The Simple Plex assays, which are validated for over 250 protein targets, exemplify the company's dedication to minimizing errors and ensuring data quality in clinical applications. Bio-Techne aims to expand its contributions to regulated applications across various healthcare sectors.
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON OCTOBER 31, 2023, TO ANNOUNCE FIRST QUARTER FISCAL 2024 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, October 31, 2023, at 8:00 a....
Bio-Techne Corporation (NASDAQ: TECH) announced a conference call scheduled for October 31, 2023, at 8:00 a.m. CDT to discuss its first quarter fiscal 2024 financial results. The conference call will provide access for both domestic and international callers, and a recorded rebroadcast will be available shortly after the event. Bio-Techne is recognized for its strong product portfolio, which includes various solutions for biomedical research and diagnostics.
Read more →TECHDR. JORDAN LASER AWARDED AMP MERITORIOUS SERVICE AWARD Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Jordan Laser has received the AMP Meritorious Service Award from the Association for...
Bio-Techne Corporation announced that Dr. Jordan Laser has been awarded the AMP Meritorious Service Award for his outstanding work in molecular diagnostics. As Senior Director of Clinical and Medical Affairs, he has played a significant role in advocating for proper regulation and reimbursement of molecular testing, especially during the COVID-19 pandemic. Dr. Laser's contributions to the Association for Molecular Pathology and the diagnostics industry at large have been pivotal in promoting innovation and improving patient access to testing. The award underlines the increasing significance of this field within healthcare.
Read more →TECHSCIENTISTS AT CE PHARM CONFERENCE DESCRIBE HOW Maurice™ AND MauriceFlex™ SYSTEMS TRANSFORM THEIR PROTEIN ANALYSIS Bio-Techne Corporation (NASDAQ: TECH) was pleased to host presentations by three industry experts yesterday at the CASSS CE Pharm conference in...
At the recent CASSS CE Pharm conference in Philadelphia, Bio-Techne Corporation (NASDAQ: TECH) hosted presentations by experts from Eli Lilly, Mereana Therapeutics, and Pfizer, who discussed the benefits of the Maurice and MauriceFlex systems in protein analysis. The presentations illustrated the systems' capabilities in automating protein charge analysis and size analysis, with specific case studies highlighting improved workflows. Key findings included the development of comparability protocols for protein charge heterogeneity analysis and successful identification of charge variants in monoclonal antibodies. The results indicate these systems could significantly enhance protein characterization in biotherapeutic development.
Read more →TECHBIO-TECHNE INTEGRATES ITS MAURICE SYSTEM WITH THE THERMO SCIENTIFIC CHROMELEON CHROMATOGRAPHY DATA SYSTEM Bio-Techne Corporation (NASDAQ: TECH) is pleased to launch the new Maurice Chromeleon Driver Kit, which enables control of its Maurice™ instrument...
Bio-Techne Corporation has announced the launch of the Maurice Chromeleon Driver Kit, which integrates the Maurice instrument with the Thermo Scientific Chromeleon Chromatography Data System. This new integration allows for enhanced data analysis capabilities, particularly within laboratories that utilize Chromeleon CDS. The collaboration aims to improve workflows, elevate productivity, and provide greater insights into protein analysis. President Will Geist emphasized the commitment to advancing analytical technologies through this integration.
Read more →TECHBIO-TECHNE ISSUES 2023 CORPORATE SUSTAINABILITY REPORT Bio-Techne Corporation (NASDAQ: TECH) today issued its 2023 Corporate Sustainability Report (CSR), detailing the continued progress advancing its...
Bio-Techne Corporation (NASDAQ: TECH) has published its 2023 Corporate Sustainability Report, highlighting significant advancements in its Environmental, Social and Governance (ESG) initiatives. The report is structured around four main pillars, reflecting the company’s commitment to sustainability and corporate culture. CEO Chuck Kummeth praised the team's progress and dedication to supporting innovation and operational integrity. The updated CSR is accessible on Bio-Techne’s website, highlighting the organization's mission to foster a sustainable future in healthcare.
Read more →TECHCizzle and Bio-Techne Announce Completion of Evaluation Programme for Detection of CIZ1B Using ProteinSimple Branded Simple Western™ Platform Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc, the UK-based diagnostics developer, are pleased to announce recent...
Bio-Techne Corporation and Cizzle Biotechnology Holdings plc have successfully completed an evaluation program focusing on CIZ1B, a cancer biomarker associated with early-stage lung cancer. The use of the Simple Western platform is intended to enhance high throughput detection capabilities. The collaboration aims to innovate early detection methods for lung cancer, a field of growing market importance, especially as new guidelines expand the eligibility for screening in the U.S. This affiliation holds potential for significant advancements in patient outcomes.
Read more →TECHBIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor healthcare conferences: 2023 Wells Fargo...
Bio-Techne Corporation (NASDAQ: TECH) has announced its participation in several upcoming investor healthcare conferences, including the Wells Fargo Healthcare Conference and the Baird 2023 Global Healthcare Conference. The presentations are scheduled between September 6 and September 13, 2023. This move highlights the company's ongoing commitment to connecting with investors and showcasing its broad range of products and services in the biopharma sector. Bio-Techne's extensive portfolio includes high-quality proteins, reagent solutions, and genomic tools vital for biomedical research and clinical applications.
Read more →TECHBIO-TECHNE ANNOUNCES 2023 INVESTOR DAY AND WEBCAST Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host its 2023 Investor Day on Friday, September 8, 2023, starting at 8:30...
Bio-Techne Corporation (NASDAQ: TECH) has announced it will host its 2023 Investor Day on September 8, 2023, at the JW Marriott Essex House in New York City. The event will feature presentations from the senior leadership team and include a Q&A session. Investors and analysts who cannot attend are invited to participate via a live webcast available on the company's Investor Relations website. Bio-Techne is known for its development of high-quality purified proteins and diagnostic products.
Read more →TECHBIO-TECHNE TO PRESENT AT THE UBS MEDTECH, TOOLS AND GENOMICS SUMMIT 2023 Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the UBS...
Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, its Executive Vice President and CFO, will present at the UBS MedTech, Tools and Genomics Summit 2023 on August 17, 2023. This event highlights Bio-Techne’s engagement with key industry discussions surrounding medtech and genomics. The company is known for its extensive range of high-quality biochemical products, which play a crucial role in both research and clinical applications. With substantial net sales reported for fiscal 2023, Bio-Techne continues to position itself as a leader in the biotechnology space.
Read more →TECHBIO-TECHNE ENDS COLLABORATION PROGRAM WITH AKOYA TO AUTOMATE RNASCOPE ON THE PHENOCYCLER FUSION Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic...
Bio-Techne has announced the end of its collaboration program with Akoya to automate the RNAscope technology on the PhenoCycler Fusion system. Despite this development, the company remains committed to enhancing its RNAscope capabilities for spatial biology applications. Bio-Techne plans to accelerate the creation of a fully automated multiomics workflow and will continue to support customers using RNAscope assays alongside Akoya's Opal reagents and PhenoImager HT systems.
Read more →TECHBIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2023 RESULTS Minneapolis/
Bio-Techne Corporation has released its financial results for the fourth quarter and full fiscal year 2023, reporting a 5% increase in organic revenue to $301.3 million. The company achieved strong growth in its Diagnostics and Genomics segment, which recorded a 10% increase in organic revenue. GAAP earnings per share rose to $0.47, up from $0.38 in the previous year. Despite notable achievements, Bio-Techne also faced challenges from a lower biotech funding climate and economic conditions in China.
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 8, 2023, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2023 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, August 8, 2023, at 8:00 a.m....
Bio-Techne Corporation (NASDAQ: TECH) has announced a conference call scheduled for August 8, 2023, to discuss its fourth quarter and fiscal 2023 financial results. The call will provide insights into the company's financial performance and future outlook. Stakeholders can access the live discussion via phone or webcast, with a recorded rebroadcast available thereafter. Bio-Techne's extensive product portfolio includes high-quality proteins, reagent solutions, and diagnostic products, contributing to its reported revenue of approximately $1.1 billion in fiscal 2022.
Read more →TECHBIO-TECHNE COMPLETES LUNAPHORE ACQUISITION Bio-Techne Corporation (NASDAQ:TECH) today announced it has completed the acquisition of Lunaphore Technologies SA, a leading developer of fully...
Bio-Techne Corporation has successfully completed the acquisition of Lunaphore Technologies SA, a firm renowned for its automated spatial biology solutions. This acquisition aims to enhance Bio-Techne's capabilities in translational and clinical research markets. Lunaphore's flagship product, the COMET™ platform, allows for high-throughput tissue analysis with unmatched automation. However, the integration of Lunaphore's products poses potential risks and uncertainties regarding market acceptance and competition.
Read more →TECHBIO-TECHNE TO ACQUIRE LUNAPHORE Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical...
Bio-Techne Corporation has announced its agreement to acquire Lunaphore, Inc., with the transaction expected to close in the first quarter of fiscal 2024. This acquisition aims to enhance Bio-Techne's offerings in spatial biology, particularly through Lunaphore's COMET platform, which provides automated, high-throughput analysis of biomarkers. The companies also recently formed a partnership to develop a fully automated spatial multiomic workflow. Both parties are optimistic that the merger will improve their market position and capabilities in the growing spatial biology sector.
Read more →TECHBIO-TECHNE SUCCESSFUL ON CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies it...
Bio-Techne Corporation has successfully prevailed in a legal claim against Miltenyi Biotec for reverse engineering its proprietary TIGIT and CCR-7 antibodies. The Regional Court of Cologne confirmed that Miltenyi's antibodies were nearly identical to those of Bio-Techne, indicating unlawful activity. As a result, Bio-Techne is set to receive monetary damages and additional information regarding Miltenyi's actions. The ruling emphasizes Bio-Techne's commitment to safeguarding its intellectual property, although Miltenyi has the option to appeal the decision.
Read more →TECHBIO-TECHNE TO PRESENT AT THE 2023 JEFFERIES HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 ...
Bio-Techne Corporation announced that Jim Hippel, the CFO, will present at the 2023 Jefferies Healthcare Conference on June 8, 2023. This event underscores the company's commitment to sharing its advancements and innovations in biopharmaceuticals. Bio-Techne is known for its high-quality purified proteins, reagent solutions, and diagnostic products, contributing significantly to biomedical research and clinical applications.
Read more →TECHEXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TEST Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a previously...
Bio-Techne Corporation (NASDAQ: TECH) announced interim results from a study evaluating the ExoDx Prostate Test, which targets prostate cancer risk assessment. The study involved over 1,000 men, demonstrating that patients deemed low risk by the test required fewer biopsies and were less likely to be diagnosed with high-grade prostate cancer later on. The findings suggest that the ExoDx Prostate Test offers a promising alternative to traditional screening methods, potentially aiding in early detection and treatment decisions for prostate cancer.
Read more →TECHBIO-TECHNE COMMERCIALIZES RNASCOPE SPATIAL BIOLOGY WORKFLOW FOR THE STANDARD BIOTOOLS HYPERION IMAGING SYSTEM Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic...
Bio-Techne (NASDAQ: TECH) has announced the commercialization of a multiomic workflow for its RNAscope in situ hybridization technology, designed for use with the Standard BioTools Hyperion Imaging System. This new RNAscope HiPlex12 Flex Kit allows researchers to visualize over 40 RNA biomarkers in a single tissue imaging step, enhancing the analytical capabilities for diseases. Key presentations showcasing these advancements will take place during upcoming scientific conferences in Montreal, Canada. This strategy is part of Bio-Techne's continued effort to support researchers in advancing therapeutic and diagnostic developments.
Read more →TECHBIO-TECHNE TO PRESENT AT THE 2023 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 ...
Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, Executive Vice President and CFO, will present at the 2023 RBC Capital Markets Global Healthcare Conference on May 16, 2023. The company specializes in developing a wide array of high-quality purified proteins and reagent solutions, contributing significantly to biomedical research. Bio-Techne's diverse offerings include diagnostic products and genomic tools, which are essential for clinical testing and drug discovery. Its extensive product portfolio and strong financial performance illustrate its role in advancing healthcare solutions.
Read more →TECHBIO-TECHNE ANNOUNCES LAUNCH OF KAPPA AND LAMBDA RNAscope ISH PROBES AS ANALYTE SPECIFIC REAGENTS (ASRs) FOR THE DETECTION OF IMMUNOGLOBULIN KAPPA AND LAMBDA LIGHT CHAINS mRNA Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic...
Bio-Techne announced the launch of two new RNAscope in situ Hybridization Probes, Kappa and Lambda, aimed at detecting immunoglobulin kappa and lambda light chains mRNA in B-cells. These probes are intended to enhance the identification of monoclonal B-cell populations, which are often linked to malignancies. Designed as analyte specific reagents (ASRs), they support the development of laboratory tests while ensuring regulatory compliance and accuracy. The introduction of these tools reflects Bio-Techne's commitment to innovation in the diagnostic field.
Read more →TECHBIO-TECHNE RELEASES THIRD QUARTER FISCAL 2023 RESULTS Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2023. Third Quarter FY2023...
Bio-Techne Corporation (NASDAQ: TECH) reported its financial results for Q3 FY2023, showing a net sales increase of 1% to $294.1 million. The company's Cell Therapy and Exosome Diagnostics segments achieved significant growth, with the ExoDx Prostate test revenue growing over 85% year-over-year. Despite a strong overall performance, there were declines in GAAP operating income and the Diagnostics and Genomics segment's revenue. The company noted its strategic focus and indications of recovery in the Chinese market.
Read more →TECHBIO-TECHNE TO PRESENT AT THE BofA SECURITIES 2023 HEALTH CARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the BofA Securities...
Bio-Techne Corporation (NASDAQ: TECH) announced that its CEO, Chuck Kummeth, will present at the BofA Securities 2023 Health Care Conference on May 10, 2023. The presentation will be accessible via a live webcast on Bio-Techne's Investor Relations website. As a leading developer of purified proteins, reagents, and diagnostic products, Bio-Techne continues to play a significant role in biomedical research and clinical applications.
Read more →TECHBIO-TECHNE AND LUNAPHORE ESTABLISH STRATEGIC PARTNERSHIP TO DEVELOP THE FIRST FULLY AUTOMATED SAME-SLIDE SPATIAL MULTIOMICS SOLUTION Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic...
Bio-Techne and Lunaphore have announced a strategic partnership to create a fully automated spatial multiomics workflow, featuring same-slide detection of protein and RNA biomarkers. This collaboration aims to provide researchers with an end-to-end solution that combines advanced technologies from both companies. The new workflow is expected to facilitate improved understanding of diseases and faster development of novel therapeutics. An initial proof-of-concept demonstration will occur at the AACR Annual Meeting.
Read more →TECHBIO-TECHNE TO SHOWCASE INNOVATIVE CANCER RESEARCH, CELL THERAPY AND MANUFACTURING TOOLS AT AACR 2023 CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to advance cancer research and enable...
Bio-Techne Corporation will present its extensive portfolio of products and solutions aimed at advancing cancer research and enabling cell and gene therapy manufacturing at the AACR 2023 conference. The event, taking place from April 14-19 in Orlando, Florida, will feature multiple presentations by company scientists discussing innovative technologies and advancements in the field. The President and CEO emphasized the company's significant impact on cancer research and patient care, showcasing their contributions to next-generation therapies.
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON MAY 3, 2023, TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 3, 2023, at 8:00 a.m. ...
Bio-Techne Corporation (NASDAQ: TECH) has announced a conference call scheduled for May 3, 2023, at 8:00 a.m. CDT to discuss its third quarter 2023 financial results. The call will allow stakeholders to access the latest information regarding the company’s financial performance. A recorded rebroadcast of the call will be made available for those unable to attend live, ensuring wider access to the information shared.
Read more →TECHBIO-TECHNE CELEBRATES MILESTONE WITH MORE THAN 1,000 ELLA™ INSTRUMENTS NOW IN OPERATION Bio-Techne Corporation (NASDAQ: TECH) today announced it that it has reached a significant milestone with more than 1,000 Ella™ automated immunoassay ...
Bio-Techne Corporation has reached a significant milestone by deploying over 1,000 Ella™ automated immunoassay instruments, reflecting increased demand in scientific and clinical research. The Ella platform simplifies workflows and improves efficiency by reducing manual processes, leading to more reliable biomarker analysis. The system's ability to rapidly produce analyzed data enhances research capabilities across multiple therapeutic areas. Bio-Techne also boasts a growing menu of over 250 analytes, further solidifying its position in the life sciences market.
Read more →TECHBIO-TECHNE COMPLETES INVESTMENT IN WILSON WOLF MANUFACTURING Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its investment in Wilson Wolf Manufacturing. Wilson Wolf achieved the trailing ...
Bio-Techne Corporation has completed a significant investment of $257 million in Wilson Wolf Manufacturing, securing a 20% ownership stake. This investment was triggered by Wilson Wolf achieving a trailing 12-month EBITDA of $55 million. The agreement allows Bio-Techne to acquire a larger ownership stake for $1 billion upon reaching specified revenue milestones by the end of 2027. Wilson Wolf is known for its innovative G-Rex technology in cell and gene therapy, being utilized by over 800 market participants.
Read more →TECHBIO-TECHNE ANNOUNCES COMPLETION OF CELL AND GENE THERAPY CATAPULT PROCESS ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical...
Bio-Techne Corporation has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology consortium. This multi-year initiative involved 24 partner organizations and aims to develop specific analytical technologies for cell and gene therapies. The project seeks to foster collaborations among academia, industry, and healthcare to promote innovation in the field. Bio-Techne's involvement highlights its commitment to advancing therapies that could enhance treatment outcomes for diseases with limited effective options.
Read more →TECHBIO-TECHNE TO PRESENT AT THE BARCLAYS GLOBAL HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the...
Bio-Techne Corporation announced that Jim Hippel, Executive Vice President and CFO, will present at the Barclays Global Healthcare Conference on March 14, 2023. The company is a leading developer and manufacturer of high-quality purified proteins, reagent solutions, and genomic diagnostic products. Its expansive product portfolio supports significant contributions to biomedical research and drug discovery. Bio-Techne reportedly generated approximately $1.1 billion in net sales in fiscal 2022, underscoring its market presence.
Read more →TECHBIO-TECHNE ANNOUNCES INVESTMENT IN WILSON WOLF Bio-Techne Corporation (NASDAQ:TECH) today announced Wilson Wolf Manufacturing has met the trailing 12-month earnings before interest, taxes,...
Bio-Techne Corporation has announced an investment in Wilson Wolf Manufacturing, acquiring a 20% ownership stake following the latter's financial performance meeting specified targets. The $257 million investment aims to support Wilson Wolf's advancements in cell production technology crucial for Cell and Gene Therapy (CGT). An agreement allows Bio-Techne to further acquire the remaining ownership for $1 billion upon achieving additional revenue and EBITDA milestones by the end of 2027. This partnership is expected to simplify the manufacturing process of cell therapies, potentially saving time and costs for CGT companies.
Read more →TECHBIO-TECHNE TO PRESENT AT THE COWEN 43rd ANNUAL HEALTH CARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Cowen 43rd...
Bio-Techne Corporation announced that its President and CEO, Chuck Kummeth, will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023. The live webcast of the presentation will be available through Bio-Techne's Investor Relations website. The company specializes in high-quality purification of proteins, reagents, diagnostic products, and genomic tools, catering to biomedical and clinical research. With net sales of approximately $1.1 billion in fiscal 2022, Bio-Techne maintains a robust presence in the industry.
Read more →TECHExoDx PROSTATE TEST GRANTED EXPANDED COVERAGE BY MEDICARE Bio-Techne Corporation (NASDAQ: TECH) today announced that a newly finalized local coverage determination (LCD) from National Government Services,...
Bio-Techne Corporation announced that Medicare's National Government Services has expanded coverage to include the ExoDx Prostate Test. This test will now be available annually for men at high risk of prostate cancer who have previously had a negative biopsy. The new local coverage determination is effective March 1, 2023, and aims to facilitate earlier detection while reducing the need for invasive procedures. The decision is based on updated NCCN recommendations relevant to high-risk patients.
Read more →TECHBIO-TECHNE TO PRESENT AT THE CITI 2023 HEALTHCARE SERVICES, MEDTECH, TOOLS & HCIT CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi ...
Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, the Executive Vice President and CFO, will present at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023. The presentation is part of the company's strategy to engage stakeholders and shareholders. Bio-Techne specializes in high-quality purified proteins and reagent solutions that support scientific research and clinical diagnostics. The company generated significant revenue in the last fiscal year, reflecting its strong market position.
Read more →TECHBIO-TECHNE AND CELL SIGNALING TECHNOLOGY ANNOUNCE PARTNERSHIP TO VALIDATE SIMPLE WESTERN ANTIBODIES Bio-Techne Corporation (NASDAQ: TECH) and Cell Signaling Technology (CST) announced today the addition of Simple Western™ validation to CST...
Bio-Techne Corporation (NASDAQ: TECH) and Cell Signaling Technology (CST) have formed a partnership to enhance the validation of Simple Western antibodies. This collaboration aims to streamline the study of molecular signaling pathways, providing researchers with faster and more reliable tools for drug discovery and development. CST's validated antibodies will be integrated seamlessly into existing workflows, offering an expanded catalog and contributing to the advancement of biotherapeutic research.
Read more →TECHBIO-TECHNE RELEASES SECOND QUARTER FISCAL 2023 RESULTS Minneapolis/
Bio-Techne Corporation reported its financial results for the second quarter ended December 31, 2022. The company achieved a 4% increase in organic revenue, driven by strong growth in its ExoDx Prostate test and cell therapy platform. However, GAAP earnings per share declined, influenced by prior non-recurring gains, and the financial results were negatively affected by foreign currency exchange rates. Despite these challenges, the firm is positioning itself for future growth with strategic investments in facilities and product offerings.
Read more →TECHBIO-TECHNE ANNOUNCES RETIREMENT, APPOINTMENT OF GENERAL COUNSEL Minneapolis/
Bio-Techne Corporation has announced the appointment of Shane Bohnen as the new Senior Vice President and General Counsel, effective March 3, 2023, following the retirement of Brenda Furlow. Brenda Furlow has served the company for nine years and will continue to provide transition support until her retirement. Shane Bohnen, who has been with Bio-Techne since 2019 as Associate General Counsel, brings over 20 years of legal experience and has been involved in M&A activities and corporate sustainability initiatives. His extensive background in legal and regulatory risk management is expected to be crucial for the company's growth strategy.
Read more →TECHBIO-TECHNE LAUNCHES THE MauriceFlex™ SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYS Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of its ProteinSimple-branded MauriceFlex™ during the WCBP conference in Washington D....
Bio-Techne Corporation has launched the ProteinSimple-branded MauriceFlex™ system at the WCBP conference in Washington D.C. This new system enhances protein characterization by enabling both charge variant fractionation and routine assays through capillary isoelectric focusing (cIEF) and CE-SDS methods. The MauriceFlex™ system allows scientists to streamline workflows as it simplifies the analysis of protein charge variants, ensuring that samples can be processed efficiently in one day. Notably, a major biotech company presented data using MauriceFlex™ to evaluate thermal degradation pathways of a therapeutic antibody.
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 2, 2023, TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, February 2, 2023, at 8:00...
Bio-Techne Corporation has scheduled a conference call on February 2, 2023, at 8:00 a.m. CST to discuss its second quarter 2023 financial results. The call will provide investors and stakeholders with insights into the company's recent performance. A webcast will also be available for those unable to join the call live. Bio-Techne is noted for its contributions to the biomedical and diagnostic sectors, presenting a diverse range of products to aid research and clinical applications.
Read more →TECHBIO-TECHNE LAUNCHES RNASCOPE PLUS ASSAY TO ADVANCE GENE THERAPY DEVELOPMENT Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of its Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization...
Bio-Techne Corporation has launched the RNAscope Plus smRNA-RNA detection assay, enhancing its Advanced Cell Diagnostics (ACD) portfolio. This assay allows for the simultaneous fluorescent detection of small regulatory RNAs and multiple target RNAs within tissues, offering precision at the single-cell level. Designed for scalability, it is compatible with the Leica Bond Rx platform and manual applications. The assay combines proprietary RNAscope and miRNAscope technologies, providing a valuable tool for researchers in gene therapy development and enhancing therapeutic efficacy.
Read more →TECHBIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 41st Annual J.P. ...
MINNEAPOLIS , Dec. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 , at 8:15 a.m. PST . A
Read more →TECHBIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS Bio-Techne Corporation (NASDAQ: TECH) today announced the introduction of MitoBrilliant™ probes. These novel probes enable the fluorescent labeling...
MINNEAPOLIS , Dec. 5, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the introduction of MitoBrilliant ™ probes. These novel probes enable the fluorescent labeling and tracking of mitochondria in live and fixed cells. Fluorescent probes that enable h
Read more →TECHBio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the market Asuragen, a Bio-Techne brand (NASDAQ: TECH) and Oxford Nanopore Technologies plc (Oxford Nanopore) (LSE: ONT), today announce a collaboration to...
New collaboration will develop assays that offer a streamlined workflow for analysing even the most challenging genes. MINNEAPOLIS , Dec. 1, 2022 /PRNewswire/ -- Asuragen, a Bio-Techne brand (NASDAQ: TECH ) and Oxford Nanopore Technologies plc (Oxford Nanopore) (LSE: ONT), today
Read more →TECHBIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Fifth Annual...
MINNEAPOLIS , Nov. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Fifth Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022 , at 8:50 a.m. EST . A
Read more →TECHNAMOCELL HIGHLIGHTED IN NATURE PUBLICATION FOR EFFICIENT SINGLE CELL CLONING OF HUMAN PLURIPOTENT STEM CELLS Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell™ Single Cell...
MINNEAPOLIS , Nov. 17, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the publication of a single-cell cloning workflow study using the Namocell ™ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent s
Read more →TECHBIO-TECHNE ANNOUNCES OPENING OF NEW IMMUNOASSAY MANUFACTURING FACILITY Bio-Techne Corporation (NASDAQ: TECH) today announced the opening of its new 52,000 square foot state-of-the-art product innovation and manufacturing ...
About Bio-Techne Corporation (NASDAQ: TECH ) Contact: David Clair , Vice President, Investor Relations [email protected] 612-656-441 SOURCE Bio-Techne Corporation 21 %
Read more →TECHBIO-TECHNE TO PRESENT AT THE STEPHENS ANNUAL INVESTMENT CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the...
MINNEAPOLIS , Nov. 10, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Stephens Annual Investment Conference on Thursday, November 17, 2022 , at 10:00 a.m. CST
Read more →TECHBIO-TECHNE TO PRESENT AT THE STIFEL 2022 HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the...
MINNEAPOLIS , Nov. 8, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 , at 2:25 p.m. EST . A liv
Read more →TECHBIO-TECHNE TO PRESENT AT THE CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Credit Suisse...
MINNEAPOLIS , Nov. 3, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Credit Suisse 31 st Annual Healthcare Conference on Wednesday, November 9, 2022 , at 8:35 a.m. PST . A
Read more →TECHBIO-TECHNE DECLARES CASH DIVIDEND AND STOCK DIVIDEND Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended...
MINNEAPOLIS , Nov. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2022 . The quarterly dividend will be payable November 28, 2022 , to all co
Read more →TECHBIO-TECHNE RELEASES FIRST QUARTER FISCAL 2023 RESULTS Minneapolis/
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2023 RESULTS Minneapolis/November 1, 2022/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2022. First Quarter FY2023 Highlights The Company's financial statements are
Read more →TECHAsuragen to Showcase Innovative Diagnostic Lab Solutions at AMP 2022 Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, will present its diagnostic lab solutions at the upcoming...
Company also launches new Armored DNA ™ molecular controls for monkeypox and closely related viruses MINNEAPOLIS , Oct. 31, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Asuragen, a Bio-Techne brand, will present its diagnostic lab solutions at
Read more →TECHNew Publication from Exosome Diagnostics Demonstrates Proof-of-Concept for Monitoring Astronaut Health in Space Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported results from a proof-of-concept...
Study indicates that noninvasive exosome-based liquid biopsy would be feasible for monitoring health and disease in people traveling in space MINNEAPOLIS , Oct. 18, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Exosome Diagnostics, a Bio-Techne
Read more →TECHBIO-TECHNE SETS A NEW STANDARD IN HIGHLY SENSITIVE RNA IMAGING WITH THE INTRODUCTION OF VIVID FLUORESCENT DYES FOR SPATIAL BIOLOGY Bio-Techne Corporation (NASDAQ: TECH) today announced the introduction of 3 novel TSA Vivid Fluorophores for highly sensitive fluorescent detection...
Bio-Techne brings together gold-standard spatial biology RNAscope™ ISH technology with exceptionally bright TSA Vivid™ Fluorophores to provide industry leading, highly-sensitive RNA detection for any gene, species, or tissue. MINNEAPOLIS , Oct. 12, 2022 /PRNewswire/ -- Bio-Techn
Read more →TECHBIO-TECHNE INTRODUCES NEW SIMPLE PLEX AAV VIRAL TITER ASSAYS Bio-Techne Corporation (NASDAQ: TECH) and PROGEN announced today the release of three new Simple Plex™ Adeno-Associated Virus (AAV) viral titer...
Simple Plex AAV assays combine industry leading AAV antibody reagents from PROGEN with convenience and simplicity of the fully automated Ella platform. MINNEAPOLIS , Oct. 11, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) and PROGEN announced today the release of th
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON NOVEMBER 1, 2022, TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 1, 2022, at 8:00 a....
MINNEAPOLIS , Oct. 10, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call and webcast on Tuesday, November 1, 2022 , at 8:00 a.m. CDT to review first quarter 2023 financial results. Access to the discussion may
Read more →TECHBIO-TECHNE COMMERCIALIZES AUTOMATED MULTI-OMIC RNASCOPE ASSAYS FOR SPATIAL VISUALIZATION OF RNA AND PROTEIN BIOMARKERS IN FFPE TISSUES Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization...
Bringing together Bio-Techne's gold-standard spatial biology RNAscope ISH technology with Roche's industry-leading chromogen detection portfolio for the Roche DISCOVER ULTRA Platform MINNEAPOLIS , Oct. 6, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announce
Read more →TECHBio-Techne Files Patent Infringement Lawsuit Against Molecular Instruments Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical ...
Bio-Techne enforces intellectual property for gold standard RNAscope® ISH technology in spatial biology and clinical applications. MINNEAPOLIS , Sept. 26, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a global life sciences company providing innovative tools and b
Read more →TECHMAURICE FLEX™ icIEF ANALYSIS ADDS FRACTIONATION, ENABLING MASS SPEC PEAK CHARACTERIZATION Bio-Techne Corporation (NASDAQ: TECH) today announced data demonstrating icIEF fractionation from their soon to be launched Maurice Flex™ instrument...
MINNEAPOLIS , Sept. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced data demonstrating icIEF fractionation from their soon to be launched Maurice Flex™ instrument was presented at the 2022 CE Pharm conference. Data generated using customer and Nati
Read more →TECHBIO-TECHNE ISSUES 2022 CORPORATE SUSTAINABILITY REPORT Bio-Techne Corporation (NASDAQ: TECH) today issued its 2022 Corporate Sustainability Report (CSR), detailing the continued progress advancing its...
MINNEAPOLIS , Sept. 19, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today issued its 2022 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized ar
Read more →TECHBIO-TECHNE PRESENTS INITIAL DATA ON SJÖGREN'S SYNDROME MONITORING ASSAY Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, will present initial data on their novel...
MINNEAPOLIS , Sept. 8, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Exosome Diagnostics, a Bio-Techne brand, will present initial data on their novel non-invasive saliva profiling assay for Sjögren's Syndrome diagnosis and monitoring at the 15
Read more →TECHBIO-TECHNE TO PRESENT AT THE BAIRD 2022 GLOBAL HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Baird 2022...
MINNEAPOLIS , Sept. 6, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022 , at 12:50 p.m. EST . A live
Read more →TECHBIO-TECHNE TO SEEK APPROVAL TO IMPLEMENT FOUR-FOR-ONE STOCK SPLIT Bio-Techne Corporation (NASDAQ: TECH) today announced its plan to request shareholder approval during its upcoming 2022 Annual Meeting of...
MINNEAPOLIS , Sept. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced its plan to request shareholder approval during its upcoming 2022 Annual Meeting of Shareholders (the "Annual Meeting") for an increase in the total number of authorized shares of c
Read more →TECHBIO-TECHNE TO PRESENT AT THE MORGAN STANLEY 20th ANNUAL GLOBAL HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the...
MINNEAPOLIS , Aug. 30, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley 20 th Annual Global Healthcare Conference on Tuesday, September 13, 2022 ,
Read more →TECHBIO-TECHNE TO PRESENT AT THE 2022 WELLS FARGO HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2022 ...
MINNEAPOLIS , Aug. 29, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 , at 9:10 a.m. EST
Read more →TECHMAURICE icIEF ESTABLISHED AS A GREEN METHOD FOR CHARACTERIZATION OF AAV IDENTITY AND STABILITY Bio-Techne Corporation (NASDAQ: TECH) announced the publication of a study in the Green Analytical Chemistry journal, titled Establishment of a...
MINNEAPOLIS , Aug. 25, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced the publication of a study in the Green Analytical Chemistry journal, titled Establishment of a Platform Imaged Capillary Isoelectric Focusing (icIEF) Characterization Method for Adeno-As
Read more →TECHBIO-TECHNE INCLUDED IN THE FORBES BEST-IN-STATE EMPLOYERS 2022 LIST Bio-Techne Corporation (NASDAQ: TECH) today announced that it has been included in the Forbes list of Best-in-State Employers 2022. This prestigious...
MINNEAPOLIS , Aug. 24, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that it has been included in the Forbes list of Best-in-State Employers 2022. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics portal an
Read more →TECHBIO-TECHNE ANNOUNCES RELEASE OF QUANTIST LUMINEX® DATA ANALYSIS SOFTWARE Bio-Techne Corporation (NASDAQ: TECH) today announced that R&D Systems®, a Bio-Techne brand, has released its new Quantist Luminex® data analysis...
MINNEAPOLIS , Aug. 18, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that R&D Systems®, a Bio-Techne brand, has released its new Quantist Luminex® data analysis software. Compatible with all available Luminex xMAP® instruments, Quantist software prov
Read more →TECHBIO-TECHNE ANNOUNCES CEO TRANSITION PLAN Bio-Teche Corporation (NASDAQ: TECH) today announced Chuck Kummeth's planned two-year transition from his position as Bio-Techne's Chief Executive...
MINNEAPOLIS , Aug. 4, 2022 /PRNewswire/ -- Bio-Teche Corporation (NASDAQ: TECH ) today announced Chuck Kummeth's planned two-year transition from his position as Bio-Techne's Chief Executive Officer (CEO) effective June 30, 2024 . The Company's Board of Directors has begun its se
Read more →TECHBIO-TECHNE DECLARES DIVIDEND Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended...
MINNEAPOLIS , Aug. 4, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2022. The quarterly dividend will be payable August 29 , 2022, to all common sha
Read more →TECHBIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2022 RESULTS Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ended June 30, 2022. Fourth Quarter FY2022...
MINNEAPOLIS , Aug. 4, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the fourth quarter ended June 30, 2022 . Fourth Quarter FY2022 Highlights The Company's financial statements are prepared in accordance with accounting pri
Read more →TECHBIO-TECHNE ANNOUNCES LICENSING AGREEMENT AND PARTNERSHIP WITH UNIVERSITY OF DUNDEE Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of an exclusive licensing agreement to commercialize The University of Dundee's...
MINNEAPOLIS and DUNDEE, Scotland , July 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the signing of an exclusive licensing agreement to commercialize The University of Dundee's BromoTAG® system and fund the recruitment of postdoctoral researcher
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 4, 2022, TO ANNOUNCE FOURTH QUARTER 2022 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, August 4, 2022, at 8:00...
MINNEAPOLIS , July 14, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call and webcast on Thursday, August 4, 2022 , at 8:00 a.m. CDT to review fourth quarter 2022 financial results. Access to the discussion may
Read more →TECHBIO-TECHNE LAUNCHES NEW TURBO CE-SDS™ CARTRIDGE, ACCELERATING PROTEIN PURITY ANALYSIS THROUGHPUT BY 400% Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has launched the innovative Maurice™ Turbo CE-SDS...
MINNEAPOLIS , July 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that ProteinSimple, a Bio-Techne brand, has launched the innovative Maurice™ Turbo CE-SDS cartridge. As the name suggests, Turbo enables high speed and high resolution analysis of p
Read more →TECHBio-Techne Announces Launch of the CE-IVD RNAscope™ ISH Probe High Risk HPV Assay for Head and Neck Cancer Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic...
A highly accurate new tool for the direct detection of HPV mRNA in FFPE tissue specimens MINNEAPOLIS , July 6, 2022 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH ), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnost
Read more →TECHBIO-TECHNE ANNOUNCES COMPLETION OF NAMOCELL ACQUISITION Bio-Techne Corporation (NASDAQ:TECH), today announced it has completed the acquisition of Namocell, Inc. The Namocell acquisition adds easy-to-use...
MINNEAPOLIS , July 5, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), today announced it has completed the acquisition of Namocell, Inc. The Namocell acquisition adds easy-to-use single cell sorting and dispensing platforms that are gentle to cells and preserve cell
Read more →TECHBIO-TECHNE TO ACQUIRE NAMOCELL Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical...
MINNEAPOLIS and MOUNTAIN VIEW, Mo. , June 22, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agre
Read more →TECHBio-Techne Celebrates 40,000 Unique RNAscope™ in situ Hybridization Probes, Targeting Any Gene, Any Tissue, Any Species. Bio-Techne Corporation (NASDAQ: TECH) today announced Advanced Cell Diagnostics (ACD), a brand of Bio-Techne, reached an extraordinary milestone of...
Bio-Techne is extending ACD's leadership in the spatial biology market by passing a milestone of offering 40,000 custom probes in over four hundred species MINNEAPOLIS , May 26, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced Advanced Cell Diagnostics
Read more →TECHGLOBAL STUDY DEMONSTRATES ICE3 AND MAURICE CAPILLARY ISOELECTRIC FOCUSING COMPARABILITY IN THE JOURNAL OF ELECTROPHERESIS Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a global study in the Journal of Electrophoresis: Global Intercompany...
MINNEAPOLIS , May 25, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the publication of a global study in the Journal of Electrophoresis: Global Intercompany Assessment of icIEF Platform Comparability for the Characterization of Therapeutic Proteins .
Read more →TECHBIO-TECHNE TO PRESENT AT THE JEFFERIES HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2022...
MINNEAPOLIS , May 19, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 , at 9:30 a.m. EDT . A live webcast of
Read more →TECHBio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer Test Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively...
MINNEAPOLIS and LOS ANGELES , May 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) and Nonagen Bioscience today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria ® bladder cancer diagnostic panel usi
Read more →TECHBIO-TECHNE TO PRESENT AT ANNUAL AMERICAN UROLOGICAL ASSOCIATION CONFERENCE IN NEW ORLEANS Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, will have a major scientific presence at the...
MINNEAPOLIS , May 10, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Exosome Diagnostics, a Bio-Techne brand, will have a major scientific presence at the annual American Urological Association Conference (AUA) taking place May 13-16 in New Orlea
Read more →TECHBIO-TECHNE RELEASES THIRD QUARTER FISCAL 2022 RESULTS Minneapolis/
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2022 RESULTS Minneapolis/May 4, 2022/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2022. Third Quarter FY2022 Highlights The Company's financial statements are prepared
Read more →TECHBIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the BofA Securities...
MINNEAPOLIS , May 2, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 , at 2:40 p.m. PST . A live webca
Read more →TECHBIO-TECHNE INCLUDED ON THE FORBES BEST EMPLOYERS FOR DIVERSITY 2022 LIST Bio-Techne Corporation (NASDAQ: TECH) today announced that it has been included on the Forbes list of Best Employers for Diversity 2022. This...
MINNEAPOLIS , April 26, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that it has been included on the Forbes list of Best Employers for Diversity 2022. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics por
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON MAY 4, 2022, TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. ...
MINNEAPOLIS , April 13, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call and webcast on Wednesday, May 4, 2022 , at 8:00 a.m. CDT to review third quarter fiscal 2022 financial results. Access to the discussio
Read more →TECHBIO-TECHNE AND CYGNUS TECHNOLOGIES, PART OF MARAVAI LIFESCIENCES, INTRODUCE NEW SIMPLE PLEX HEK 293 HCP 3G IMMUNOASSAY Bio-Techne Corporation (NASDAQ: TECH) and Cygnus Technologies, part of Maravai LifeSciences (NASDAQ: MRVI), announced today the launch of the Simple...
MINNEAPOLIS , April 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) and Cygnus Technologies, part of Maravai LifeSciences (NASDAQ: MRVI ), announced today the launch of the Simple Plex™ HEK 293 HCP 3G assay for automated process impurity testing on the Ella™ immun
Read more →TECHBIO-TECHNE TO PRESENT AT THE BARCLAYS GLOBAL HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Barclays Global...
MINNEAPOLIS , March 9, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022 , at 8:30 a.m. EST . A live webcas
Read more →TECHBIO-TECHNE TO PRESENT AT THE COWEN 42ND ANNUAL HEALTH CARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the...
MINNEAPOLIS , Feb. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Cowen 42 nd Annual Health Care Conference on Monday, March 7, 2022 , at 11:10 a.m. EST .
Read more →TECHBIO-TECHNE ANNOUNCES EXCLUSIVE DEVELOPMENT AND LICENSE AGREEMENT WITH THERMO FISHER SCIENTIFIC FOR ExoTRU® KIDNEY TRANSPLANT REJECTION ASSAY Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement with Thermo Fisher Scientific to exclusively complete development of and...
MINNEAPOLIS , Feb. 22, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize the ExoTRU kidney transplant rejection test developed by Exosome Diagnostics, a B
Read more →TECHBIO-TECHNE TO PRESENT AT THE CITI 2022 VIRTUAL HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi ...
MINNEAPOLIS , Feb. 22, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Citi 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 , at 10:15 a.m. ES
Read more →TECHBIO-TECHNE ANNOUNCES PUBLICATION OF NEW DATA DEMONSTRATING EXODX PROSTATE TEST CORRELATION WITH POST-PROSTATECTOMY PATHOLOGY OUTCOMES Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in World Journal of Urology, entitled Pre–diagnosis urine exosomal RNA...
MINNEAPOLIS , Feb. 14, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced an important publication in World Journal of Urology, entitled Pre–diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post–prostatectomy pathology outcome . Principal
Read more →TECHBIO-TECHNE TO PRESENT AT THE 11th ANNUAL SVB LEERINK GLOBAL HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 11th Annual SVB...
MINNEAPOLIS , Feb. 11, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 11 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 , at 9:20 a.m. E
Read more →TECHBIO-TECHNE AWARDED ON THE FORBES AMERICA'S BEST EMPLOYERS 2022 LIST Bio-Techne Corporation (NASDAQ: TECH) today announced that it has been awarded on the Forbes list of America's Best Employers 2022. This prestigious...
MINNEAPOLIS , Feb. 10, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that it has been awarded on the Forbes list of America's Best Employers 2022. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics portal an
Read more →TECHBIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended...
MINNEAPOLIS , Feb. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2021 . The quarterly dividend will be payable February 25, 2022 , to all com
Read more →TECHBIO-TECHNE RELEASES SECOND QUARTER FISCAL 2022 RESULTS Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2021. Second Quarter FY2022...
MINNEAPOLIS , Feb. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the second quarter ended December 31, 2021 . Second Quarter FY2022 Snapshot The Company's financial statements are prepared in accordance with accounting p
Read more →TECHBIO-TECHNE ANNOUNCES COMMERCIAL RELEASE OF HIGH SENSITIVITY FLUORESCENT DETECTION STELLAR NIR / IR™ MODULES FOR JESS AUTOMATED WESTERN BLOTTING SYSTEM Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, released its Stellar NIR / IR™ Detection Modules for...
MINNEAPOLIS , Jan. 18, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that ProteinSimple, a Bio-Techne brand, released its Stellar NIR / IR ™ Detection Modules for Jess. Stellar fluorescence modules enable detection of low abundance proteins while mul
Read more →TECHBIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2022 TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 1, 2022, at 8:00 a....
MINNEAPOLIS , Jan. 17, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call and webcast on Tuesday, February 1, 2022 , at 8:00 a.m. CST to review second quarter fiscal 2022 financial results. Access to the discus
Read more →TECHBIO-TECHNE ANNOUNCES UPDATED PRESENTATION TIME AT THE J.P. MORGAN HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 40th Annual J.P. ...
MINNEAPOLIS , Jan. 7, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 , at 8:15 a.m. EST . Thi
Read more →TECHBio-Techne and Akoya Biosciences Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed and Resolution Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic...
MINNEAPOLIS and MARLBOROUGH, Mass. , Jan. 5, 2022 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH ), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and Akoya Biosciences, Inc., (NASDAQ: AKYA ), The S
Read more →TECHBIO-TECHNE TO PRESENT AT THE J.P. MORGAN HEALTHCARE CONFERENCE Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 40th Annual J.P. ...
MINNEAPOLIS , Jan. 3, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 , at 4:30 p.m. EST . A l
Read more →TECHBIO-TECHNE ANNOUNCES APPOINTMENT OF BRENDA EVERSON AS SVP HUMAN RESOURCES Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Brenda Everson as Senior Vice President, Human Resources effective January...
MINNEAPOLIS , Dec. 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the appointment of Brenda Everson as Senior Vice President, Human Resources effective January 10, 2022 . Ms. Everson succeeds Struan Robertson , who will be retiring from the Compan
Read more →TECHBIO-TECHNE ANNOUNCES APPOINTMENT OF WILL GEIST AS PRESIDENT, PROTEIN SCIENCES SEGMENT Bio-Techne Corporation (NASDAQ: TECH) today announced William A. Geist has been appointed President, Protein Sciences Segment, effective January 3,...
MINNEAPOLIS , Dec. 21, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced William A. Geist has been appointed President, Protein Sciences Segment, effective January 3 , 2022. Mr. Geist succeeds N. David Eansor , who will be retiring from the Company. Mr.
Read more →TECHBIO-TECHNE ANNOUNCES FUTURE WILSON WOLF PURCHASE AGREEMENT Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical ...
MINNEAPOLIS and ST. PAUL, Minn. , Dec. 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has entered into an op
Read more →TECHBio-Techne Announces Publication of Lateral Flow Technology Proof-of-Concept Data Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of an important manuscript in the journal Scientific Reports, a Nature Research ...
MINNEAPOLIS , Dec. 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the publication of an important manuscript in the journal Scientific Reports , a Nature Research journal, showing proof-of-concept of its proprietary lateral flow technology. The man
Read more →TECHBio-Techne To Present At Upcoming Investor Conferences Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at two upcoming investor conferences. Chuck Kummeth, President and Chief...
MINNEAPOLIS , Nov. 22, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that it will present at two upcoming investor conferences. Chuck Kummeth , President and Chief Executive Officer will present at the Stephens Annual Investment Conference on Thursd
Read more →TECHBio-Techne To Present At The Stifel 2021 Virtual Healthcare Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the...
MINNEAPOLIS , Nov. 9, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 10:00 a.m. EDT
Read more →TECHAsuragen Launches New Kit to Enable Broader Coverage of Gene Variants Linked to Cystic Fibrosis Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, Inc., a Bio-Techne brand, has launched a new kit to detect pathogenic variants in ...
MINNEAPOLIS , Nov. 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Asuragen, Inc., a Bio-Techne brand, has launched a new kit to detect pathogenic variants in the CFTR gene. The AmplideX ® PCR/CE CFTR Kit, intended for research use only, provid
Read more →TECHBio-Techne To Present At The Credit Suisse 30th Annual Healthcare Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present virtually...
MINNEAPOLIS , Nov. 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present virtually at the Credit Suisse 30 th Annual Healthcare Conference on Tuesday, November 9, 2021 at
Read more →TECHBio-Techne Announces Commercial Availability Of GMP-Grade Proteins From Dedicated GMP Facility Bio-Techne Corporation (NASDAQ: TECH) today announced the commercial availability of GMP-grade materials manufactured at its St. Paul, MN GMP (Good...
MINNEAPOLIS , Nov. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the commercial availability of GMP-grade materials manufactured at its St. Paul, MN GMP (Good Manufacturing Practices) manufacturing facility . The facility is dedicated to supportin
Read more →TECHBio-Techne Named in Inc.'s First-Annual Best-Led Companies Bio-Techne Corporation (NASDAQ: TECH) today announced inclusion in Inc.'s first annual Best-Led Companies list, an exciting 12-point measure of...
MINNEAPOLIS , Nov. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced inclusion in Inc. 's first annual Best-Led Companies list, an exciting 12-point measure of management excellence across the middle market — a select, data-driven list of the very str
Read more →TECHBio-Techne Releases First Quarter Fiscal 2022 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2021. First Quarter FY2022...
MINNEAPOLIS , Nov. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the first quarter ended September 30, 2021 . First Quarter FY2022 Snapshot The Company's financial statements are prepared in accordance with accounting pr
Read more →TECHBio-Techne Declares Dividend Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended...
MINNEAPOLIS , Nov. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2021 . The quarterly dividend will be payable November 26, 2021 to all comm
Read more →TECHBio-Techne Announces ExoDx Prostate Test Data Publication in the Journal of Prostate Cancer and Prostatic Diseases Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published important clinical research in the...
MINNEAPOLIS , Oct. 13, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Exosome Diagnostics, a Bio-Techne brand, has published important clinical research in the journal Prostate Cancer and Prostatic Diseases , entitled Predicting high-grade prosta
Read more →TECHBio-Techne To Host Conference Call On November 2, 2021 To Announce First Quarter 2022 Financial Results Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 2, 2021, at 8:00 a....
MINNEAPOLIS , Oct. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call and webcast on Tuesday, November 2, 2021 , at 8:00 a.m. CDT to review first quarter 2022 financial results. Access to the discussion may
Read more →TECHBio-Techne Launches ExCellerate™ iPSC Expansion Medium Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem...
MINNEAPOLIS , Sept. 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows. The ExCellerate™ i
Read more →TECHBio-Techne And Carterra Initiate A Clinical Research Collaboration For COVID-19 Variant Analysis Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and ...
MINNEAPOLIS and SALT LAKE CITY , Sept. 8, 2021 /PRNewswire/ -- Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screeni
Read more →TECHBio-Techne To Present At The 2021 Virtual Wells Fargo Healthcare Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 Virtual...
MINNEAPOLIS , Sept. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021 at 2:00 p.m. EDT . A li
Read more →TECHBio-Techne Releases Fourth Quarter Fiscal 2021 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2021. Fourth Quarter FY2021 Snapshot...
MINNEAPOLIS , Aug. 5, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the fourth quarter ended June 30, 2021 . Fourth Quarter FY2021 Snapshot The Company's financial statements are prepared in accordance with accounting princ
Read more →TECHBio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2 Bio-Techne Corporation (NASDAQ: TECH) today announced that scientists at the U.S. Centers for Disease Control and Prevention (CDC) recently...
MINNEAPOLIS , Aug. 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that scientists at the U.S. Centers for Disease Control and Prevention (CDC) recently highlighted the importance of fixed tissue analysis for retrospective diagnosis of SARS-CoV-2 in
Read more →TECHBio-Techne Announces 2021 Investor Day and Webcast Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host its 2021 Investor Day on Friday, September 10, 2021, starting at 9:00 ...
MINNEAPOLIS , Aug. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host its 2021 Investor Day on Friday, September 10, 2021 , starting at 9:00 a.m. EDT . The meeting will take place at the Lotte New York Palace Hotel, 455 Madiso
Read more →TECHBio-Techne and PROGEN Introduce New Simple Plex AAV2 Immunoassay Bio-Techne Corporation (NASDAQ: TECH) and PROGEN today announced the launch of the Simple Plex™ Adeno-Associated Virus (AAV2) viral titer assay for...
MINNEAPOLIS , July 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) and PROGEN today announced the launch of the Simple Plex™ Adeno-Associated Virus (AAV2) viral titer assay for AAV2 total capsid quantification. Bio-Techne, owner of the leading ProteinSimple brande
Read more →TECHBio-Techne Announces Commercial Release of RNAscope™ HiPlex V2 Assay for Single Cell Validation and Spatial Transcriptomic Profiling of Complex Tissues on FFPE, Fixed and Fresh Frozen Samples. Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope in situ...
MINNEAPOLIS , July 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope in situ hybridization technology portfolio with the release of new RNAscope HiPlex V2 assay for fo
Read more →TECHBio-Techne To Host Conference Call On August 5, 2021 To Announce Fourth Quarter 2021 Financial Results Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, August 5, 2021, at 8:00...
MINNEAPOLIS , July 13, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call and webcast on Thursday, August 5, 2021 , at 8:00 a.m. CDT to review fourth quarter 2021 financial results. Access to the discussion may
Read more →TECHBio-techne Announces Opening Of New Ireland Facility Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Ireland facility located in Dublin. This new facility reflects...
MINNEAPOLIS , June 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the opening of its new Ireland facility located in Dublin . This new facility reflects Bio-Techne's commitment to supporting the broader life sciences industry in Europe as well as
Read more →TECHBio-Techne and Catamaran Bio Announce Expanded Collaboration for CAR-NK Cell Manufacturing Technologies Bio-Techne Corporation (NASDAQ: TECH) and Catamaran Bio today announced an expansion of their collaboration for the development of cell engineering...
MINNEAPOLIS and CAMBRIDGE, Mass. , June 24, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) and Catamaran Bio today announced an expansion of their collaboration for the development of cell engineering and cell process technologies for use by Catamaran in the manufact
Read more →TECHBio-Techne Further Enhances Its Gene Engineering & Cell & Gene Therapy Manufacturing Capabilities Bio-Techne Corporation (NASDAQ: TECH), a leader in developing innovative tools and technologies for cell and gene therapy research and manufacturing, ...
MINNEAPOLIS and LONDON , June 10, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a leader in developing innovative tools and technologies for cell and gene therapy research and manufacturing, has partnered with Autolomous to implement a first of its kind electronic
Read more →TECHBio-Techne Joins Cell and Gene Therapy Catapult Process Analytical Technology Consortium Bio-Techne Corporation (NASDAQ: TECH) today announced it is joining the Cell and Gene Therapy Catapult process analytical technology (PAT)...
MINNEAPOLIS , June 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced it is joining the Cell and Gene Therapy Catapult process analytical technology (PAT) consortium, which includes over 20 pharmaceutical companies, technology providers, therapy develo
Read more →TECHBio-Techne To Present At The Jefferies Virtual Healthcare Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies...
MINNEAPOLIS , May 19, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:00 p.m. EDT . A live webcast of
Read more →TECHBio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications Bio-Techne Corporation (NASDAQ: TECH) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology...
MINNEAPOLIS , May 18, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ell
Read more →TECHMultisite Study Demonstrates Utility of Asuragen Kit for Identifying Variants Linked to Spinal Muscular Atrophy Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand, and scientific collaborators have published the results of a...
MINNEAPOLIS , May 10, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Asuragen, a Bio-Techne brand, and scientific collaborators have published the results of a multisite evaluation study of the AmplideX ® PCR/CE SMA Plus* Kit that validates its p
Read more →TECHBio-Techne Releases Third Quarter Fiscal 2021 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2021. Third Quarter FY2021 Snapshot...
MINNEAPOLIS , May 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the third quarter ended March 31, 2021 . Third Quarter FY2021 Snapshot The Company's financial statements are prepared in accordance with accounting princip
Read more →TECHBio-Techne and 908 Devices Announce Joint Collaboration Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution...
MINNEAPOLIS and BOSTON , May 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) and 908 Devices (NASDAQ: MASS ) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company prov
Read more →TECHBio-Techne Announces Commercial Release of Novel DNAscope™ in situ Hybridization Assays for Chromogenic Detection of DNA Copy Number and Structural Variations Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope™ technology...
MINNEAPOLIS , April 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope™ technology with release of new DNAscope Assays. The RNAscope technology is an advanced in situ h
Read more →TECHBio-Techne Announces Launch of Professional Assay Services - Dedicated Source for RNA in situ Hybridization Assays in Spatial Gene Expression Analysis Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne brand, completed an extensive rebranding...
MINNEAPOLIS , April 15, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne brand, completed an extensive rebranding effort in response to increased demand for its Assay Services offered at its Newark, CA
Read more →TECHBio-Techne Announces Licensing of Proprietary Antibody to Xencor for Therapeutic Development Bio-Techne Corporation (NASDAQ: TECH) today announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a...
MINNEAPOLIS , April 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokin
Read more →TECHBio-Techne Announces Commercial Release of Abby Automated Western System for Simple Western and Introduces Stellar Modules for Jess Bio-Techne Corporation (NASDAQ:TECH) today announced that ProteinSimple, a Bio-Techne brand, released Abby, its next generation chemiluminescence...
MINNEAPOLIS , April 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that ProteinSimple, a Bio-Techne brand, released Abby, its next generation chemiluminescence system that automates traditional Western blotting. This latest addition to the Simple W
Read more →TECHBio-Techne Completes Acquisition of Asuragen, Inc. Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial...
MINNEAPOLIS , April 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon th
Read more →TECHBio-Techne To Host Conference Call On May 6, 2021 To Announce Third Quarter 2021 Financial Results Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, May 6, 2021, at 8:00 a.m....
MINNEAPOLIS , April 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call and webcast on Thursday, May 6, 2021 , at 8:00 a.m. CDT to review third quarter 2021 financial results. Access to the discussion may be
Read more →TECHBio-Techne Announces Launch of Cultrex UltiMatrix BME to Support Organoid and Pluripotent Stem Cell Cultures Bio-Techne Corporation (NASDAQ: TECH) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME),...
MINNEAPOLIS , March 29, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an extracellular matrix hydrogel that provides significant performance and consistenc
Read more →TECHBio-Techne Announces Receipt of COVID-19 Innovation Award from CiteAb Bio-Techne Corporation (NASDAQ: TECH) today announced that its R&D Systems and Novus brands have been named winners of the CiteAb COVID-19 Innovation ...
MINNEAPOLIS , March 26, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that its R&D Systems and Novus brands have been named winners of the CiteAb COVID-19 Innovation Award. This award celebrates innovative solutions or products that helped shape the
Read more →TECHBio-Techne's Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in...
MINNEAPOLIS , March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagnostic (IVD) version of the ExoDx™ Prostate test (EPI) kit enabling self-cert
Read more →TECHBio-Techne Announces ISO 9001:2015 Certification for its Bristol Manufacturing Facility. Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical ...
MINNEAPOLIS , March 15, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that its Bristol site in the United Kingdom
Read more →TECHBio-Techne Announces ExoTRU Kidney Transplant Rejection Assay Data Publication Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney...
According to Dr. Azzi, "Kidney transplant providers currently have sub-optimal tools to care for transplant patients and need more reliable tools to ensure post-operative success of kidney transplants, particularly for those patients that are far from academic centers." He contin
Read more →TECHBio-Techne to Acquire Asuragen Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical ...
MINNEAPOLIS and AUSTIN, Texas , March 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement
Read more →TECHBio-Techne To Present At The Barclays Global Healthcare Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Barclays Global...
MINNEAPOLIS , March 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 9:10 a.m. EST . A live webcast o
Read more →TECHBio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana Bio-Techne Corporation (NASDAQ:TECH) today announced that Humana has awarded a contract effective April 1, 2021 to its Exosome Diagnostics...
MINNEAPOLIS , March 1, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Humana has awarded a contract effective April 1, 2021 to its Exosome Diagnostics laboratory, covering the ExoDx™ Prostate (EPI) test for men. Humana is the nation's largest Med
Read more →TECHBio-Techne Announces ISO 14001:2015 Certification for the EMEA region of Bio-Techne. Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its sites in Abingdon, Langley,...
MINNEAPOLIS , Feb. 25, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a leading provider of proteins, antibodies and cytokines today announced that its sites in Abingdon, Langley, Rennes and Wiesbaden received ISO 14001:2015 certification for Environmental Managemen
Read more →TECHBio-Techne and Luminary Therapeutics sign license agreement for use of Bio-Techne's TcBuster™ for the development of Luminary's CAR-T cell therapies Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster™ for the...
MINNEAPOLIS , Feb. 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster ™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary n
Read more →TECHBio-Techne To Present At Citi's 2021 Healthcare Services, Medtech, Tools & HCIT Virtual Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at Citi's 2021...
MINNEAPOLIS , Feb. 16, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at Citi's 2021 Healthcare Services, Medtech, Tools & HCIT Virtual Conference on Thursday, February 25, 2021
Read more →TECHBio-Techne Announces Paper Publication In Annals Of Oncology Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled...
MINNEAPOLIS , Feb. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges (Yu, W et al.) , in the h
Read more →TECHBio-Techne To Present At The 2021 SVB Leerink Global Healthcare Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 SVB Leerink ...
MINNEAPOLIS , Feb. 10, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 2021 SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 11:20 a.m. EST . A l
Read more →TECHBio-Techne Announces Expanded Simple Plex Immunoassay Cartridge Portfolio Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple PlexTM immunoassay cartridge...
MINNEAPOLIS , Feb. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple Plex TM immunoassay cartridge portfolio to include nine new cartridge formats. These new cartridge offerings provide S
Read more →TECHBio-Techne Releases Second Quarter Fiscal 2021 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020. Second Quarter FY2021...
MINNEAPOLIS , Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the second quarter ended December 31, 2020 . Second Quarter FY2021 Snapshot The Company's financial statements are prepared in accordance with accounting p
Read more →TECHBio-Techne Announces Strategic Investment In Eminence Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical...
MINNEAPOLIS , Jan. 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced an initial minority strategic equity investme
Read more →TECHBio-Techne To Host Conference Call On February 2, 2021 To Announce Second Quarter 2021 Financial Results Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021, at 8:00 a....
MINNEAPOLIS , Jan. 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021 , at 8:00 a.m. CST to review second quarter 2021 financial results. Access to the discussion ma
Read more →TECHBio-Techne To Present At The 39th Annual J.P. Morgan Healthcare Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 39th Annual J.P. ...
MINNEAPOLIS , Dec. 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 2:00 p.m. EST . A li
Read more →TECHRegulus Therapeutics Collaborates With Bio-Techne For Biomarker Development Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis...
MINNEAPOLIS , Dec. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) and Regulus Therapeutics (NASDAQ: RGLS ) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Diseas
Read more →TECHBio-Techne To Present At The Stephens Annual Investment Conference 2020 Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stephens Annual...
MINNEAPOLIS , Nov. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Stephens Annual Investment Conference 2020 on Tuesday, November 17, 2020 at 3:00 p.m. EST . A live we
Read more →TECHBio-Techne Releases First Quarter Fiscal 2021 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2020. First Quarter FY2021...
MINNEAPOLIS , Nov. 5, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the first quarter ended September 30, 2020 . First Quarter FY2021 Snapshot The Company's financial statements are prepared in accordance with accounting pr
Read more →TECHBio-Techne To Present At The Stifel 2020 Virtual Healthcare Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stifel 2020...
MINNEAPOLIS , Nov. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 1:20 p.m. EST . A live webca
Read more →TECHBio-Techne To Present At The 29th Annual Credit Suisse Virtual Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer, will present at the 29th Annual Credit Suisse Virtual...
MINNEAPOLIS , Nov. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Chief Financial Officer, will present at the 29 th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, 2020 at 4:15 p.m. EST . A live webc
Read more →TECHBio-Techne Announces Commercial Release Of New SARS-CoV-2 Multi-Antigen Serology Assay Kit For Simple Western Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module...
MINNEAPOLIS , Oct. 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module for Jess and Wes Simple Western automated western blotting systems. The SARS-CoV-2 mult
Read more →TECHBio-Techne Announces ISO 13485:2016 Certification for the Woburn, MA Manufacturing Facility Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its Woburn, Massachusetts site...
MINNEAPOLIS , Oct. 15, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a leading provider of proteins, antibodies and cytokines today announced that its Woburn, Massachusetts site received ISO 13485:2016 certification for Medical Device and Quality Management Systems
Read more →TECHBio-Techne To Host Conference Call On November 5, 2020 To Announce First Quarter 2021 Financial Results Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, November 5, 2020, at 8:00...
MINNEAPOLIS , Oct. 13, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call and webcast on Thursday, November 5, 2020 , at 8:00 a.m. CST to review first quarter 2021 financial results. Access to the discussion ma
Read more →TECHBio-Techne Announces Opening Of New Canadian Facility Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Canadian office located in Toronto. This new office will be the workplace ...
MINNEAPOLIS , Oct. 1, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the opening of its new Canadian office located in Toronto . This new office will be the workplace for approximately 40 Bio-Techne employees and reflects the Company's commitment to s
Read more →TECHBio-Techne Announces Grand Opening Of GMP Manufacturing Facility Bio-Techne Corporation (NASDAQ: TECH) today announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP (Good...
MINNEAPOLIS , Sept. 30, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufacturing Practices) manufacturing facility. Located in St. Paul, MN , the new facility is
Read more →TECHBio-Techne Announces Publication Of ExoDx Prostate Test Study In Patients With Prior Negative Prostate Biopsy Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test...
MINNEAPOLIS , Sept. 23, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biop
Read more →TECHBio-Techne Announces Commercial Release Of New Co-Detection Assays For Simultaneous Detection Of RNA And Protein On The Same Sample Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release...
MINNEAPOLIS , Sept. 22, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release of the new RNA-Protein Co-Detection Assays. The RNAscope technology is an advanced in
Read more →TECHBio-Techne Rebrands B-MoGen Biotechnologies As Part Of The R&D Systems Product Portfolio Bio-Techne Corporation (NASDAQ: TECH) today announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic...
MINNEAPOLIS , Sept. 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic manufacturing services, and its proprietary transposon-transposase gene transfer system,
Read more →TECHBio-Techne and QIAGEN Announce Expansion and Extension of Exosome Partnership Bio-Techne Corporation (NASDAQ: TECH) and QIAGEN N.V. today announced the expansion and extension of a non-exclusive partnership to co-market exosome ...
MINNEAPOLIS , Sept. 17, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) and QIAGEN N.V. today announced the expansion and extension of a non-exclusive partnership to co-market exosome technology to existing and potential biopharma partners as well as the joint develop
Read more →TECHBio-Techne And Hall Of Famer Cal Ripken Jr -Announce Partnership To Raise Awareness And Education To Empower Men With Prostate Cancer Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with Hall of...
MINNEAPOLIS , Sept. 8, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with Hall of Famer and baseball's all-time "Iron Man", Cal Ripken Jr. This year marks 25 years since
Read more →TECHBio-Techne To Present At The 2020 Wells Fargo Virtual Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2020 Wells Fargo...
MINNEAPOLIS , Sept. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9, 2020 at 11:20 a.m. EDT . A
Read more →TECHBio-Techne Corporation and Leica Biosystems are Accelerating Disease Research with RNAscope™ COVID-19 Probes and the BOND RX* Bio-Techne Corporation (NASDAQ:TECH), in partnership with Leica Biosystems, today announced the automation of RNAscope™ COVID-19 probes on BOND RX*,...
MINNEAPOLIS , Aug. 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), in partnership with Leica Biosystems, today announced the automation of RNAscope™ COVID-19 probes on BOND RX*, Leica's staining platform, for research use only. Researchers now have the ability to
Read more →TECHBio-Techne Announces Release of a New SARS-CoV-1/2 Spike RBD LlaMABody™ Recombinant Antibody that Blocks Viral Entry Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the...
MINNEAPOLIS , Aug. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain (RBD) and blocks the virus from binding to its
Read more →TECHBio-Techne And NanoString Announce Offering Of RNAscope Reagents Validated For Use With The GeoMx Digital Spatial Profiler Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic...
MINNEAPOLIS and SEATTLE , Aug. 6, 2020 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH ), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic markets and NanoString Technologies, Inc. (NASDAQ: NSTG ), a leading provid
Read more →TECHBio-Techne Releases Fourth Quarter Fiscal 2020 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2020. Fourth Quarter FY2020 Snapshot...
MINNEAPOLIS , Aug. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the fourth quarter ended June 30, 2020 . Fourth Quarter FY2020 Snapshot The company's consolidated financial statements are prepared in accordance with acc
Read more →TECHBio-Techne And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC...
MINNEAPOLIS and NEW YORK , Aug. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) and the Mount Sinai Health System in New York , through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kant
Read more →TECHBio-Techne Announces Appointment Of Julie L. Bushman To Its Board Of Directors Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Julie L. Bushman to serve as an independent director on the company's board...
MINNEAPOLIS , Aug. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the appointment of Julie L. Bushman to serve as an independent director on the company's board of directors, effective as of July 31, 2020 . Following the appointment, the board of B
Read more →TECHBio-Techne Announces Launch Of ExoCovid-19 Test For Detection Of SARS-CoV-2 In Patient Samples Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed validation testing for COVID-19...
MINNEAPOLIS , July 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed validation testing for COVID-19 caused by the novel coronavirus (SARS-CoV-2) and now offers the ExoCovid-19 test for dete
Read more →TECHBio-Techne Announces Commercial Release Of New Assay For Detecting ASOs, miRNAs, And siRNAs In Tissue Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the RNAscope™ platform with the release of the miRNAscope™ Assay. The RNAscope...
MINNEAPOLIS , July 20, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the expansion of the RNAscope™ platform with the release of the miRNAscope™ Assay. The RNAscope technology is an advanced in situ hybridization assay for the spatial visualization o
Read more →TECHBio-Techne To Host Conference Call On August 4, 2020 To Announce Fourth Quarter 2020 Financial Results MINNEAPOLIS, July 13, 2020 Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday,...
MINNEAPOLIS , July 13, 2020 Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call and webcast on Tuesday, August 4, 2020 , at 8:00 a.m. CDT to review fourth quarter 2020 financial results. Access to the discussion may be obtained as f
Read more →TECHBio-Techne And ZERO - The End Of Prostate Cancer Announce Partnership To Fund Education And Awareness Campaigns To Empower Men With Prostate Cancer Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The...
MINNEAPOLIS , June 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of Prostate Cancer, the leading national nonprofit organization in the fight agai
Read more →TECHBio-Techne Continues to Expand Its Portfolio to Support SARS-CoV-2 and COVID-19 Research and Therapeutic Development Bio-Techne Corporation (NASDAQ:TECH) is at the forefront of coronavirus disease 2019 (COVID-19) and SARS-CoV-2 research. This is evidenced by the...
MINNEAPOLIS , June 9, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) is at the forefront of coronavirus disease 2019 (COVID-19) and SARS-CoV-2 research. This is evidenced by the large number of published research papers on the subject that have cited Bio-Techne produ
Read more →TECHBio-Techne Announces Release of GMP ProDots Proteins to Support Cell and Gene Therapy Manufacturing Workflows Bio-Techne Corporation (NASDAQ:TECH) today announced the release of GMP ProDots™ Proteins to support cell and gene therapy manufacturing workflows....
MINNEAPOLIS , June 8, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the release of GMP ProDots™ Proteins to support cell and gene therapy manufacturing workflows. GMP ProDots™ Proteins address a critical need to precisely dose and safely add essentia
Read more →TECHBio-Techne To Present At The Jefferies Virtual Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the virtual Jefferies ...
MINNEAPOLIS , May 27, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the virtual Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 10:30 a.m. EDT . A live we
Read more →TECHLeica Biosystems and Bio-Techne Announce European Launch of the CE-IVD RNAscope In Situ Hybridization Detection Kit Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic...
MINNEAPOLIS , May 26, 2020 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH ), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities and Leica Biosystems, a global leader in workflow solutions and automation,
Read more →TECHBio-Techne And Kantaro Biosciences Announce Partnership To Develop And Scale Production Of COVID-19 Serology Test Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC...
MINNEAPOLIS and NEW YORK , May 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) and the Mount Sinai Health System in New York , through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced a partnership to initiate scaled manufacturing and di
Read more →TECHBio-Techne Announces Release of GMP Cloudz™ Human T Cell Activation Kit Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the GMP Cloudz™ Human T Cell Activation Kit. This is the first GMP-grade kit...
MINNEAPOLIS , May 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the release of the GMP Cloudz™ Human T Cell Activation Kit. This is the first GMP-grade kit within the Cloudz product line addressing the need for robust, yet safe products within th
Read more →TECHBio-Techne Announces Publication of ExoDx™ Prostate (IntelliScore) EPI Test Clinical Utility Study Bio-Techne Corporation (NASDAQ:TECH) today announced a major publication in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical...
MINNEAPOLIS , May 7, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced a major publication in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of the exosome based ExoDx™ Prostate (IntelliScore) EPI test in men presenting
Read more →TECHBio-Techne To Present At The BofA Securities 2020 Health Care Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the virtual BofA...
MINNEAPOLIS , May 5, 2020 / /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the virtual BofA Securities 2020 Health Care Conference on Wednesday, May 13, 2020 at 9:40 a.m. EDT . A l
Read more →TECHBio-Techne Releases Third Quarter Fiscal 2020 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2020. Third Quarter FY2020 Snapshot...
MINNEAPOLIS , April 30, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the third quarter ended March 31, 2020 . Third Quarter FY2020 Snapshot The Company's financial statements are prepared in accordance with accounting prin
Read more →TECHBio-Techne Introduces RePlex Capabilities For Simple Western Assays On Jess™ Bio-Techne Corporation (NASDAQ: TECH) today announced the upcoming release of RePlex™ for use on the Jess instrument, a member of the Simple Western™ ...
MINNEAPOLIS , April 16, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the upcoming release of RePlex™ for use on the Jess instrument, a member of the Simple Western™ instrument family. RePlex adds to Jess's already advanced, fully automated, capillar
Read more →TECHBio-Techne's Exosome Diagnostics Launches ExoDx Prostate At-Home Collection Kit Bio-Techne Corporation (NASDAQ:TECH) announced today that Exosome Diagnostics, a Bio-Techne brand, is launching an ExoDx™ Prostate Test At-Home...
MINNEAPOLIS , April 15, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced today that Exosome Diagnostics, a Bio-Techne brand, is launching an ExoDx™ Prostate Test At-Home Collection Kit for patients who are concerned about their prostate health. Millions of me
Read more →TECHBio-Techne To Host Conference Call On April 30, 2020 To Announce Third Quarter 2020 Financial Results Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, April 30, 2020, at 8:00...
MINNEAPOLIS , April 8, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call and webcast on Thursday, April 30, 2020 , at 8:00 a.m. CDT to review third quarter 2020 financial results. Access to the discussion may
Read more →TECHDr. Roeland Nusse: Gairdner Award Recipient and Bio-Techne Board of Directors Member Bio-Techne Corporation (NASDAQ:TECH) today announced a member of its board of directors, Dr. Roeland Nusse, has become one of the 2020 Canada...
MINNEAPOLIS , April 1, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced a member of its board of directors, Dr. Roeland Nusse , has become one of the 2020 Canada Gairdner International Award recipients. The Gairdner Foundation was established in 1957 w
Read more →TECHExtracellular Vesicles From Plasma Have Higher Tumor RNA Fraction Than Platelets Bio-Techne Corporation (NASDAQ:TECH) today announced researchers from its Munich-based laboratory, Exosome Diagnostics, in a paper published in the...
MINNEAPOLIS , March 30, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced researchers from its Munich -based laboratory, Exosome Diagnostics, in a paper published in the scientific Journal of Extracellular Vesicles (JEV) ( link ), showed that tumor- deri
Read more →TECHBio-Techne's Ella On The Front Lines In Fight Against COVID-19 Bio-Techne Corporation (NASDAQ:TECH) today shared news from clinical partners on the use of the ProteinSimple™-branded Ella™ Automated Immunoassay...
MINNEAPOLIS , March 25, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today shared news from clinical partners on the use of the ProteinSimple™-branded Ella ™ Automated Immunoassay platform in the fight against COVID-19. In a March 23, 2020 press release, the Icahn
Read more →TECHBio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With General Services Administration Bio-Techne Corporation (NASDAQ:TECH) today announced that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement...
About Bio-Techne Corporation (NASDAQ: TECH ) ExosomeDx a Bio-Techne Brand Contact: David Clair , Senior Director, Business Development [email protected] SOURCE Bio-Techne Corporation 21 %
Read more →TECHBio-Techne To Present At The Barclays Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Barclays Global...
MINNEAPOLIS , Feb. 27, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 11, 2020 at 9:30 a.m. EST . The conference
Read more →TECHBio-Techne To Present At The Cowen 40th Annual Health Care Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Chief Financial Officer, will present at the Cowen 40th Annual Health Care...
MINNEAPOLIS , Feb. 24, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Chief Financial Officer, will present at the Cowen 40 th Annual Health Care Conference on Wednesday, March 4, 2020 at 8:00 a.m. EST . The conference will be held a
Read more →TECHBio-Techne To Present At The SVB Leerink 9th Annual Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer, will present at the SVB Leerink 9th Annual Global...
MINNEAPOLIS , Feb. 17, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Chief Financial Officer, will present at the SVB Leerink 9 th Annual Global Healthcare Conference on Wednesday, February 26, 2020 at 11:30 a.m. EST . The conferenc
Read more →TECHBio-Techne Announces Availability Of Next Generation ELISA Kits Bio-Techne Corporation (NASDAQ: TECH), a global leader and the most cited manufacturer of immunoassay kits, announced the release of the Quantikine...
MINNEAPOLIS , Feb. 5, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a global leader and the most cited manufacturer of immunoassay kits, announced the release of the Quantikine QuicKit™ ELISA product line. This next generation ELISA product line expands the capabil
Read more →TECHBio-Techne Releases Second Quarter Fiscal 2020 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2019. Second Quarter FY2020...
MINNEAPOLIS , Feb. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the second quarter ended December 31, 2019 . Second Quarter FY2020 Snapshot The Company's financial statements are prepared in accordance with accounting p
Read more →TECHBio-Techne To Host Conference Call On February 4, 2020 To Announce Second Quarter 2020 Financial Results Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call on Tuesday, February 4, 2020, at 8:00 a.m. CST to...
MINNEAPOLIS , Jan. 9, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, February 4, 2020 , at 8:00 a.m. CST to review second quarter 2020 financial results. Access to the discussion may be obtained
Read more →TECHBio-Techne Rebrands Atlanta Biologicals Serum And Media As Part Of The R&D Systems Product Portfolio Bio-Techne Corporation (NASDAQ: TECH) today announced that the Atlanta Biologicals portfolio of serum and media will be rebranded as R&D Systems. As...
MINNEAPOLIS , Jan. 7, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that the Atlanta Biologicals portfolio of serum and media will be rebranded as R&D Systems. As part of the rebranding, the Atlanta Biologicals website will be retired and the entire
Read more →TECHBio-Techne To Present At The 38th Annual J.P. Morgan Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 38th Annual J.P....
MINNEAPOLIS , Jan. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 38 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 3:00 p.m. PST . The c
Read more →TECHBio-Techne's Exosome Diagnostics Lab Receives Accreditation From College of American Pathologists (CAP) Bio-Techne Corporation (NASDAQ:TECH) today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded...
MINNEAPOLIS , Dec. 17, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its Exosome Diagnostics (ExosomeDx) laboratory based on results of a rece
Read more →TECHBio-Techne To Present At The Evercore ISI 2nd Annual HealthCONx Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Evercore ISI 2nd ...
MINNEAPOLIS , Nov. 25, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Evercore ISI 2 nd Annual HealthCONx Conference on Wednesday, December 4, 2019 at 11:45 a.m. EST . The
Read more →TECHBio-Techne To Present At The 2019 Stifel Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stifel 2019...
MINNEAPOLIS , Nov. 7, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 1:50 p.m. EST . The conference will
Read more →TECHBio-Techne Licenses aTAG Technology from C4 Therapeutics, Inc. Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique and leading portfolio of reagents and instruments for life science and...
MINNEAPOLIS , Nov. 6, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a family of brands with a unique and leading portfolio of reagents and instruments for life science and clinical research, today announced the signing of an agreement with C4 Therapeutics, Inc. to
Read more →TECHBio-Techne To Present At The Stephens Nashville Investment Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer, will present at the Stephens Nashville Investment...
MINNEAPOLIS , Nov. 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Chief Financial Officer, will present at the Stephens Nashville Investment Conference on Wednesday, November 13, 2019 at 9:45 a.m. CST . The conference will be held
Read more →TECHBio-Techne Releases First Quarter Fiscal 2020 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2019. First Quarter FY2020...
MINNEAPOLIS , Oct. 29, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the first quarter ended September 30, 2019 . First Quarter FY2020 Snapshot The Company's financial statements are prepared in accordance with accounting p
Read more →TECHBio-Techne Announces Investment For New GMP Manufacturing Facility Bio-Techne Corporation (NASDAQ: TECH), a global leader in the development and manufacturing of Good Manufacturing Practices (GMP)-grade raw and...
MINNEAPOLIS , Oct. 28, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a global leader in the development and manufacturing of Good Manufacturing Practices (GMP)-grade raw and ancillary reagents, announced a commitment to invest between $40 million and $50 million to
Read more →TECHMedicare Issues Final Local Coverage Decision For Bio-Techne's ExoDx™ Prostate(IntelliScore) Test Bio-Techne Corporation (NASDAQ:TECH) today announced that the Medicare Administrative Contractor (MAC) National Government Services, Inc. issued a...
The EPI test is a non-invasive, non-DRE requiring, urine-based, liquid biopsy test intended for men 50 years of age and older who have an elevated Prostate Specific Antigen (PSA) level between 2 – 10 ng/mL and who are being considered for a prostate biopsy. This liquid biopsy tes
Read more →TECHBio-Techne To Host Conference Call On October 29, 2019, To Announce First Quarter 2020 Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, October 29, 2019, at 8:00 a.m. CDT to...
MINNEAPOLIS , Oct. 8, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, October 29, 2019 , at 8:00 a.m. CDT to review first quarter 2020 financial results. Access to the discussion may be obtained
Read more →TECHBio-Techne Leverages The RNAscope™ Technology To Advance A Multiomic Approach To Antibody Validation Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique and leading portfolio of reagents and instruments for life science and...
MINNEAPOLIS , Oct. 7, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a family of brands with a unique and leading portfolio of reagents and instruments for life science and clinical research, has been validating a growing number of immunohistochemistry (IHC) antibod
Read more →TECHBio-Techne Attains ISO 9001:2015 Certification for Fetal Bovine Serum Manufacturing Facility Bio-Techne Corporation (NASDAQ: TECH) today announced that it has attained ISO 9001:2015 certification at its fetal bovine serum (FBS) and specialty...
MINNEAPOLIS , Sept. 16, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that it has attained ISO 9001:2015 certification at its fetal bovine serum (FBS) and specialty media manufacturing facility in Flowery Branch, Georgia . ISO 9001:2015 is an interna
Read more →TECHBio-Techne Introduces Maurice Empower® Control Kit For The Maurice™ System Bio-Techne Corporation (NASDAQ: TECH) today announced the release of the Maurice Empower® Control Kit for the ProteinSimple™-branded Maurice platform....
MINNEAPOLIS , Aug. 20, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the release of the Maurice Empower ® Control Kit for the ProteinSimple™-branded Maurice platform. This new kit enables users to collect, manage and report Maurice results with the i
Read more →TECHBio-Techne To Present At The Baird 2019 Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Baird 2019 Global ...
MINNEAPOLIS , Aug. 15, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Baird 2019 Global Healthcare Conference on Wednesday, September 4, 2019 , at 10:15 a.m. EDT . The con
Read more →TECHBio-Techne And Cygnus Technologies Announce Partnership For 3G CHO-HCP Assay Bio-Techne Corporation and Cygnus Technologies, part of Maravai LifeSciences, announced today a strategic partnership for the quantification of...
MINNEAPOLIS and SOUTHPORT, N.C. , Aug. 13, 2019 /PRNewswire/ -- Bio-Techne Corporation and Cygnus Technologies, part of Maravai LifeSciences, announced today a strategic partnership for the quantification of Chinese hamster ovary host cell proteins (CHO-HCP) on the ProteinSimple™
Read more →TECHBio-Techne Releases Fourth Quarter Fiscal 2019 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2019. Fourth Quarter FY2019 Snapshot...
MINNEAPOLIS , Aug. 6, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the fourth quarter ended June 30, 2019 . Fourth Quarter FY2019 Snapshot The company's consolidated financial statements are prepared in accordance with acc
Read more →TECHUman Diagnostics And Bio-Techne Announce License And Supply Agreement For Neurofilament Light Assay Uman Diagnostics, now part of Quanterix, and Bio-Techne announced today a strategic License and Supply Agreement for the antibodies used in the...
MINNEAPOLIS , July 23, 2019 /PRNewswire/ -- Uman Diagnostics, now part of Quanterix, and Bio-Techne announced today a strategic License and Supply Agreement for the antibodies used in the quantification of neurofilament light (Nf-L) on the ProteinSimple™-branded Ella™ immunoassay
Read more →TECHBio-Techne To Host Conference Call On August 6, 2019, To Announce Fourth Quarter 2019 Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, August 6, 2019, at 8:00 a.m. CDT to...
MINNEAPOLIS , July 18, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, August 6, 2019 , at 8:00 a.m. CDT to review fourth quarter 2019 financial results. Access to the discussion may be obtained
Read more →TECHBio-Techne Releases 32x8 Cartridge For The Ella Platform Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of a new 8-Plex cartridge format for the ProteinSimple™-branded Ella™ automated...
MINNEAPOLIS , July 17, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the launch of a new 8-Plex cartridge format for the ProteinSimple™-branded Ella™ automated immunoassay platform. This new cartridge format analyzes 32 samples for eight distinct ana
Read more →TECHBio-Techne Announces Commercial Release Of RNAscope® HiPlex Assay: A Multiplex In Situ Hybridization Assay For Tissues Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics™-branded RNAscope platform with release of the...
MINNEAPOLIS , July 11, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the expansion of the Advanced Cell Diagnostics™-branded RNAscope platform with release of the RNAscope HiPlex Assay. The RNAscope platform is an advanced in situ hybridization assay
Read more →TECHBio-Techne CEO Chuck Kummeth Wins Entrepreneur Of The Year® 2019 Award In The Heartland Bio-Techne Corporation (NASDAQ: TECH) today announced that its President and CEO, Chuck Kummeth, was recently honored with the EY Entrepreneur Of The ...
MINNEAPOLIS , July 9, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that its President and CEO, Chuck Kummeth , was recently honored with the EY Entrepreneur Of The Year ® 2019 Award in the Heartland. The EY awards program recognizes entrepreneurs an
Read more →TECHBio-Techne China Recognized With Decade of Contribution Award Bio-Techne Corporation (NASDAQ: TECH) was recently honored with the Decade of Contribution Award at the 2019 (10th) International Conference on...
MINNEAPOLIS , June 26, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) was recently honored with the "Decade of Contribution Award" at the 2019 (10th) International Conference on Cell Therapy conference. This award recognized the commitment of Bio-Techne's team in Chi
Read more →TECHBio-Techne Appoints Rupert Vessey to Board of Directors Bio-Techne Corporation today announced the appointment of Dr. Rupert Vessey to the company's Board of Directors as an independent director. Dr....
MINNEAPOLIS , June 25, 2019 /PRNewswire/ -- Bio-Techne Corporation today announced the appointment of Dr. Rupert Vessey to the company's Board of Directors as an independent director. Dr. Vessey's appointment brings the total number of Bio-Techne Board members to nine. Rupert Ve
Read more →TECHFDA Grants Breakthrough Device Designation To Bio-Techne's ExoDx™ Prostate IntelliScore™ (EPI) Test Bio-Techne today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its ExoDx Prostate...
MINNEAPOLIS , June 17, 2019 /PRNewswire/ -- Bio-Techne today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its ExoDx Prostate IntelliScore (EPI) test, making it the first exosome-based liquid biopsy test to receive a Bre
Read more →TECHBio-Techne Receives Approval To Offer The ExoDx™ Prostate Intelliscore™ (EPI) Test In New York State Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx...
MINNEAPOLIS , June 13, 2019 /PRNewswire/ -- Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate IntelliScore (EPI) test in New York , providing a valuable tool to help Urologists r
Read more →TECHBio-Techne To Acquire B-MoGen Biotechnologies Inc. Bio-Techne Corporation (NASDAQ: TECH) announced today it has reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc. The...
MINNEAPOLIS , June 4, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced today it has reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc. The transaction has been completed and is being financed through available cash on hand. "We are
Read more →TECHBio-Techne To Present At The Goldman Sachs 40th Annual Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Goldman Sachs...
MINNEAPOLIS , June 3, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Goldman Sachs 40 th Annual Global Healthcare Conference on Tuesday, June 11 th , 2019, at 1:20 p.m. PD
Read more →TECHBio-Techne's New Exosome-Based Liquid Biopsies Helping To Advance Personalized Care In Lung Cancer Diagnostics Bio-Techne today announced the publication of a recent validation study demonstrating that the proprietary exosome-based liquid biopsy tests from...
MINNEAPOLIS , May 28, 2019 /PRNewswire/ -- Bio-Techne today announced the publication of a recent validation study demonstrating that the proprietary exosome-based liquid biopsy tests from Bio-Techne's Exosome Diagnostics brand may be used to assess the mutational status of the E
Read more →TECHBio-Techne To Present At The Jefferies 2019 Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2019...
MINNEAPOLIS , May 21, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5 th , 2019, at 9:30 a.m. EDT . The con
Read more →TECHBio-Techne To Present At The UBS Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the UBS Global...
MINNEAPOLIS , May 14, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 22 nd , 2019, at 9:00 a.m. EDT . The conference wil
Read more →TECHBio-Techne To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer will present at the Bank of America Merrill Lynch 2019...
MINNEAPOLIS , May 2, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Chief Financial Officer will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15 th , 2019, at 2:20 p.m. PDT . The conferen
Read more →TECHBio-Techne Releases Third Quarter Fiscal 2019 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2019. Third Quarter FY2019 Snapshot...
MINNEAPOLIS , April 30, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the third quarter ended March 31, 2019 . Third Quarter FY2019 Snapshot The company's consolidated financial statements are prepared in accordance with ac
Read more →TECHElpiscience and Bio-Techne Announce Strategic Collaboration Elpiscience BioPharma and Bio-Techne Corporation announced today that the companies have entered into a strategic collaboration for the development...
SHANGHAI and MINNEAPOLIS , April 22, 2019 /PRNewswire/ -- Elpiscience BioPharma and Bio-Techne Corporation announced today that the companies have entered into a strategic collaboration for the development of anti-cancer therapeutics. Under the terms of the agreement, Elpiscience
Read more →TECHBio-Techne To Host Conference Call On April 30, 2019 To Announce Third Quarter 2019 Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, April 30, 2019 at 8:00 a.m. CDT to...
MINNEAPOLIS , April 9, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, April 30, 2019 at 8:00 a.m. CDT to review third quarter 2019 financial results. Access to the discussion may be obtained as
Read more →TECHBio-Techne and NanoString Partner to Co-Develop Integrated Workflow for RNA Spatial Profiling Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic...
MINNEAPOLIS , March 28, 2019 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH ), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and NanoString Technologies, Inc. (NASDAQ: NSTG ), a provider of life sc
Read more →TECHBio-Techne Scores A Trio Of CiteAb 2019 Awards Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities,...
MINNEAPOLIS , March 5, 2019 /PRNewswire/ -- Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, was honored with three prestigious 2019 CiteAb Awards. The CiteAb Awards celebrate the ve
Read more →TECHBio-Techne To Present At The Barclays Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer will present at the Barclays Global Healthcare...
MINNEAPOLIS , March 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Chief Financial Officer will present at the Barclays Global Healthcare Conference on Wednesday, March 13 th , 2019, at 9:00 a.m. EST . The conference will be held
Read more →TECHBio-Techne Signs Strategic Cooperation Agreement with Lisen Imprinting Diagnostics Bio-Techne has entered into a strategic cooperation agreement in the precision medicine field with Lisen Imprinting Diagnostics Wuxi Co., Ltd, China. ...
Liwen Pei commented, "I am excited about the collaboration with Lisen. The emerging molecular diagnostic market requires technical innovation as well as first-class quality reagents on which to build these novel tests." Ning Zhou added, "As a high-tech diagnostic development com
Read more →TECHBio-Techne To Present At The 8th Annual SVB Leerink Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer will present at the 8th Annual SVB...
MINNEAPOLIS , Feb. 20, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer will present at the 8 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27 th , 2019, at 10:30 a.m
Read more →TECHBio-Techne Releases Second Quarter Fiscal 2019 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2018. Second Quarter FY2019...
MINNEAPOLIS , Feb. 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the second quarter ended December 31, 2018 . Second Quarter FY2019 Snapshot The company's consolidated financial statements are prepared in accordance with
Read more →TECHExoDx® Prostate(IntelliScore) (EPI) Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection Bio-Techne Corporation (NASDAQ:TECH) today announced the National Comprehensive Cancer Network (NCCN) decision to include EPI as a recommended test...
The NCCN Guidelines are the recognized clinical standard for cancer care by clinicians and payors in the United States . The guidelines are developed and revised by a panel of expert physicians from 28 leading U.S. cancer centers. The panel revises recommended practice guidelines
Read more →TECHBio-Techne Introduces 48-Digoxigenin Cartridge for the Ella Platform Bio-Techne today announced the launch of a new customizable cartridge format for their ProteinSimple-branded Ella™ immunoassay platform. Ella allows...
MINNEAPOLIS , Jan. 29, 2019 /PRNewswire/ -- Bio-Techne today announced the launch of a new customizable cartridge format for their ProteinSimple-branded Ella™ immunoassay platform. Ella allows users to perform high-quality immunoassays in under 90 minutes without manual intervent
Read more →TECHBio-Techne Introduces CE-SDS PLUS for Maurice™ System Bio-Techne today announced the launch of the CE-SDS PLUS system for its ProteinSimple-branded Maurice™ platform. This new system further expands the...
MINNEAPOLIS , Jan. 28, 2019 /PRNewswire/ -- Bio-Techne today announced the launch of the CE-SDS PLUS system for its ProteinSimple-branded Maurice ™ platform. This new system further expands the usability of Maurice's proprietary cartridge and reduces undesirable protein fragmenta
Read more →TECHBio-Techne Launches Cell and Gene Therapy Portfolio Bio-Techne announces the launch of their cell and gene therapy portfolio. As a leading manufacturer of GMP-grade ancillary materials and automated...
MINNEAPOLIS , Jan. 24, 2019 /PRNewswire/ -- Bio-Techne announces the launch of their cell and gene therapy portfolio. As a leading manufacturer of GMP-grade ancillary materials and automated instrumentation, Bio-Techne is uniquely able to offer solutions that advance the translat
Read more →TECHBio-Techne To Host Conference Call On February 5, 2019, To Announce Second Quarter 2019 Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, February 5, 2019, at 8:00 a.m. CST to...
MINNEAPOLIS , Jan. 16, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, February 5, 2019 , at 8:00 a.m. CST to review second quarter 2019 financial results. Access to the discussion may be obtaine
Read more →TECHBio-Techne To Present At The 37th Annual J.P. Morgan Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer will present at the 37th Annual J.P....
MINNEAPOLIS , Dec. 20, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer will present at the 37 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9 th , 2019, at 7:30 a.m. PST . T
Read more →TECHBio-Techne Releases GMP ROCK Inhibitor and CHIR 99021 for Stem Cell Therapy Bio-Techne has further added to its cell therapy portfolio by expanding the range of Tocris Bioscience-branded cGMP small molecules to include the...
MINNEAPOLIS , Dec. 4, 2018 /PRNewswire/ -- Bio-Techne has further added to its cell therapy portfolio by expanding the range of Tocris Bioscience-branded cGMP small molecules to include the commonly used stem cell compounds, Y-27632 (ROCK inhibitor) and CHIR 99021. Y-27632 is a
Read more →TECHBio-Techne To Present At The Citi 2018 Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Dave Eansor, President Protein Sciences will present at the Citi 2018 Global Healthcare...
MINNEAPOLIS , Nov. 20, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Dave Eansor , President Protein Sciences will present at the Citi 2018 Global Healthcare Conference on Wednesday, December 5, 2018 , at 2:10 p.m. EST . The conference will be h
Read more →TECHBio-Techne Releases First Quarter Fiscal 2019 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2018. First Quarter FY2019...
MINNEAPOLIS , Oct. 30, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the first quarter ended September 30, 2018 . First Quarter FY2019 Snapshot The company's financial statements are prepared in accordance with accounting p
Read more →TECHBio-Techne To Present At The 2018 Stephens NY Investment Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2018 Stephens NY...
MINNEAPOLIS , Oct. 26, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 2018 Stephens NY Investment Conference on Wednesday, November 7, 2018 , at 10:30 a.m. EST . The confe
Read more →TECHBio-Techne Signs Strategic Cooperation Agreement with Micropoint Bioscience Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China. Chuck Kummeth, President and CEO of...
MINNEAPOLIS , Oct. 12, 2018 /PRNewswire/ -- Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China . Chuck Kummeth , President and CEO of Bio-Techne, Yan Pingyi, Chairman of Micropoint Bioscience, and Wang Bin, Executive Vice P
Read more →TECHBio-Techne To Host Conference Call On October 30, 2018 To Announce First Quarter 2019 Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, October 30, 2018 at 8:00 a.m. CDT to...
MINNEAPOLIS , Oct. 11, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, October 30, 2018 at 8:00 a.m. CDT to review first quarter 2019 financial results. Access to the discussion may be obtained a
Read more →TECHBio-Techne Scientist Presented with the CASSS CE Pharm Award Bio-Techne is proud to announce that one of its Principal Scientists, Jiaqi Wu, Ph.D., was presented with the CE Pharm Award at this year's CE Pharm...
MINNEAPOLIS , Oct. 2, 2018 /PRNewswire/ -- Bio-Techne is proud to announce that one of its Principal Scientists, Jiaqi Wu , Ph.D., was presented with the CE Pharm Award at this year's CE Pharm meeting , September 9-12, 2018 , for his contributions to the capillary electrophoresis
Read more →TECHBio-Techne Announces Cell and Gene Therapy Initiative Bio-Techne, a global leader of research and manufacturing-grade reagents, has announced a corporate initiative to advance cell and gene therapy...
MINNEAPOLIS , Sept. 27, 2018 /PRNewswire/ -- Bio-Techne, a global leader of research and manufacturing-grade reagents, has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing. Through strategic acquisitions and internal scientifi
Read more →TECHBio-Techne Supports International Antibody Validation Meetings Bio-Techne is proud to be sharing its 30+ years of industry leading expertise in antibody development and validation from its R&D Systems and Novus...
MINNEAPOLIS , Sept. 19, 2018 /PRNewswire/ -- Bio-Techne is proud to be sharing its 30+ years of industry leading expertise in antibody development and validation from its R&D Systems and Novus Biologicals brands at the 3 rd International Antibody Validation Meeting on September 2
Read more →TECHBio-Techne Announces Publication of Data Demonstrating Additional Clinical Validation of its EPI Test in European Urology Journal Bio-Techne today announced the online publication of its second prospective US clinical validation study of the Exosome Diagnostics-branded ExoDx®...
About the EPI Test ExoDx® Prostate(IntelliScore) (EPI) is the first exosomal urine-based liquid biopsy test, designed to risk stratify patients presenting for prostate biopsy. The test is a purely genomic test that examines the presence of three gene signatures known to be expre
Read more →TECHBio-Techne Fills a Need for Simple Tools to Study Glycobiology Bio-Techne researchers publish papers that promise to open the field of glycobiology to the masses. Sugars, also known as glycans, are attached to...
MINNEAPOLIS , Sept. 6, 2018 /PRNewswire/ -- Bio-Techne researchers publish papers that promise to open the field of glycobiology to the masses. Sugars, also known as glycans, are attached to many proteins found both inside and on the surface of cells. This modification of protei
Read more →TECHBio-Techne To Present At The Morgan Stanley 16th Annual Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Morgan Stanley...
MINNEAPOLIS , Sept. 5, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Morgan Stanley 16 th Annual Global Healthcare Conference on Thursday, September 13 , 2018, at 8:00 a.
Read more →TECHBio-Techne To Present At The Baird 2018 Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Baird 2018 Global ...
MINNEAPOLIS , Aug. 28, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Baird 2018 Global Healthcare Conference on Thursday, September 6 , 2018, at 9:40 a.m. EDT . The confe
Read more →TECHBio-Techne Introduces GMP Small Molecules for Stem Cell Therapy Development Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for...
MINNEAPOLIS , Aug. 8, 2018 /PRNewswire/ -- Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for use as ancillary materials in the development of stem cell therapies. Bio-Techne has a hi
Read more →TECHBio-Techne Releases Fourth Quarter Fiscal 2018 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2018. Fourth Quarter and Full Year...
MINNEAPOLIS , Aug. 7, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the fourth quarter ended June 30, 2018 . Fourth Quarter and Full Year FY2018 Snapshot The company's financial statements are prepared in accordance with ac
Read more →TECHBio-Techne Announces 2018 Investor Day And Webcast Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host its 2018 Investor Day on Friday, September 7, 2018, starting at 9:00 a....
MINNEAPOLIS , Aug. 2, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host its 2018 Investor Day on Friday, September 7, 2018 , starting at 9:00 a.m. EDT . The meeting will take place at the Lotte New York Palace Hotel, 455 Madison
Read more →TECHBio-Techne Corporation Completed Its Acquisition of Exosome Diagnostics, Inc. Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Exosome Diagnostics, Inc. The transaction consideration...
MINNEAPOLIS , Aug.1, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced it has completed its acquisition of Exosome Diagnostics, Inc. The transaction consideration includes an upfront payment of $250 million plus an additional $325 million that can be max
Read more →TECHBio-Techne Introduces New Member of the Simple Western™ Family, with IR/NIR Detection Capabilities Bio-Techne again disrupts protein analysis technology with the introduction of the newest member of their ProteinSimple-branded Simple Western...
MINNEAPOLIS , July 24, 2018 /PRNewswire/ -- Bio-Techne again disrupts protein analysis technology with the introduction of the newest member of their ProteinSimple-branded Simple Western family, Jess. This evolutionary technology simplifies protein expression analysis, while spee
Read more →TECHBio-Techne To Host Conference Call On August 7, 2018 To Announce Fourth Quarter 2018 Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, August 7, 2018 at 8:00 a.m. CDT to...
MINNEAPOLIS , July 12, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, August 7, 2018 at 8:00 a.m. CDT to review fourth quarter 2018 financial results. Access to the discussion may be obtained as
Read more →TECHBio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique and leading portfolio of antibody-based reagents for life science and...
MINNEAPOLIS , July 10, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a family of brands with a unique and leading portfolio of antibody-based reagents for life science and clinical research, has been validating an extensive and growing number of antibodies using re
Read more →TECHBio-Techne Expands RNAscope® Assay Services Portfolio to Shorten Development Times and Save Costs Bio-Techne has added new capabilities and options to its Advanced Cell Diagnostics (ACD)-branded RNAscope® and BaseScope™ in situ hybridization (ISH) ...
MINNEAPOLIS , June 26, 2018 /PRNewswire/ -- Bio-Techne has added new capabilities and options to its Advanced Cell Diagnostics (ACD)-branded RNAscope ® and BaseScope™ in situ hybridization (ISH) Assay Services Portfolio to improve biotech and pharma discovery timelines and costs.
Read more →TECHBio-Techne To Acquire Exosome Diagnostics, Inc. Bio-Techne Corporation (NASDAQ: TECH) announced today that it has reached agreement to acquire Exosome Diagnostics, Inc. for $250 million in cash...
MINNEAPOLIS and WALTHAM, Mass. , June 25, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced today that it has reached agreement to acquire Exosome Diagnostics, Inc. for $250 million in cash plus contingent consideration of up to $325 million due upon the achie
Read more →TECHBio-Techne To Acquire Quad Technologies Bio-Techne Corporation (NASDAQ: TECH) announced today it has reached agreement to acquire all of the stock of QT Holdings Corporation d/b/a Quad...
MINNEAPOLIS , June 7, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced today it has reached agreement to acquire all of the stock of QT Holdings Corporation d/b/a Quad Technologies. The transaction is expected to close in early July and to be financed through
Read more →TECHBio-Techne To Present At The William Blair 38th Annual Growth Stock Conference Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the William Blair...
MINNEAPOLIS , June 4, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the William Blair 38 th Annual Growth Stock Conference on Wednesday, June 13, 2018 , at 1:20 p.m. CDT . Th
Read more →TECHBio-Techne To Present At The Jefferies 2018 Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2018...
MINNEAPOLIS , May 24, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 , at 2:00 p.m. EDT . The conference will
Read more →TECHBio-Techne Releases Third Quarter Fiscal 2018 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2018. Third Quarter FY2018 Snapshot...
MINNEAPOLIS , May 2, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the third quarter ended March 31, 2018 . Third Quarter FY2018 Snapshot The company's financial statements are prepared in accordance with accounting princip
Read more →TECHBio-Techne To Present At The Deutsche Bank 43rd Annual Health Care Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Deutsche Bank...
MINNEAPOLIS , May 1, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Deutsche Bank 43 rd Annual Health Care Conference on Tuesday, May 8, 2018 , at 8:40 a.m. EDT . The conf
Read more →TECHBio-Techne Leads the Way in Scientific Support for Autophagy Research Bio-Techne, a family of brands providing a unique portfolio of products and services for basic and clinical research, has a leading role supporting...
MINNEAPOLIS , April 26, 2018 /PRNewswire/ -- Bio-Techne, a family of brands providing a unique portfolio of products and services for basic and clinical research, has a leading role supporting autophagy research. Autophagy (or "self-eating") is an important basic cellular proces
Read more →TECHBio-Techne Announces New Leadership Appointment Bio-Techne Corporation announced today that it has hired Kim Kelderman as President, Diagnostics and Genomics, effective April 30, 2018. Mr....
MINNEAPOLIS , April 24, 2018 /PRNewswire/ -- Bio-Techne Corporation announced today that it has hired Kim Kelderman as President, Diagnostics and Genomics, effective April 30 , 2018. Mr. Kelderman will be based in California and will lead Bio-Techne's diagnostics business; he wil
Read more →TECHBio-Techne Expands RNAscope® ISH Automation - Facilitating Drug Discovery and Development Bio-Techne has expanded the automation capabilities of its popular Advanced Cell Diagnostics (ACD)-branded RNAscope® in situ hybridization (ISH)...
MINNEAPOLIS , March 21, 2018 /PRNewswire/ -- Bio-Techne has expanded the automation capabilities of its popular Advanced Cell Diagnostics (ACD)-branded RNAscope® in situ hybridization (ISH) technology with the launch of several new and updated assays. The developments increase bo
Read more →TECHBio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract Bio-Techne has released MimEX™ GI, a new product line for generating 3-dimensional (3-D) gastrointestinal tissue on a 2-D surface. 3-D cell culture...
MINNEAPOLIS , March 14, 2018 /PRNewswire/ -- Bio-Techne has released MimEX™ GI , a new product line for generating 3-dimensional (3-D) gastrointestinal tissue on a 2-D surface. 3-D cell culture and organoid models of the gastrointestinal epithelium are quickly being adopted for
Read more →TECHBio-Techne Named Researchers' Choice by CiteAb Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities,...
MINNEAPOLIS , Feb. 7, 2018 /PRNewswire/ -- Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, was honored with the prestigious 2018 CiteAb Award for Researchers' Choice. The CiteAb Awa
Read more →TECHBio-Techne Releases Second Quarter Fiscal 2018 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2017. Second Quarter FY2018...
MINNEAPOLIS , Feb. 6, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the second quarter ended December 31, 2017 . Second Quarter FY2018 Snapshot The company's financial statements are prepared in accordance with accounting p
Read more →TECHBio-Techne To Present At The Leerink Partners 7th Annual Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Jim Hippel, Chief Financial...
MINNEAPOLIS , Feb. 5, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, and Jim Hippel , Chief Financial Officer will present at the Leerink Partners 7 th Annual Global Healthcare Conference on
Read more →TECHBio-Techne's Ella™ Added to BioAgilytix Portfolio of Industry-Leading Immunoassay Platforms Bio-Techne's ProteinSimple-branded Ella™ platform has recently been added to the suite of advanced immunoassay technology at BioAgilytix, a leading...
MINNEAPOLIS , Jan. 30, 2018 /PRNewswire/ -- Bio-Techne's ProteinSimple-branded Ella™ platform has recently been added to the suite of advanced immunoassay technology at BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecul
Read more →TECHBio-Techne To Host Conference Call On February 6, 2018 To Announce Second Quarter 2018 Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on February 6, 2018, at 8:00 a.m. CST to review...
MINNEAPOLIS , Jan. 18, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on February 6, 2018 , at 8:00 a.m. CST to review second quarter 2018 financial results. Access to the discussion may be obtained as foll
Read more →TECHAdvanced Immunolabeling Reagents and Tools from Vector Laboratories Now from Bio-Techne Bio-Techne now offers reagents and kits from Vector Laboratories, a leader in advanced labeling and detection solutions. Their innovative proprietary ...
MINNEAPOLIS , Jan. 15, 2018 /PRNewswire/ -- Bio-Techne now offers reagents and kits from Vector Laboratories, a leader in advanced labeling and detection solutions. Their innovative proprietary immunolabeling kits offer reliable, sensitive, and low background detection. In Octobe
Read more →TECHBio-Techne To Present At The 36th Annual J.P. Morgan Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Jim Hippel, Chief Financial...
MINNEAPOLIS , Dec. 28, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, and Jim Hippel , Chief Financial Officer will present at the 36 th Annual J.P. Morgan Healthcare Conference on Tuesday, J
Read more →TECHBio-Techne's RNAscope® Technology Enabling Robust Gene Expression and Biomarker Analysis Advances Wide-ranging Research with over 1000 Publications Advanced Cell Diagnostics (ACD), a Bio-Techne brand, is celebrating a milestone in the adoption of its RNAscope® in situ hybridization (ISH)...
MINNEAPOLIS , Nov. 28, 2017 /PRNewswire/ -- Advanced Cell Diagnostics (ACD), a Bio-Techne brand, is celebrating a milestone in the adoption of its RNAscope ® in situ hybridization (ISH) technology. Reaching 1,000 publications and increasing to an average of more than one publicat
Read more →TECHBio-Techne Offers Updated Novus Panel Builder, Facilitating Multicolor Flow Cytometry Panel Design Bio-Techne updated its Flow Cytometry Panel Builder tool in July 2017 to support the use of its vast selection of over 18,000 conjugated antibodies,...
MINNEAPOLIS , Nov. 20, 2017 /PRNewswire/ -- Bio-Techne updated its Flow Cytometry Panel Builder tool in July 2017 to support the use of its vast selection of over 18,000 conjugated antibodies, across targets and colors. The Flow Cytometry Panel Builder, a version of the FluoroFin
Read more →TECHBio-Techne Awards 40,000 USD Research Grant to Innovative Cancer Researcher Advanced Cell Diagnostics (ACD), a Bio-Techne brand, has announced the winner of its 'RNAscope ISH Get Hybridized' giveaway, designed to recognize...
MINNEAPOLIS , Nov. 14, 2017 /PRNewswire/ -- Advanced Cell Diagnostics (ACD), a Bio-Techne brand, has announced the winner of its 'RNAscope ISH Get Hybridized' giveaway, designed to recognize and support groundbreaking research with RNAscope ® in situ hybridization (ISH) technolog
Read more →TECHBio-Techne Releases First Quarter Fiscal 2018 Results Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2017. First Quarter FY2018...
MINNEAPOLIS , Oct. 31, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the first quarter ended September 30, 2017 . First Quarter FY2018 Snapshot The company's financial statements are prepared in accordance with accounting p
Read more →TECHBio-Techne To Present At The Stephens Fall Investment Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Jim Hippel, Chief Financial...
MINNEAPOLIS , Oct. 27, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, and Jim Hippel , Chief Financial Officer will present at the Stephens Fall Investment Conference on Tuesday, November 7,
Read more →TECHBio-Techne Adds Two New Directors to Its Board Bio-Techne Corporation (NASDAQ: TECH) announced today the election of Dr. Alpna Seth and Dr. Joe Keegan to the company's board of directors for a...
MINNEAPOLIS , Oct. 26, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced today the election of Dr. Alpna Seth and Dr. Joe Keegan to the company's board of directors for a first term, effective today. Seth is Chief Operating Officer of Vir Biotechnology, Inc. a
Read more →TECHBio-Techne To Host Conference Call On October 31, 2017 To Announce First Quarter 2018 Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on October 31, 2017, at 8:00 a.m. CDT to review...
MINNEAPOLIS , Oct. 11, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on October 31, 2017 , at 8:00 a.m. CDT to review first quarter 2018 financial results. Access to the discussion may be obtained as follo
Read more →TECHBio-Techne Unveils a New Multi-Analyte Cartridge Format for the Ella™ Immunoassay Platform, Improving Sample Throughput ProteinSimple®, a Bio-Techne brand, announced today an expansion of the Ella immunoassay platform with the launch of a 32x4 Simple Plex™ cartridge....
SAN JOSE, Calif. , Sept. 20, 2017 /PRNewswire/ -- ProteinSimple®, a Bio-Techne brand, announced today an expansion of the Ella immunoassay platform with the launch of a 32x4 Simple Plex™ cartridge. This new cartridge simultaneously measures up to 32 different samples from serum,
Read more →TECHBio-Techne Introduces a New Luminex Multi-analyte Assay Kit R&D Systems, a Bio-Techne brand, today announced the release of its new XL Cytokine Discovery Luminex® High Performance Panel. As with all R&D...
MINNEAPOLIS , Sept. 13, 2017 /PRNewswire/ -- R&D Systems, a Bio-Techne brand, today announced the release of its new XL Cytokine Discovery Luminex® High Performance Panel. As with all R&D Systems® Luminex Assays, this new panel is compatible with all Luminex instrumentation syste
Read more →TECHBio-Techne Releases A Highly Sensitive and Specific Serological Assay to Detect Zika Virus Infections R&D Systems®, a Bio-Techne brand, announced today the release of a new rapid, solid phase, enzyme-linked immunosorbent assay (ELISA) designed to...
MINNEAPOLIS , Sept. 6, 2017 /PRNewswire/ -- R&D Systems®, a Bio-Techne brand, announced today the release of a new rapid, solid phase, enzyme-linked immunosorbent assay (ELISA) designed to measure anti-Zika virus immunoglobulin G (IgG) antibodies in human serum. A unique feature
Read more →TECHBio-Techne Acquires Trevigen Inc. Bio-Techne Corporation (NASDAQ: TECH) announced today that it has acquired all of the stock of Trevigen Inc. for cash. The transaction is financed...
MINNEAPOLIS , Sept. 5, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced today that it has acquired all of the stock of Trevigen Inc. for cash. The transaction is financed through available cash on hand. Charles R. Kummeth , President and Chief Executive Offi
Read more →TECHBio-Techne To Present At The Wells Fargo Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer, will present at the 2017 Wells Fargo Healthcare...
MINNEAPOLIS , Aug. 28, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Jim Hippel , Chief Financial Officer, will present at the 2017 Wells Fargo Healthcare Conference on Thursday, September 7, 2017 , at 2:15 p.m. EDT . The conference will be held
Read more →TECHBio-Techne To Present At The Baird 2017 Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Jim Hippel, Chief Financial...
MINNEAPOLIS , Aug. 22, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, and Jim Hippel , Chief Financial Officer will present at the Baird 2017 Global Healthcare Conference on Wednesday, Septem
Read more →TECHBIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2017 RESULTS Minneapolis/
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2017 RESULTS Minneapolis/August 8, 2017/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter and full year end ended June 30, 2017. Fourth Quarter and Full Year FY2017 Snapshot The company's
Read more →TECHBio-Techne To Host Conference Call On August 8, 2017 To Announce Fourth Quarter Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on August 8, 2017, at 8:00 a.m. CDT to review fourth ...
MINNEAPOLIS , July 12, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on August 8, 2017 , at 8:00 a.m. CDT to review fourth quarter 2017 financial results. Access to the discussion may be obtained as follow
Read more →TECHBio-Techne To Present At The Jefferies 2017 Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies...
MINNEAPOLIS , May 24, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 7 th , 2017, at 3:30 p.m. EDT . Bio-Techne Corpora
Read more →TECHBio-Techne To Present At The Bank Of America Merrill Lynch Health Care Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Bank of America...
MINNEAPOLIS , May 8, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 18, 2017 , at 8:40 a.m. PDT . The
Read more →TECHBIO-TECHNE RELEASES THIRD QUARTER FISCAL 2017 RESULTS Minneapolis/
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2017 RESULTS Minneapolis/May 2, 2017/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2017. Third Quarter FY2017 Snapshot The company's financial statements are prepared in
Read more →TECHBio-Techne To Present At The Deutsche Bank 42nd Annual Health Care Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Deutsche Bank...
MINNEAPOLIS , April 24, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Deutsche Bank 42 nd Annual Health Care conference on Wednesday, May 3, 2017 , at 2:10 p.m. EDT . The
Read more →TECHBio-Techne To Host Conference Call On May 2, 2017 To Announce Third Quarter Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on May 2, 2017, at 8:00 a.m. CDT to review third...
MINNEAPOLIS , April 18, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on May 2, 2017 , at 8:00 a.m. CDT to review third quarter fiscal 2017 financial results. Access to the discussion may be obtained as fo
Read more →TECHBio-Techne Signs Exclusive License Agreement with Multiclonal Therapeutics for Adult Ground-state Stem Cell Technology Bio-Techne has entered into an exclusive license agreement with Multiclonal Therapeutics (MCT) to commercialize reagents and media systems in the...
MINNEAPOLIS , March 7, 2017 /PRNewswire/ -- Bio-Techne has entered into an exclusive license agreement with Multiclonal Therapeutics (MCT) to commercialize reagents and media systems in the research reagent field intended for cloning, propagating, and differentiating adult "groun
Read more →TECHInnovative Veterinary Diagnostic Setting A New Standard Bio-Techne Corporation has partnered with Brazil-based DK Diagnostics to release its first diagnostic tool for the veterinary market. The PARATEST...
MINNEAPOLIS , March 1, 2017 /PRNewswire/ -- Bio-Techne Corporation has partnered with Brazil -based DK Diagnostics to release its first diagnostic tool for the veterinary market. The PARATEST system is an innovative parasitological system which contains the only non-toxic, biodeg
Read more →TECHBio-Techne To Present At The Leerink Partners 6th Annual Global Healthcare Conference Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, Chief Executive Officer, will present at the Leerink Partners 6th Annual...
MINNEAPOLIS , Feb. 13, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Chuck Kummeth , Chief Executive Officer, will present at the Leerink Partners 6 th Annual Global Healthcare conference on Thursday, February 16, 2017 , at 11:30 a.m. EST . The
Read more →TECHBio-Techne Named Company of the Year by Instrument Business Outlook Bio-Techne has been named the 2016 Company of the Year by Instrument Business Outlook (IBO). IBO is the most authoritative newsletter for tracking...
MINNEAPOLIS , Feb. 9, 2017 /PRNewswire/ -- Bio-Techne has been named the 2016 Company of the Year by Instrument Business Outlook (IBO). IBO is the most authoritative newsletter for tracking developments in the analytical and life science instrumentation and consumables market. Bi
Read more →TECHBIO-TECHNE RELEASES SECOND QUARTER FISCAL 2017 RESULTS Minneapolis/
BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2017 RESULTS Minneapolis/February 7, 2017/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2016. Second Quarter FY2017 Snapshot The company's financial statements are
Read more →TECHBio-Techne To Host Conference Call On February 7, 2017 To Announce Second Quarter Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, February 7, 2017, at 8:00 a.m. CST to...
MINNEAPOLIS , Jan. 25, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, February 7, 2017 , at 8:00 a.m. CST to review second quarter fiscal 2017 financial results. Access to the discussion may be
Read more →TECHBio-Techne Congratulates Astute Medical on Clinical Trial Results In a major study released this weekend from the University Hospital Muenster, Germany1...
MINNEAPOLIS , Jan. 24, 2017 /PRNewswire/ -- In a major study released this weekend from the University Hospital Muenster, Germany 1 ( http://www.multivu.com/players/English/7899551-nephrocheck-test-acute-kidney-injury-outcomes/ ), Astute Medical's CE marked and FDA cleared Nephro
Read more →TECHCOPD Biomarker Qualification Consortium Partners with Bio-Techne to Identify COPD Indicator The COPD Foundation-sponsored COPD Biomarker Qualification Consortium (CBQC) today announced that it has partnered with the Bio-Techne Corporation, a ...
WASHINGTON and MINNEAPOLIS , Jan. 11, 2017 /PRNewswire/ -- The COPD Foundation-sponsored COPD Biomarker Qualification Consortium (CBQC) today announced that it has partnered with the Bio-Techne Corporation, a manufacturer of biotechnology products for life science research and di
Read more →TECHBio-Techne And Astute Medical Form Strategic Partnership Bio-Techne Corporation (NASDAQ: TECH) today closed on a strategic equity investment in Astute Medical, Inc. (San Diego, CA), a diagnostic company...
MINNEAPOLIS and SAN DIEGO , Dec. 14, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today closed on a strategic equity investment in Astute Medical, Inc. ( San Diego, CA ), a diagnostic company devoted to improving patient healthcare outcomes through the identificati
Read more →TECHBIO-TECHNE RELEASES FIRST QUARTER FISCAL 2017 RESULTS Minneapolis/
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2017 RESULTS Minneapolis/October 31, 2016/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2016. First Quarter FY2017 Highlights The company's financial statements are
Read more →TECHBio-Techne Declares Dividend Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended...
MINNEAPOLIS , Oct. 31, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30 , 2016. The quarterly dividend will be payable November 28, 2016 to all com
Read more →TECHBio-Techne To Host Conference Call On October 31, 2016 To Announce First Quarter Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Monday, October 31, 2016, at 8:00 a.m. CDT to...
MINNEAPOLIS , Oct. 17, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Monday, October 31, 2016 , at 8:00 a.m. CDT to review first quarter fiscal 2017 financial results. Access to the discussion may be ob
Read more →TECHBio-Techne Announces Investor Day And Webcast Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host its 2016 Investor Day on Thursday, September 15, 2016, starting at...
MINNEAPOLIS , Aug. 31, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host its 2016 Investor Day on Thursday, September 15, 2016 , starting at 9:00 a.m. EST . The meeting will take place at the Lotte New York Palace Hotel, 455 Mad
Read more →TECHBIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2016 RESULTS Minneapolis/
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2016 RESULTS Minneapolis/August 17, 2016/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter and full year ended June 30, 2016. Fourth Quarter and Full Year FY2016 Highlights Fourth quarte
Read more →TECHBio-Techne To Host Conference Call On August 17, 2016 To Announce Fourth Quarter Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Wednesday, August 17, 2016, at 8:00 a.m. CDT to...
MINNEAPOLIS , Aug. 3, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Wednesday, August 17, 2016 , at 8:00 a.m. CDT to review fourth quarter fiscal 2016 financial results. Access to the discussion may be
Read more →TECHMinneapolis, MN
Minneapolis, MN August 01, 2016 Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Advanced Cell Diagnostics of Newark, CA. This represents the 9th acquisition for Bio-Techne in the last three years. With these acquisitions, Minneapolis-bas
Read more →TECHBio-Techne Corporation Completed its Acquisition of Advanced Cell Diagnostics Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Advanced Cell Diagnostics of Newark, CA. This represents...
MINNEAPOLIS , Aug. 1, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced it has completed its acquisition of Advanced Cell Diagnostics of Newark, CA. This represents the 9 th acquisition for Bio-Techne in the last three years. With these acquisitions, Min
Read more →TECHBIO- TECHNE ANNOUNCES AGREEMENT TO ACQUIRE ADVANCED CELL DIAGNOSTICS Minneapolis/
BIO-TECHNE ANNOUNCES AGREEMENT TO ACQUIRE ADVANCED CELL DIAGNOSTICS Minneapolis/July 6, 2016/--Bio-Techne Corporation (NASDAQ: TECH) announced today that it has agreed to acquire Advanced Cell Diagnostics (ACD) for $250 million in cash plus contingent consideration of $75 milli
Read more →TECHBio-Techne Acquires Space Import-Export And Strengthens European Leadership Team Bio-Techne Corporation (NASDAQ: TECH) announced today the acquisition of Space Import-Export Srl (Space) of Milan, Italy. Space is a long and trusted ...
MINNEAPOLIS , July 1, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced today the acquisition of Space Import-Export Srl (Space) of Milan, Italy . Space is a long and trusted partner of Bio-Techne, distributing its products since 1985 and creating a very effec
Read more →TECHBIO-TECHNE RELEASES THIRD QUARTER FISCAL 2016 RESULTS Minneapolis/
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2016 RESULTS Minneapolis/May 3, 2016/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2016. Third Quarter FY2016 Highlights The company's financial statements are prepared
Read more →TECHBio-Techne To Host Conference Call On May 3, 2016 To Announce Third Quarter Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, May 3, 2016, at 8:00 a.m. CDT to review...
MINNEAPOLIS , April 11, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, May 3, 2016 , at 8:00 a.m. CDT to review third quarter fiscal 2016 financial results. Access to the discussion may be obtai
Read more →TECHBio-Techne Corporation Agrees to Acquire Zephyrus Biosciences, Inc. Bio-Techne Corporation (NASDAQ: TECH) announced today that it has completed the acquisition of Zephyrus Biosciences. Zephyrus Biosciences will be...
MINNEAPOLIS , March 21, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced today that it has completed the acquisition of Zephyrus Biosciences. Zephyrus Biosciences will be integrated into the Protein Platforms Division of Bio-Techne. Zephyrus Biosciences prov
Read more →TECHBIO-TECHNE RELEASES SECOND QUARTER FISCAL 2016 RESULTS Minneapolis/
BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2016 RESULTS Minneapolis/February 2, 2016/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2015. Second Quarter 2016 Highlights Adjusted EPS, adjusted earnings, adjust
Read more →TECHBio-Techne To Host Conference Call On February 2, 2016 To Announce Second Quarter Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, February 2, 2016, at 8:00 a.m. CST to...
MINNEAPOLIS , Jan. 12, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, February 2, 2016 , at 8:00 a.m. CST to review second quarter fiscal 2016 financial results. Access to the discussion may be
Read more →TECHBIO-TECHNE DECLARES DIVIDEND Minneapolis/
BIO-TECHNE DECLARES DIVIDEND Minneapolis/October 29, 2015/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2015. The quarterly dividend will be payable November 27,
Read more →TECHBIO-TECHNE RELEASES FIRST QUARTER FISCAL 2016 RESULTS Minneapolis/
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2016 RESULTS Minneapolis/October 28, 2015/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2015. First Quarter 2016 Snapshot Adjusted EPS, adjusted earnings, adjusted g
Read more →TECHBio-Techne Certifies over 1,000 Antibodies for Simple Western Bio-Techne Corporation announced today that its R&D Systems®, Novus Biologicals®, and ProteinSimple® brands have collaborated to certify over 1,000...
MINNEAPOLIS , Oct. 26, 2015 /PRNewswire/ -- Bio-Techne Corporation announced today that its R&D Systems ® , Novus Biologicals ® , and ProteinSimple ® brands have collaborated to certify over 1,000 antibodies for the Simple Western™ platform. This milestone demonstrates the power
Read more →TECHBio-Techne To Host Conference Call On October 28, 2015 To Announce First Quarter Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Wednesday, October 28, 2015, at 8:00 a.m. CDT to...
MINNEAPOLIS , Oct. 14, 2015 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Wednesday, October 28, 2015 , at 8:00 a.m. CDT to review first quarter fiscal 2016 financial results. Access to the discussion may be
Read more →TECHBIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2015 RESULTS Minneapolis/
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2015 RESULTS Minneapolis/August 6, 2015/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2015. Fourth Quarter Snapshot and Full Year 2015 Highlights Adjusted EPS, adjusted
Read more →TECHBio-Techne To Host Conference Call On August 6, 2015 To Announce Fourth Quarter Financial Results Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call on Thursday, August 6, 2015, at 8:00 a.m. CDT to...
MINNEAPOLIS , July 14, 2015 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Thursday, August 6, 2015 , at 8:00 a.m. CDT to review fourth quarter fiscal 2015 financial results. Access to the discussion may be o
Read more →TECHBio-Techne Corporation Agrees to Acquire Cliniqa Corporation MINNEAPOLIS
Bio-Techne Corporation Agrees to Acquire Cliniqa Corporation MINNEAPOLIS, June 5, 2015/PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) announced today that it has agreed to acquire 100% ownership of Cliniqa Corporation. Cliniqa specializes in the manufacturing and commercial
Read more →TECHBIO-TECHNE RELEASES THIRD QUARTER FISCAL 2015 RESULTS Minneapolis/May 5th, 2015/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2015 RESULTS Minneapolis/May 5th, 2015/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2015. Third Quarter Snapshot Adjusted EPS, adjusted earnings, adjusted gross margin,
Read more →TECHBio-Techne To Host Conference Call On May 5, 2015 To Announce Third Quarter Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, May 5, 2015, at 8:00 a.m. CDT to review...
MINNEAPOLIS , April 23, 2015 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, May 5, 2015 , at 8:00 a.m. CDT to review third quarter fiscal 2015 financial results. Access to the discussion may be obtai
Read more →TECHBIO-TECHNE RELEASES SECOND QUARTER FISCAL 2015 RESULTS Minneapolis/
BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2015 RESULTS Minneapolis/February 3, 2015/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for second quarter ended December 31, 2014. Second Quarter Highlights Adjusted EPS, adjusted earnings, adjusted gross
Read more →TECHBio-Techne To Host Conference Call On February 3, 2015 To Announce Second Quarter Financial Results Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, February 3, 2015, at 8:00 a.m. CST to...
MINNEAPOLIS , Jan. 27, 2015 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that management will host a conference call on Tuesday, February 3, 2015 , at 8:00 a.m. CST to review second quarter fiscal 2015 financial results. Access to the discussion may be
Read more →TECHBio-Techne Launches Simple Plex Platform Bio-Techne Corporation (NASDAQ: TECH) announced today that it has launched Ella, the first member of the new Simple Plex platform through its...
MINNEAPOLIS , Jan. 22, 2015 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced today that it has launched Ella , the first member of the new Simple Plex platform through its Proteins Platform division under the ProteinSimple brand. This launch represents the re-bran
Read more →TECHBio-Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division Bio‑Techne Corporation (NASDAQ: TECH) announced today that it has appointed Robert Gavin to serve in a newly created position of Senior Vice...
MINNEAPOLIS , Nov. 25, 2014 /PRNewswire/ -- Bio‑Techne Corporation (NASDAQ: TECH ) announced today that it has appointed Robert Gavin to serve in a newly created position of Senior Vice President of the Protein Platforms Division. Mr. Gavin will be responsible for managing the op
Read more →TECHBio-Techne Announces Agreement To Acquire CyVek Bio-Techne Corporation (NASDAQ: TECH) announced today that it has agreed to acquire CyVek, Inc. (CyVek) for $60 million in cash, plus a potential...
MINNEAPOLIS , Nov. 4, 2014 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) announced today that it has agreed to acquire CyVek, Inc. (CyVek) for $60 million in cash, plus a potential earn-out payment of up to $35 million based on CyVek revenue over the 30-month period foll
Read more →TECHBIO-TECHNE ANNOUNCES AGREEMENT TO ACQUIRE CYVEK Minneapolis/
BIO-TECHNE ANNOUNCES AGREEMENT TO ACQUIRE CYVEK Minneapolis/November 4, 2014/ Bio-Techne Corporation (NASDAQ: TECH) announced today that it has agreed to acquire CyVek, Inc. (CyVek) for $60 million in cash, plus a potential earn-out payment of up to $35 million based on CyVek r
Read more →TECHBIO-TECHNE RELEASES FIRST QUARTER FISCAL 2015 RESULTS Minneapolis/
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2015 RESULTS Minneapolis/October 28, 2014/ Techne Corporation (NASDAQ:TECH), (d/b/a Bio-Techne) today reported its financial results for the first quarter ended First Quarter Highlights Our teams executed very well considering the marke
Read more →TECHBIO-TECHNE RELEASES FOURTH QUARTER AND FULL YEAR 2014 RESULTS Minneapolis/
BIO-TECHNE RELEASES FOURTH QUARTER AND FULL YEAR 2014 RESULTS Minneapolis/August 11, 2014/ Techne Corporation (NASDAQ:TECH), (d/b/a Bio-Techne) today reported its financial results for the fourth quarter and full year ended June 30, 2014. Fourth Quarter and Full Year 2014 High
Read more →TECHBIO-TECHNE ANNOUNCES PROTEINSIMPLE ACQUISITION COMPLETION Minneapolis
BIO-TECHNE ANNOUNCES PROTEINSIMPLE ACQUISITION COMPLETION August 1, 2014 Techne Corporation (NASDAQ: TECH) (d/b/a Bio-Techne) announced today that it has finalized its previously announced acquisition of ProteinSimple for a total cash transaction of approximately $300 million i
Read more →TECHBIO-TECHNE ANNOUNCES AGREEMENT TO ACQUIRE NOVUS BIOLOGICALS Minneapolis/
BIO-TECHNE ANNOUNCES AGREEMENT TO ACQUIRE NOVUS BIOLOGICALS Minneapolis/July 2, 2014/ Techne Corporation (NASDAQ: TECH) (d/b/a Bio-Techne) announced today that it has acquired Novus Biologicals for $60 million in cash. The transaction was financed with cash on hand. Novus Biol
Read more →TECHBIO-TECHNE ANNOUNCES AGREEMENT TO ACQUIRE PROTEINSIMPLE Minneapolis/
BIO-TECHNE ANNOUNCES AGREEMENT TO ACQUIRE PROTEINSIMPLE Minneapolis/June 17, 2014/ Techne Corporation (NASDAQ: TECH) (d/b/a Bio-Techne) announced today that it has agreed to acquire ProteinSimple for $300 million in cash. The closing of the acquisition is subject to the satisfa
Read more →TECHBIO-TECHNE ANNOUNCES THE APPOINTMENT OF HAROLD WIENS TO THE BOARD OF DIRECTORS Minneapolis/
BIO-TECHNE ANNOUNCES THE APPOINTMENT OF HAROLD WIENS TO THE BOARD OF DIRECTORS 2014/ Techne Corporation (NASDAQ:TECH) (d/b/a Bio-Techne) announces that Harold Wiens, a 30+ year veteran of 3M company, has joined the board of Bio-Techne, adding additional seasoned global business
Read more →TECHBIO-TECHNE RELEASES UNAUDITED THIRD QUARTER AND NINE MONTH FISCAL YEAR 2014 RESULTS Minneapolis/
BIO-TECHNE RELEASES UNAUDITED THIRD QUARTER AND NINE MONTH FISCAL YEAR 2014 RESULTS Minneapolis/April 28, 2014/ Techne Corporation s (NASDAQ:TECH), (d/b/a Bio-Techne) financial results for the third quarter and nine months ended March 31, 2014 include the following highlights:
Read more →TECHBIO-TECHNE ANNOUNCES INVESTMENT IN CYVEK, INC. Minneapolis/
BIO-TECHNE ANNOUNCES INVESTMENT IN CYVEK, INC. Minneapolis/ April 4, 2014/ Techne Corporation (NASDAQ: TECH), d/b/a Bio-Techne, announced today that it has made a $10 million equity investment in CyVek, Inc. (CyVek), with a commitment to acquire CyVek if certain future mileston
Read more →TECHTECHNE CORPORATION ANNOUNCES APPOINTMENT OF JAMES T. HIPPEL AS CHIEF FINANCIAL OFFICER Minneapolis/
TECHNE CORPORATION ANNOUNCES APPOINTMENT OF JAMES T. HIPPEL AS CHIEF FINANCIAL OFFICER Minneapolis/February 6, 2014/ Techne Corporation (NASDAQ:TECH) announces the appointment of James T. Hippel as Chief Financial Officer (CFO) effective April 1, 2014. Mr. Hippel is a finance e
Read more →TECHTECHNE CORPORATION ANNOUNCES ACQUISITION AGREEMENT Minneapolis/
TECHNE CORPORATION ANNOUNCES ACQUISITION AGREEMENT Minneapolis/June 18, 2013/ Techne Corporation (NASDAQ: TECH) (Techne) announced today that it has agreed to acquire 100% ownership of Bionostics Holdings Limited and its operating subsidiary Bionostics, Inc. (Bionostics). Biono
Read more →Competitive Position
How TECH ranks across every disease it competes inCompetitive Position is a premium feature
See how TECH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial